literature_id,reaction_id,inhibitor_name,inhibition_type,inhibitor_smiles,synonyms,activity_qualitative,inhibition_qualitative,details,notes
PMID32031984,reaction_1,20(S)-ginsenoside Rg3,,CC(=CCC[C@](C)(O)[C@H]1CC[C@@]2(C)[C@H]1[C@H](O)C[C@H]1[C@H]2CC[C@]2(C)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C(C)(C)CC[C@H]12)C,,,"Reduced the percentage of SNA-I positive HepG2 cells from ~95% (control) to ~60% at 100 µM concentration after 24h incubation, indicating inhibition of α2,6-sialylation.",,
PMID32031984,reaction_1,20(R)-ginsenoside Rg3,,CC(=CCC[C@@](C)(O)[C@H]1CC[C@@]2(C)[C@H]1[C@H](O)C[C@H]1[C@H]2CC[C@]2(C)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C(C)(C)CC[C@H]12)C,,,"Reduced the percentage of SNA-I positive HepG2 cells from ~95% (control) to ~55% at 100 µM concentration after 24h incubation, indicating inhibition of α2,6-sialylation.",,
PMID32031984,reaction_1,20(S)-ginsenoside Rh2,,CC(=CCC[C@](C)(O)[C@H]1CC[C@@]2(C)[C@H]1[C@H](O)C[C@H]1[C@H]2CC[C@]2(C)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C(C)(C)CC[C@H]12)C,,,Showed the most significant inhibition. Reduced the percentage of SNA-I positive HepG2 cells from ~95% (control) to ~20% at 100 µM concentration after 24h incubation.,,
PMID32031984,reaction_1,20(R)-ginsenoside Rh2,,CC(=CCC[C@@](C)(O)[C@H]1CC[C@@]2(C)[C@H]1[C@H](O)C[C@H]1[C@H]2CC[C@]2(C)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C(C)(C)CC[C@H]12)C,,,"Reduced the percentage of SNA-I positive HepG2 cells from ~95% (control) to ~40% at 100 µM concentration after 24h incubation, indicating inhibition of α2,6-sialylation.",,
PMID32031984,reaction_2,20(S)-ginsenoside Rg3,,CC(=CCC[C@](C)(O)[C@H]1CC[C@@]2(C)[C@H]1[C@H](O)C[C@H]1[C@H]2CC[C@]2(C)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C(C)(C)CC[C@H]12)C,,,"Reduced the percentage of MAL-II positive HepG2 cells from ~25% (control) to ~18% at 100 µM concentration after 24h incubation, indicating inhibition of α2,3-sialylation.",,
PMID32031984,reaction_2,20(R)-ginsenoside Rg3,,CC(=CCC[C@@](C)(O)[C@H]1CC[C@@]2(C)[C@H]1[C@H](O)C[C@H]1[C@H]2CC[C@]2(C)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C(C)(C)CC[C@H]12)C,,,"Reduced the percentage of MAL-II positive HepG2 cells from ~25% (control) to ~15% at 100 µM concentration after 24h incubation, indicating inhibition of α2,3-sialylation.",,
PMID32031984,reaction_2,20(S)-ginsenoside Rh2,,CC(=CCC[C@](C)(O)[C@H]1CC[C@@]2(C)[C@H]1[C@H](O)C[C@H]1[C@H]2CC[C@]2(C)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C(C)(C)CC[C@H]12)C,,,"Reduced the percentage of MAL-II positive HepG2 cells from ~25% (control) to ~10% at 100 µM concentration after 24h incubation, indicating inhibition of α2,3-sialylation.",,
PMID32031984,reaction_2,20(R)-ginsenoside Rh2,,CC(=CCC[C@@](C)(O)[C@H]1CC[C@@]2(C)[C@H]1[C@H](O)C[C@H]1[C@H]2CC[C@]2(C)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C(C)(C)CC[C@H]12)C,,,"Reduced the percentage of MAL-II positive HepG2 cells from ~25% (control) to ~12% at 100 µM concentration after 24h incubation, indicating inhibition of α2,3-sialylation.",,
PMID32034864,reaction_1,Aclonifen,Competitive (assumed),,,,,,
PMID32034864,reaction_2,Aclonifen,Competitive (assumed),,,,,,
PMID32034864,reaction_3,Aclonifen,No significant inhibition observed at 10 µM concentration.,,,,,,
PMID32034864,reaction_4,Aclonifen,No significant inhibition observed at 10 µM concentration.,,,,,,
PMID32034864,reaction_5,Aclonifen,No significant inhibition observed at 10 µM concentration.,,,,,,
PMID32034864,reaction_6,Aclonifen,No significant inhibition observed at 10 µM concentration.,,,,,,
PMID32034864,reaction_7,Aclonifen,Not inhibited by 10 µM aclonifen; pI50 < 5.,,,,,,
PMID32034864,reaction_8,Aclonifen,Extremely weak inhibition; pI50 < 5.,,,,,,
PMID32034864,reaction_9,Aclonifen,Unable to inhibit; pI50 < 4.5.,,,,,,
PMID32034864,reaction_10,Aclonifen,Binding confirmed by X-ray crystallography at 2.4 Å resolution. Binds at the dimer interface in the elongation cavity.,,,,,,
PMID32039339,reaction_3,Ca2+,Apparent reversible inhibition,,,,,"Observed at high Ca2+ concentrations (>3 mM), possibly due to the formation of an inactive PQQ/Ca2+ complex in solution, which reduces the amount of free PQQ available for reconstitution.",
PMID32039535,reaction_1,Physcion,Non-competitive (inferred from binding site description),Oc1cc(OC)cc2c1C(=O)c1c(O)cc(C)cc1C2=O,,,,,
PMID32039535,reaction_1,S3,,O=C1c2cccc(O)c2C(=O)c2c(O)cccc21,,,,,
PMID32039535,reaction_1,N-Benzoylindole,Noncompetitive,O=C(c1ccccc1)n1ccc2ccccc21,,,,,
PMID32039535,reaction_1,N-(4-chlorobenzoyl) indole,Competitive,O=C(c1ccc(Cl)cc1)n1ccc2ccccc21,,,,,
PMID32039535,reaction_1,1H-Indol-1-il(tiyofen-2-il)methanon,Competitive,O=C(c1cccs1)n1ccc2ccccc21,,,,,
PMID32042062,reaction_1,hNAA50,Allosteric,,,,,Decreased hNatA activity by ~50% at concentrations >100 nM.,
PMID32042062,reaction_1,MBP-HYPK,Allosteric,,,,,Showed ~90% inhibition of hNatA activity at concentrations >100 nM.,
PMID32044025,reaction_1,6-HCP,product inhibition,,,,,,
PMID32051772,reaction_2,Nitrite,Substrate inhibition,,,,,,
PMID32051772,reaction_7,Nitrite,Substrate inhibition,,,,,,
PMID32059844,reaction_1,O-isobutenyl oxalylhydroxamate,Competitive,,,,,,
PMID32060291,reaction_1,rotenone,Specific inhibitor of NDH-1,,,,,,
PMID32086051,reaction_1,Epalrestat,Not specified,,,,,,
PMID32086051,reaction_1,Compound 6g,Uncompetitive,,,,,,
PMID32086051,reaction_1,Compound 6e,Uncompetitive,,,,,,
PMID32086051,reaction_1,Compound 6i,Uncompetitive,,,,,,
PMID32086051,reaction_1,Compound 6h,Uncompetitive,,,,,,
PMID32086051,reaction_1,Compound 6f,Uncompetitive,,,,,,
PMID32086051,reaction_1,Compound 6j,Uncompetitive,,,,,,
PMID32086051,reaction_1,Compound 6c,Uncompetitive,,,,,,
PMID32086051,reaction_1,Compound 6a,Uncompetitive,,,,,,
PMID32086051,reaction_1,Compound 6k,Uncompetitive,,,,,,
PMID32086051,reaction_1,Compound 6l,Uncompetitive,,,,,,
PMID32086051,reaction_1,Compound 6b,Uncompetitive,,,,,,
PMID32086051,reaction_1,Compound 6d,Uncompetitive,,,,,,
PMID32086387,reaction_1,Compound C,Pharmacological inhibitor of AMPK used at 10 µM. It reversed the antiviral effects of AMPK activators.,,,,,,
PMID32086387,reaction_1,Zika virus (ZIKV) infection,"Indirect inhibition. ZIKV infection resulted in a time-dependent decrease in the phosphorylation of AMPK's substrate, ACC, indicating impaired AMPK activity.",,,,,,
PMID32090335,reaction_1,Histamine,Substrate inhibition,,,,,,
PMID32094184,reaction_1,Cyanide,Competitive,,,,,,
PMID32094184,reaction_1,Cyanate,Mixed,,,,,,Mixed type inhibition with Kic = 0.9 mM and Kiu = 1.2 mM. The ki field contains the Kic value.
PMID32094184,reaction_1,Azide,,,,,,,
PMID32094184,reaction_2,Cyanide,Competitive,,,,,,
PMID32094184,reaction_2,Cyanate,Mixed,,,,,,Mixed type inhibition with Kic = 0.9 mM and Kiu = 1.2 mM. The ki field contains the Kic value.
PMID32094184,reaction_2,Azide,,,,,,,
PMID32094184,reaction_3,Cyanide,Competitive,,,,,,
PMID32094184,reaction_3,Cyanate,Mixed,,,,,,Mixed type inhibition with Kic = 0.9 mM and Kiu = 1.2 mM. The ki field contains the Kic value.
PMID32094184,reaction_3,Azide,,,,,,,
PMID32099742,reaction_1,Ag+,,,,,,1 mM Ag+ resulted in 12.7 ± 1.6 % residual activity.,
PMID32099742,reaction_1,SDS,,,,,,1% (m/v) SDS resulted in 9.0 ± 0.1 % residual activity.,
PMID32099742,reaction_1,Cu2+,,,,,,1 mM Cu2+ resulted in 82.8 ± 2.3 % residual activity.,
PMID32099742,reaction_1,Fe2+,,,,,,1 mM Fe2+ resulted in 66.3 ± 3.8 % residual activity.,
PMID32101363,reaction_1,PDT-PAO-F16,Not specified,,,,,,
PMID32101363,reaction_2,PDT-PAO-F16,Not specified,,,,,,
PMID32101363,reaction_3,PDT-PAO-F16,Not specified,,,,,,
PMID32101363,reaction_4,PDT-PAO-F16,Not specified,,,,,,
PMID32101363,reaction_5,PDT-PAO-F16,Not specified,,,,,,
PMID32112503,reaction_1,triclosan,Not specified,,,,,,"FabMG is resistant to triclosan. At 0.98 µM triclosan, 87% of activity was maintained. At 7.80 µM and 31.25 µM, activity was reduced to 38% and 10%, respectively."
PMID32112503,reaction_2,triclosan,Not specified,,,,,,Activity was reduced to 20% at 0.98 µM triclosan. No activity was detected at higher triclosan concentrations.
PMID32113843,reaction_1,Compound 1,Reversible,,,,,,
PMID32113843,reaction_1,Compound 4 (racemic),Reversible,,,,,,
PMID32113843,reaction_1,Compound 5 (R-enantiomer),Reversible,,,,,,
PMID32113843,reaction_1,Compound 6 (S-enantiomer),Reversible,,,,,,
PMID32113843,reaction_1,Compound 7 (racemic),Reversible,,,,,,
PMID32113843,reaction_1,Compound 7E1,Reversible,,,,,,
PMID32113843,reaction_1,Compound 7E2,Reversible,,,,,,
PMID32113843,reaction_1,Compound 8 (racemic),Reversible,,,,,,
PMID32113843,reaction_1,Compound 9E1,Reversible,,,,,,
PMID32113843,reaction_1,Compound 9E2,Reversible,,,,,,
PMID32113843,reaction_1,Compound 10E1,Reversible,,,,,,
PMID32113843,reaction_1,Compound 10E2,Reversible,,,,,,
PMID32113843,reaction_1,Compound 11E2,Reversible,,,,,,
PMID32114907,reaction_2,bathocuproine sulfonate,No inhibition observed,,,,,,
PMID32114907,reaction_8,tungsten,Inhibits activity,,,,,,
PMID32117944,reaction_1,Zn2+,Activity lost,,,,,,
PMID32117944,reaction_1,Cu2+,Activity lost,,,,,,
PMID32117944,reaction_1,Co2+,Activity lost,,,,,,
PMID32117944,reaction_2,Zn2+,Activity lost,,,,,,
PMID32117944,reaction_2,Cu2+,Activity lost,,,,,,
PMID32117944,reaction_2,Co2+,Activity lost,,,,,,
PMID32117944,reaction_3,Zn2+,Activity lost,,,,,,
PMID32117944,reaction_3,Cu2+,Activity lost,,,,,,
PMID32117944,reaction_3,Co2+,Activity lost,,,,,,
PMID32117944,reaction_4,Zn2+,Activity lost,,,,,,
PMID32117944,reaction_4,Cu2+,Activity lost,,,,,,
PMID32117944,reaction_4,Co2+,Activity lost,,,,,,
PMID32125480,reaction_1,Menadione hydroquinol,Substrate inhibition,,,,,Relative activity drastically decreased with substrate concentrations >1.5 mM. A concentration of 3 mM almost absolutely inhibited the prenylation.,
PMID32130469,reaction_2,"Triton X-100 (0.1%, v/v)",Not specified,,,,,,Significantly inhibited vanillin production in the cascade reaction.
PMID32140842,reaction_1,EDTA,No inhibition observed,,,,,,
PMID32144268,reaction_1,AHCYL1,Negative regulation via heteromultimerization,,,,,,
PMID32146179,reaction_1,Compound 5d,,,,,,,
PMID32146179,reaction_1,Compound 5e,,,,,,,
PMID32146179,reaction_1,Compound 5l,,,,,,,
PMID32146179,reaction_1,Compound 5m,,,,,,,
PMID32146179,reaction_1,Compound 5o,,,,,,,
PMID32146179,reaction_1,Vancomycin,Positive control,,,,,,
PMID32152525,reaction_1,KES4,,,,,,,Remaining activity was 68.0 ± 0.5% at 50 µM concentration.
PMID32152525,reaction_1,Compound 3a (KET1),,,,,,,Remaining activity was 83.4 ± 1.2% at 50 µM concentration.
PMID32152525,reaction_1,Compound 3b (KET3),,,,,,,Remaining activity was 63.9 ± 0.7% at 50 µM concentration.
PMID32152525,reaction_1,Compound 3c (KET6),,,,,,,Remaining activity was 48.8 ± 2.4% at 50 µM concentration.
PMID32152525,reaction_1,Compound 3d (KET8),,,,,,,Remaining activity was 39.5 ± 0.6% at 50 µM concentration.
PMID32152525,reaction_1,Compound 3e (KET10),,,,,,,Remaining activity was 45.4 ± 1.2% at 50 µM concentration.
PMID32152525,reaction_1,Compound 3f (KET12),,,,,,,Remaining activity was 41.2 ± 0.6% at 50 µM concentration.
PMID32152525,reaction_1,Compound 3g (KET15),,,,,,,Remaining activity was 66.5 ± 2.1% at 50 µM concentration.
PMID32152525,reaction_1,Triclosan (TCS),,,,,,,Almost completely inhibited the enzyme at 50 µM concentration.
PMID32153057,reaction_1,lansoprazole,No significant inhibition observed at 3 µg/ml concentration.,Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1,,,,,
PMID32155529,reaction_1_in_vitro,Compound 5,,,,,,,
PMID32155529,reaction_1_in_vitro,Compound 13a,,,,,,,
PMID32155529,reaction_1_in_vitro,Compound 13b,,,,,,,
PMID32155529,reaction_1_in_vitro,Compound 14a,,,,,,,
PMID32155529,reaction_1_in_vitro,Compound 14b,,,,,,,
PMID32155529,reaction_1_in_vitro,Compound 27a,,,,,,,
PMID32155529,reaction_1_in_vitro,Compound 27b,,,,,,,
PMID32155529,reaction_1_in_vitro,Compound 27c,,,,,,,
PMID32155529,reaction_1_in_vitro,Compound 27d,,,,,,,
PMID32155529,reaction_1_in_vitro,Compound 27e,,,,,,,
PMID32155529,reaction_1_in_vitro,Compound 27f,,,,,,,
PMID32155529,reaction_1_in_vitro,Compound 27g,,,,,,,
PMID32155529,reaction_1_in_vitro,Compound 27h,,,,,,,
PMID32155529,reaction_1_in_vitro,Compound 27i,,,,,,,
PMID32155529,reaction_1_in_vitro,Compound 27j,,,,,,,
PMID32155529,reaction_1_in_vitro,Compound 27k,,,,,,,
PMID32155529,reaction_1_in_vitro,Compound 27l,,,,,,,
PMID32155529,reaction_1_in_vitro,Compound 27m,,,,,,,
PMID32155529,reaction_1_in_vitro,Compound 27n,,,,,,,
PMID32155529,reaction_1_in_vitro,Compound 27o,,,,,,,
PMID32155529,reaction_1_in_vitro,Compound 27p,,,,,,,
PMID32155529,reaction_1_in_vitro,Compound 27q,,,,,,,
PMID32155529,reaction_1_in_vitro,Compound 27r,,,,,,,
PMID32155529,reaction_1_in_vitro,Compound 27s,,,,,,,
PMID32155529,reaction_1_in_vitro,Compound 27t,,,,,,,
PMID32155529,reaction_1_in_vitro,Compound 27u,,,,,,,
PMID32155529,reaction_1_in_vitro,Compound 27v,,,,,,,
PMID32155529,reaction_1_in_vitro,Compound 27w,,,,,,,
PMID32155529,reaction_1_in_vitro,Compound 27x,,,,,,,
PMID32155529,reaction_1_in_vitro,Compound 27y,,,,,,,
PMID32155529,reaction_1_in_vitro,Compound 27z,,,,,,,
PMID32155529,reaction_1_in_vitro,Compound 27aa,,,,,,,
PMID32155529,reaction_1_in_vitro,Compound 27ab,,,,,,,
PMID32155529,reaction_1_in_vitro,Compound 27ac,,,,,,,
PMID32155529,reaction_1_in_vitro,Compound 33a,,,,,,,
PMID32155529,reaction_1_in_vitro,Compound 33b,,,,,,,
PMID32155529,reaction_1_in_vitro,CPI-455,,,,,,,
PMID32155529,reaction_2_in_cellulo,Compound 27ab,Not specified,,,,,,Induced significant accumulation of H3K4me2/3 in a dose-dependent manner from 0.5 µM to 20 µM after 5 days of treatment.
PMID32155529,reaction_2_in_cellulo,Compound 33a,Not specified,,,,,,"Used as a negative control, failed to induce accumulation of H3K4me2/3."
PMID32158501,reaction_1,Catalase,Scavenging of H2O2 cosubstrate,,,,,"2000 U/mL catalase clearly, but not fully, suppressed the catalytic reaction, indicating dependence on H2O2 generated from ascorbate and O2.",
PMID32158501,reaction_2,Catalase,Scavenging of H2O2 cosubstrate,,,,,"2000 U/mL catalase completely inhibited the reaction at low CDH concentrations (0.5 µM), indicating H2O2 is the key cosubstrate.",
PMID32159929,reaction_1_cyt_bo3,HQNO,noncompetitive or uncompetitive,,,,,,
PMID32159929,reaction_1_cyt_bo3,HNQ-12,,,,,,,
PMID32159929,reaction_1_cyt_bo3,HNQ-6,,,,,,,
PMID32159929,reaction_1_cyt_bo3,KCN,,,,Strong inhibition at 20 µM (positive control).,,,
PMID32159929,reaction_1_cyt_bo3,HNQ-1,,,,"Strong inhibition (>50%, ~90% relative inhibition) at 250 µM.",,,
PMID32159929,reaction_1_cyt_bo3,HNQ-2,,,,"Strong inhibition (>50%, ~80% relative inhibition) at 250 µM.",,,
PMID32159929,reaction_1_cyt_bo3,HNQ-7,,,,"Strong inhibition (>50%, ~55% relative inhibition) at 250 µM.",,,
PMID32159929,reaction_1_cyt_bo3,HNQ-5,,,,Moderate inhibition (~40% relative inhibition) at 250 µM.,,,
PMID32159929,reaction_1_cyt_bo3,HNQ-10,,,,Low inhibition (~30% relative inhibition) at 250 µM.,,,
PMID32159929,reaction_1_cyt_bo3,HNQ-3,,,,No or low inhibitory effect (<30%) at 250 µM.,,,
PMID32159929,reaction_1_cyt_bo3,HNQ-4,,,,No or low inhibitory effect (<30%) at 250 µM.,,,
PMID32159929,reaction_1_cyt_bo3,HNQ-8,,,,No or low inhibitory effect (<30%) at 250 µM.,,,
PMID32159929,reaction_1_cyt_bo3,HNQ-9,,,,No or low inhibitory effect (<30%) at 250 µM.,,,
PMID32159929,reaction_1_cyt_bo3,HNQ-11,,,,No or low inhibitory effect (<30%) at 250 µM.,,,
PMID32159929,reaction_2_cyt_bdI,HNQ-12,,,,Inhibition of 56% at 250 µM.,,,
PMID32159929,reaction_2_cyt_bdI,HNQ-1,,,,Inhibition of 30% at 250 µM.,,,
PMID32159929,reaction_2_cyt_bdI,HQNO,,,,Strong inhibition (~90% relative inhibition) at 250 µM.,,,
PMID32159929,reaction_2_cyt_bdI,HNQ-2,,,,No or low inhibitory effect (<30%) at 250 µM.,,,
PMID32159929,reaction_2_cyt_bdI,HNQ-3,,,,No or low inhibitory effect (<30%) at 250 µM.,,,
PMID32159929,reaction_2_cyt_bdI,HNQ-4,,,,No or low inhibitory effect (<30%) at 250 µM.,,,
PMID32159929,reaction_2_cyt_bdI,HNQ-5,,,,No or low inhibitory effect (<30%) at 250 µM.,,,
PMID32159929,reaction_2_cyt_bdI,HNQ-6,,,,No or low inhibitory effect (<30%) at 250 µM.,,,
PMID32159929,reaction_2_cyt_bdI,HNQ-7,,,,No or low inhibitory effect (<30%) at 250 µM.,,,
PMID32159929,reaction_2_cyt_bdI,HNQ-8,,,,No or low inhibitory effect (<30%) at 250 µM.,,,
PMID32159929,reaction_2_cyt_bdI,HNQ-9,,,,No or low inhibitory effect (<30%) at 250 µM.,,,
PMID32159929,reaction_2_cyt_bdI,HNQ-10,,,,No or low inhibitory effect (<30%) at 250 µM.,,,
PMID32159929,reaction_2_cyt_bdI,HNQ-11,,,,No or low inhibitory effect (<30%) at 250 µM.,,,
PMID32170014,reaction_1,NB-598,Active-site inhibitor,,,,,,
PMID32170014,reaction_1,Terbinafine,Active-site inhibitor,,,,,,
PMID32170014,reaction_1,Butenafine,Active-site inhibitor,,,,,,
PMID32170014,reaction_1,Naftifine,Active-site inhibitor,,,,,,
PMID32171154,reaction_1,"1-(4-methoxyphenyl)-3-(5-(5-nitrofuran-2-yl)-1,3,4-thiadiazol-2-yl)thiourea (5b)",,,,,,,
PMID32171154,reaction_1,"1-(4-fluorophenyl)-3-(5-(5-nitrofuran-2-yl)-1,3,4-thiadiazol-2-yl)thiourea (5c)",,,,,,,
PMID32171154,reaction_1,"1-(4-methoxyphenyl)-3-(5-(5-nitrothiophen-2-yl)-1,3,4-thiadiazol-2-yl)thiourea (5e)",,,,,,,
PMID32171154,reaction_1,"1-(4-chlorophenyl)-3-(5-(5-nitrothiophen-2-yl)-1,3,4-thiadiazol-2-yl)thiourea (5g)",,,,,,,
PMID32171154,reaction_1,"4-acetyl-N-(5-(5-nitrofuran-2-yl)-1,3,4-thiadiazol-2-yl)benzenesulfonamide (6c)",,,,,,,
PMID32171154,reaction_1,"((4-methoxyphenyl)carbamoyl)(5-(5-nitrothiophen-2-yl)-1,3,4-thiadiazol-2-yl)amide (Lead)",,,,,,,
PMID32171656,reaction_1,Ca2+,,,,,,,
PMID32171656,reaction_1,Zn2+,,,,,,,
PMID32171656,reaction_1,Ni2+,,,,,,,
PMID32171656,reaction_1,Cu2+,,,,,,,
PMID32171656,reaction_1,Mn2+,,,,,,,
PMID32171656,reaction_1,DTT,,,,,,,
PMID32171656,reaction_1,EDTA,,,,,,,
PMID32171656,reaction_1,β-mercaptoethanol,,,,,,,
PMID32171656,reaction_2,Ca2+,,,,,,,
PMID32171656,reaction_2,Zn2+,,,,,,,
PMID32171656,reaction_2,Ni2+,,,,,,,
PMID32171656,reaction_2,Cu2+,,,,,,,
PMID32171656,reaction_2,Mn2+,,,,,,,
PMID32171656,reaction_2,KCl,,,,,,,
PMID32171656,reaction_2,NaCl,,,,,,,
PMID32171656,reaction_2,DTT,,,,,,,
PMID32171656,reaction_2,EDTA,,,,,,,
PMID32171656,reaction_2,β-mercaptoethanol,,,,,,,
PMID32171656,reaction_3,Mg2+,,,,,,,
PMID32171656,reaction_3,Ca2+,,,,,,,
PMID32171656,reaction_3,Zn2+,,,,,,,
PMID32171656,reaction_3,Ni2+,,,,,,,
PMID32171656,reaction_3,Cu2+,,,,,,,
PMID32171656,reaction_3,Mn2+,,,,,,,
PMID32171656,reaction_3,KCl,,,,,,,
PMID32171656,reaction_3,NaCl,,,,,,,
PMID32171656,reaction_3,DTT,,,,,,,
PMID32171656,reaction_3,EDTA,,,,,,,
PMID32171656,reaction_3,β-mercaptoethanol,,,,,,,
PMID32171906,reaction_3,ATP,Not specified,,,,,,Preincubation with millimolar concentrations reduced activity by up to 90%.
PMID32171906,reaction_3,ADP,Not specified,,,,,,Preincubation with 5 mM ADP reduces the KAT activity in a similar manner as ATP.
PMID32178258,reaction_1,TO502-2403,Non-inhibitory,O=C(Nc1ccn(-c2ccccc2)n1)c1cc(-c2ccccc2)nc2ccccc12,CSFCII,,,,Had no effect on the activity of the purified viral polymerase.
PMID32178258,reaction_1,TO505-6180,Non-inhibitory,c1(C)ccc2nc(NC(=O)c3cc(-c4ccco4)nc4ccccc34)sc2c1,CSFCI,,,,Had no effect on the activity of the purified viral polymerase.
PMID32178258,reaction_1,3'-deoxyguanosine-5'-triphosphate,Nucleotide analogue inhibitor,,3'-dGTP,,,,
PMID32178258,reaction_2,TO502-2403,Non-nucleoside inhibitor,O=C(Nc1ccn(-c2ccccc2)n1)c1cc(-c2ccccc2)nc2ccccc12,CSFCII,,,,"Inhibited wild-type RC activity in a dose-dependent manner, with approximately 90% inhibition at 10 µM."
PMID32178258,reaction_2,TO505-6180,Non-nucleoside inhibitor,c1(C)ccc2nc(NC(=O)c3cc(-c4ccco4)nc4ccccc34)sc2c1,CSFCI,,,,Inhibited wild-type RC activity in a dose-dependent manner.
PMID32178974,reaction_1,Compound 1,Not specified,,,,,,
PMID32180325,reaction_2,8-vinyl chlorophyllide a,Competitive,,,,,,
PMID32181246,reaction_1,Fe2+,Not specified,,,,,,
PMID32181246,reaction_1,SDS,Not specified,,,,,,
PMID32181246,reaction_1,DTT,Not specified,,,,,,
PMID32181246,reaction_2,Cu2+,Not specified,,,,,,
PMID32181246,reaction_2,SDS,Not specified,,,,,,
PMID32181246,reaction_2,DTT,Not specified,,,,,,
PMID32182320,reaction_1,N-oxalylglycine,Inactive co-substrate analog used for co-crystallization,,,,,,
PMID32184968,reaction_1,THZ-P1-2,,,,,,,
PMID32184968,reaction_1,Compound 6,,,,,,,
PMID32184968,reaction_1,Compound 7,,,,,,,
PMID32184968,reaction_1,Compound 8,,,,,,,
PMID32184968,reaction_1,Compound 9,,,,,,,
PMID32184968,reaction_1,Compound 10,,,,,,,
PMID32184968,reaction_1,Compound 11,,,,,,,
PMID32184968,reaction_1,Compound 14,,,,,,,
PMID32184968,reaction_1,Compound 15,,,,,,,
PMID32184968,reaction_1,Compound 16,,,,,,,
PMID32184968,reaction_1,Compound 17,,,,,,,
PMID32184968,reaction_1,Compound 18,,,,,,,
PMID32184968,reaction_1,Compound 19,,,,,,,
PMID32184968,reaction_1,Compound 22,,,,,,,
PMID32184968,reaction_1,Compound 25,,,,,,,
PMID32184968,reaction_1,Compound 30,,,,,,,
PMID32184968,reaction_2,THZ-P1-2,,,,,,,
PMID32184968,reaction_2,Compound 6,,,,,,,
PMID32184968,reaction_2,Compound 7,,,,,,,
PMID32184968,reaction_2,Compound 8,,,,,,,
PMID32184968,reaction_2,Compound 9,,,,,,,
PMID32184968,reaction_2,Compound 10,,,,,,,
PMID32184968,reaction_2,Compound 11,,,,,,,
PMID32184968,reaction_2,Compound 14,,,,,,,
PMID32184968,reaction_2,Compound 15,,,,,,,
PMID32184968,reaction_2,Compound 16,,,,,,,
PMID32184968,reaction_2,Compound 17,,,,,,,
PMID32184968,reaction_2,Compound 18,,,,,,,
PMID32184968,reaction_2,Compound 19,,,,,,,
PMID32184968,reaction_2,Compound 22,,,,,,,
PMID32184968,reaction_2,Compound 25,,,,,,,
PMID32184968,reaction_2,Compound 30,,,,,,,
PMID32190117,reaction_1,H2O2,Inactivation at high concentrations,,,,,Substrate conversion rates declined with H2O2 concentrations between 1000 and 5000 µM.,
PMID32196942,reaction_1,ATP,Substrate inhibition,,,,,at pH 7.5,
PMID32196942,reaction_1,ATP,Substrate inhibition,,,,,at pH 5.5,
PMID32196942,reaction_1,ADP,Product inhibition,,,,,at pH 7.5,
PMID32196942,reaction_1,ADP,Product inhibition,,,,,at pH 5.5,
PMID32196942,reaction_1,Mg2+,Regulatory inhibition,,,,,Inhibits at pH 7.5 by binding to a regulatory site in the PAS domain.,
PMID32196942,reaction_1,Mn2+,Regulatory inhibition,,,,,"Inhibits at high concentration (2mM) at pH 7.5, similar to Mg2+.",
PMID32196942,reaction_2,ATP,Substrate inhibition,,,,,at pH 7.5,
PMID32196942,reaction_2,ATP,Substrate inhibition,,,,,at pH 5.5,
PMID32196942,reaction_2,ADP,Product inhibition,,,,,at pH 7.5,
PMID32196942,reaction_2,ADP,Product inhibition,,,,,at pH 5.5,
PMID32198779,reaction_1,3-(methylsulfonyl)-2-oxopropanic acid,Tight-binding,,E4P,,,,
PMID32198779,reaction_1,MMV688271,Tight-binding,,E10,,,,
PMID32198779,reaction_1,2-aminophenol,No inhibition observed,,2-AP,,,,
PMID32198779,reaction_1,"3-((Ethylsulfonyl)methyl)-2H-benzo[b][1,4]oxazin-2-one","Inhibitor, less active than parent compound E4",,4b,,,,
PMID32198779,reaction_1,"3-((Propylsulfonyl)methyl)-2H-benzo[b][1,4]oxazin-2-one","Inhibitor, less active than parent compound E4",,4c,,,,
PMID32198779,reaction_1,"3-(Tosylmethyl)-2H-benzo[b][1,4]oxazin-2-one",Inactive,,4d,,,,
PMID32198779,reaction_1,"3-(1-(Methylsulfonyl)propyl)-2H-benzo[b][1,4]oxazin-2-one",Inactive,,4e,,,,
PMID32198779,reaction_2,3-(methylsulfonyl)-2-oxopropanic acid,Tight-binding,,E4P,,,,
PMID32198779,reaction_2,MMV688271,Tight-binding,,E10,,,,
PMID32200327,reaction_1,7-Deazaxanthine (7DX),,,,,,,
PMID32200327,reaction_1,2-(2-methyl-1H-indol-3-yl)-N'-(4-nitrobenzylidene)acetohydrazide (1),,,,,,,
PMID32200327,reaction_1,"N'-(2,4-dihydroxybenzylidene)-2-(2-methyl-1H-indol-3-yl)acetohydrazide (2)",,,,,,,
PMID32200327,reaction_1,"N'-(3,5-dihydroxybenzylidene)-2-(2-methyl-1H-indol-3-yl)acetohydrazide (3)",,,,,,,
PMID32200327,reaction_1,N'-(2-methoxybenzylidene)-2-(2-methyl-1H-indol-3-yl)acetohydrazide (4),,,,,,,
PMID32200327,reaction_1,"N'-(3,4-dihydroxybenzylidene)-2-(2-methyl-1H-indol-3-yl)acetohydrazide (5)",,,,,,,
PMID32200327,reaction_1,"N'-(2,5-dihydroxybenzylidene)-2-(2-methyl-1H-indol-3-yl)acetohydrazide (6)",,,,,,,
PMID32200327,reaction_1,N'-(3-hydroxybenzylidene)-2-(2-methyl-1H-indol-3-yl)acetohydrazide (7),,,,,,,
PMID32200327,reaction_1,"2-(2-methyl-1H-indol-3-yl)-N'-(2,4,6-trihydroxybenzylidene)acetohydrazide (8)",,,,,,,
PMID32200327,reaction_1,N'-(4-(dimethylamino)benzylidene)-2-(2-methyl-1H-indol-3-yl)acetohydrazide (9),,,,,,,
PMID32200327,reaction_1,2-(2-methyl-1H-indol-3-yl)-N'-(2-nitrobenzylidene)acetohydrazide (10),,,,,,,
PMID32200327,reaction_1,2-(2-methyl-1H-indol-3-yl)-N'-(3-nitrobenzylidene)acetohydrazide (11),,,,,,,
PMID32200327,reaction_1,N'-(4-hydroxybenzylidene)-2-(2-methyl-1H-indol-3-yl)acetohydrazide (12),,,,,,,
PMID32200327,reaction_1,N'-(4-chlorobenzylidene)-2-(2-methyl-1H-indol-3-yl)acetohydrazide (13),,,,,,,
PMID32200327,reaction_1,methyl-4-((2-(2-(2-methyl-1H-indol-3-yl)acetyl)hydrazono)methyl)benzoate (14),,,,,,,
PMID32200327,reaction_1,2-(2-methyl-1H-indol-3-yl)-N'-(2-methylbenzylidene)acetohydrazide (15),,,,,,,
PMID32200327,reaction_1,2-(2-methyl-1H-indol-3-yl)-N'-(4-methylbenzylidene)acetohydrazide (16),,,,,,,
PMID32200327,reaction_1,N'-(3-chlorobenzylidene)-2-(2-methyl-1H-indol-3-yl)acetohydrazide (17),,,,,,,
PMID32200327,reaction_1,N'-(2-hydroxybenzylidene)-2-(2-methyl-1H-indol-3-yl)acetohydrazide (18),,,,,,,
PMID32200327,reaction_1,2-(2-methyl-1H-indol-3-yl)-N'-(3-methylbenzylidene)acetohydrazide (19),,,,,,,
PMID32200327,reaction_1,N'-(3-hydroxy-4-methoxybenzylidene)-2-(2-methyl-1H-indol-3-yl)acetohydrazide (20),,,,,,,
PMID32200327,reaction_1,"N'-(2,4-dimethoxybenzylidene)-2-(2-methyl-1H-indol-3-yl)acetohydrazide (21)",,,,,,,
PMID32200327,reaction_1,"N'-(2,3-dihydroxybenzylidene)-2-(2-methyl-1H-indol-3-yl)acetohydrazide (22)",,,,,,,
PMID32226297,reaction_1,CBR-5884,"Allosteric, covalent",,,,,,
PMID32226297,reaction_1,Disulfiram,"Allosteric, covalent",,,,,,
PMID32226297,reaction_1,NCT-503,Allosteric (non-competitive),,,,,,
PMID32226297,reaction_1,BI-4916,Orthosteric (cofactor-competitive),,,,,,
PMID32226297,reaction_1,α-ketothioamides,Not specified,,,,,,
PMID32226297,reaction_1,PKUMDL-WQ-2101,Allosteric,,,,,,
PMID32226297,reaction_1,PKUMDL-WQ-2201,Allosteric,,,,,,
PMID32226297,reaction_1,Azacoccone E,Allosteric (non-competitive),,,,,,
PMID32226297,reaction_1,Ixocarpalactone A,Allosteric (non-competitive),,,,,,
PMID32226807,reaction_1_aminopyrine_demethylation,FK866,,,,,,,Mild inhibition observed only at 100 µM concentration.
PMID32226807,reaction_1_aminopyrine_demethylation,A6,,,,,,,"Showed the greatest inhibitory activity of the tested compounds, with concentration-dependent inhibition in the 1-100 µM range."
PMID32226807,reaction_1_aminopyrine_demethylation,E5,,,,,,,"Showed potent, concentration-dependent inhibition in the 1-100 µM range."
PMID32226807,reaction_1_aminopyrine_demethylation,T1,,,,,,,"Showed potent, concentration-dependent inhibition in the 1-100 µM range."
PMID32229210,reaction_1,NaCl,Inhibition at high concentration,,,,,"Activity was significantly reduced at NaCl concentrations above 400 mM, and no synthesis was observed at 600 mM. Optimal activity between 50-200 mM.",
PMID32229210,reaction_2,dNTPs,Suppression,,,,,"Exonuclease activity is strongly inhibited by dNTPs, being absent at 5 μM dNTPs. At 4.0 μM dNTPs, the Exo/Pol ratio is 0.07.",
PMID32230972,reaction_4,H2O2,Suicide inhibition at concentrations > 100 µM,,,,,,
PMID32233071,reaction_1,5-hydroxymethylfurfural,Substrate inhibition,,,,,Significant inhibition of FDCA production was observed at HMF concentrations of 100 mM and higher in low cell density cultures. Inhibition was overcome by increasing cell density or using a fed-batch strategy.,
PMID32235505,reaction_1,"1,3-diaminopropane (DAP)",Partial inhibition observed,,,,,,
PMID32235505,reaction_1,"N1-guanyl-1,7-diaminoheptane (GC7)","Inhibition observed, stronger than DAP",,,,,,
PMID32246282,reaction_2,Acetate,,,,,,,
PMID32246282,reaction_2,Acetate,,,,,,,
PMID32246282,reaction_3,Fluoride,,,,,,,
PMID32246282,reaction_4,Imidazole,,,,,,,
PMID32246282,reaction_4,Imidazole,,,,,,,
PMID32246282,reaction_4,Imidazole,,,,,,,
PMID32246282,reaction_4,Imidazole,,,,,,,
PMID32246945,reaction_1,Premedrol,Product inhibition,,,,,,
PMID32247165,reaction_1_sGDH,glucose,Substrate inhibition,,,,,,
PMID32247165,reaction_2_mGDH,some pentoses,Inhibitor,,,,,,
PMID32247733,reaction_1,5a,,,,,,,
PMID32247733,reaction_1,5b,,,,,,,
PMID32247733,reaction_1,5c,,,,,,,
PMID32247733,reaction_1,5d,,,,,,,
PMID32247733,reaction_1,5e,,,,,,,
PMID32247733,reaction_1,5f,,,,,,,
PMID32247733,reaction_1,5g,,,,,,,
PMID32247733,reaction_1,5h,,,,,,,
PMID32247733,reaction_1,9a,,,,,,,
PMID32247733,reaction_1,9b,,,,,,,
PMID32247733,reaction_1,9c,,,,,,,
PMID32247733,reaction_1,9d,,,,,,,
PMID32247733,reaction_1,8-fluorotryptanthrin,,,,,,,
PMID32247733,reaction_1,INCB024360,,,,,,,
PMID32247733,reaction_2,5a,,,,,,,
PMID32247733,reaction_2,5b,,,,,,,
PMID32247733,reaction_2,5c,,,,,,,
PMID32247733,reaction_2,5d,,,,,,,
PMID32247733,reaction_2,5e,,,,,,,
PMID32247733,reaction_2,5f,,,,,,,
PMID32247733,reaction_2,5g,,,,,,,
PMID32247733,reaction_2,5h,,,,,,,
PMID32247733,reaction_2,9a,,,,,,,
PMID32247733,reaction_2,9b,,,,,,,
PMID32247733,reaction_2,9c,,,,,,,
PMID32247733,reaction_2,9d,,,,,,,
PMID32247733,reaction_2,8-fluorotryptanthrin,,,,,,,
PMID32247733,reaction_2,LM10,,,,,,,
PMID32247733,reaction_3,5a,,,,,,,
PMID32247733,reaction_3,5b,,,,,,,
PMID32247733,reaction_3,5c,,,,,,,
PMID32247733,reaction_3,5d,,,,,,,
PMID32247733,reaction_3,5e,,,,,,,
PMID32247733,reaction_3,5f,,,,,,,
PMID32247733,reaction_3,5g,,,,,,,
PMID32247733,reaction_3,5h,,,,,,,
PMID32247733,reaction_3,9a,,,,,,,
PMID32247733,reaction_3,9b,,,,,,,
PMID32247733,reaction_3,9c,,,,,,,
PMID32247733,reaction_3,9d,,,,,,,
PMID32247733,reaction_3,INCB024360,,,,,,,
PMID32252458,reaction_1,Letrozole,,,,,,,
PMID32252458,reaction_1,compound 5c,,,,,,,
PMID32252458,reaction_1,compound 5e,,,,,,,
PMID32252458,reaction_1,compound 5k,,,,,,,
PMID32252458,reaction_1,compound 5m,,,,,,,
PMID32257739,reaction_1,Glyphosate,Not specified,,,,,,The wild-type enzyme from P. nitroreducens strains FY43 and FY47 confers tolerance to 8.768% (518.4 mM) glyphosate when expressed in E. coli.
PMID32269094,reaction_1,concanamycin A,V-ATPase blocker,,,,,,
PMID32275825,reaction_1,Compound 27,"Partial, cooperative, non-competitive",,,,,,
PMID32275825,reaction_1,Compound 19,"Partial, cooperative, non-competitive",,,,,,
PMID32275825,reaction_1,Compound 1,,,,,,,
PMID32275825,reaction_1,Compound 31,,,,,,,
PMID32275825,reaction_2,DDD806905,"Competitive (implied, from literature on this series)",,,,,,
PMID32275825,reaction_2,Compound 27,"Partial, cooperative, non-competitive",,,,,,
PMID32275825,reaction_2,Compound 31,,,,,,,
PMID32282952,reaction_1,Hg2+,Strong inhibition observed at 10 mM,,,,,,
PMID32282952,reaction_1,Cd2+,Strong inhibition observed at 10 mM,,,,,,
PMID32283297,reaction_1,11b,,,,,,,
PMID32283297,reaction_1,11e,,,,,,,
PMID32283297,reaction_1,11g,,,,,,,
PMID32283297,reaction_1,11h,,,,,,,
PMID32283297,reaction_1,11i,,,,,,,
PMID32283297,reaction_1,11j,,,,,,,
PMID32283297,reaction_1,11k,,,,,,,
PMID32283297,reaction_1,11l,,,,,,,
PMID32283297,reaction_1,11o,,,,,,,
PMID32283297,reaction_1,11p,,,,,,,
PMID32283297,reaction_1,11v,,,,,,,
PMID32283297,reaction_1,PCPA,,,,,,,
PMID32283299,reaction_1,Polyoxin B,,,,,,,
PMID32283299,reaction_1,Compound 2b,Non-competitive,,,,,,
PMID32283299,reaction_1,Compound 2d,,,,,,,
PMID32283299,reaction_1,Compound 2s,,,,,,,
PMID32283299,reaction_1,Compound 2e,,,,,,,
PMID32283299,reaction_1,Compound 2a,,,,,,,
PMID32283299,reaction_1,Compound 2p,,,,,,,
PMID32283299,reaction_1,Compound 2h,,,,,,,
PMID32283299,reaction_1,Compound 2o,,,,,,,
PMID32283299,reaction_1,Compound 2f,,,,,,,
PMID32283299,reaction_1,Compound 2j,,,,,,,
PMID32283299,reaction_1,Compound 2c,,,,,,,
PMID32296055,reaction_1,ATP,Allosteric,,,,,,
PMID32303871,reaction_1,2-Hydroxybiphenyl,Product feedback inhibition,,,,,,
PMID32303871,reaction_1,Dibenzothiophene,Substrate inhibition,,,,,,
PMID32307572,reaction_1,N-ethylmaleimide,Irreversible,,,,,,"Treatment with the thiol alkylating agent NEM led to a large decrease in Tst/Rho activity, confirming the essential role of a cysteine residue."
PMID32325762,reaction_2,Norflurazon,Inhibitor of PDS function,,,,,,
PMID32330361,reaction_1,"2,4-PDCA (1)",,,,,,,
PMID32330361,reaction_1,"2,3-PDCA (5)",,,,,,,
PMID32330361,reaction_1,"2,5-PDCA (6)",,,,,,,
PMID32330361,reaction_1,"2,6-PDCA (7)",,,,,,,
PMID32330361,reaction_1,Compound 8,,,,,,,
PMID32330361,reaction_1,Compound 9,,,,,,,
PMID32330361,reaction_1,Compound 10,,,,,,,
PMID32330361,reaction_1,Compound 11,,,,,,,
PMID32330361,reaction_1,Compound 12,,,,,,,
PMID32330361,reaction_1,Compound 13,,,,,,,
PMID32330361,reaction_1,Compound 14,,,,,,,
PMID32330361,reaction_1,Compound 15,,,,,,,
PMID32330361,reaction_1,Compound 16,,,,,,,
PMID32330361,reaction_1,Compound 17,,,,,,,
PMID32330361,reaction_1,Compound 18,,,,,,,
PMID32330361,reaction_1,Compound 25,,,,,,,
PMID32330361,reaction_1,Compound 26,,,,,,,
PMID32330361,reaction_1,Compound 29,,,,,,,
PMID32330361,reaction_1,Compound 30,,,,,,,
PMID32330361,reaction_1,Compound 31,,,,,,,
PMID32330361,reaction_1,Compound 32,,,,,,,
PMID32330361,reaction_2,"2,4-PDCA (1)",,,,,,,
PMID32330361,reaction_2,Compound 17,,,,,,,
PMID32330361,reaction_2,Compound 18,,,,,,,
PMID32330361,reaction_2,Compound 25,,,,,,,
PMID32330361,reaction_2,Compound 26,,,,,,,
PMID32330361,reaction_2,Compound 29,,,,,,,
PMID32330361,reaction_2,Compound 30,,,,,,,
PMID32330361,reaction_2,Compound 31,,,,,,,
PMID32330361,reaction_2,Compound 32,,,,,,,
PMID32330361,reaction_3,"2,4-PDCA (1)",,,,,,,
PMID32330361,reaction_3,Compound 17,,,,,,,
PMID32330361,reaction_3,Compound 18,,,,,,,
PMID32330361,reaction_3,Compound 25,,,,,,,
PMID32330361,reaction_3,Compound 26,,,,,,,
PMID32330361,reaction_3,Compound 29,,,,,,,
PMID32330361,reaction_3,Compound 30,,,,,,,
PMID32330361,reaction_3,Compound 31,,,,,,,
PMID32330361,reaction_3,Compound 32,,,,,,,
PMID32330361,reaction_4,"2,4-PDCA (1)",,,,,,,
PMID32330361,reaction_4,Compound 17,,,,,,,
PMID32330361,reaction_4,Compound 18,,,,,,,
PMID32330361,reaction_4,Compound 25,,,,,,,
PMID32330361,reaction_4,Compound 26,,,,,,,
PMID32330361,reaction_4,Compound 29,,,,,,,
PMID32330361,reaction_4,Compound 30,,,,,,,
PMID32330361,reaction_4,Compound 31,,,,,,,
PMID32330361,reaction_4,Compound 32,,,,,,,
PMID32330646,reaction_1,Allopurinol,Not specified,,,,,,
PMID32330646,reaction_1,Baicalein,Not specified,,,,,,
PMID32330646,reaction_1,Kaempferol,Not specified,,,,,,
PMID32330646,reaction_1,Luteolin,Not specified,,,,,,
PMID32330646,reaction_1,Quercetin,Not specified,,,,,,
PMID32330646,reaction_1,Isorhamnetin,"Mixed-type (competitive and noncompetitive), Reversible",,,,,,
PMID32330646,reaction_1,Kaempferide,"Mixed-type (competitive and noncompetitive), Reversible",,,,,,
PMID32330646,reaction_1,Hesperitin,"Mixed-type (competitive and noncompetitive), Reversible",,,,,,
PMID32330646,reaction_1,Epigallocatechin gallate,"Uncompetitive (anti-competitive), Reversible",,,,,,
PMID32330646,reaction_2,Isorhamnetin,Inhibition of superoxide formation,,,,,,
PMID32334266,reaction_1,Sunitinib (6),,,,,,,"Tested as a benchmark inhibitor, but its IC50 value from this specific assay was not reported in the text."
PMID32334266,reaction_1,Compound 16,,,,,,,40% inhibition at 20 µM
PMID32334266,reaction_1,Compound 12,,,,,,,Complete loss of activity observed.
PMID32334266,reaction_1,Compound 17,,,,,,,Complete loss of activity observed.
PMID32334266,reaction_1,Compound 19,,,,,,,Loss of activity observed.
PMID32334266,reaction_1,Compound 20,,,,,,,
PMID32334266,reaction_1,Compound 21,,,,,,,
PMID32334266,reaction_1,Compound 23,,,,,,,
PMID32334266,reaction_1,Compound 57,,,,,,,
PMID32334266,reaction_1,Compound 58,,,,,,,89% inhibition at 20 µM
PMID32334266,reaction_1,Compound 61,,,,,,,
PMID32334266,reaction_1,Compound 63,,,,,,,
PMID32334266,reaction_1,Compound 64,,,,,,,
PMID32334266,reaction_1,Compound 65,,,,,,,
PMID32334266,reaction_1,Compound 67,,,,,,,
PMID32334266,reaction_1,Compound 68,,,,,,,
PMID32334266,reaction_2,Sunitinib (6),,,,,,,"Tested as a benchmark inhibitor, but its IC50 value from this specific assay was not reported in the text."
PMID32334266,reaction_2,Compound 16,,,,,,,17% inhibition at 10 µM
PMID32334266,reaction_2,Compound 12,,,,,,,Complete loss of activity observed.
PMID32334266,reaction_2,Compound 17,,,,,,,Complete loss of activity observed.
PMID32334266,reaction_2,Compound 19,,,,,,,Loss of activity observed.
PMID32334266,reaction_2,Compound 20,,,,,,,
PMID32334266,reaction_2,Compound 21,,,,,,,
PMID32334266,reaction_2,Compound 23,,,,,,,
PMID32334266,reaction_2,Compound 55,,,,,,,
PMID32334266,reaction_2,Compound 57,,,,,,,
PMID32334266,reaction_2,Compound 58,,,,,,,88% inhibition at 10 µM
PMID32334266,reaction_2,Compound 61,,,,,,,
PMID32334266,reaction_2,Compound 63,,,,,,,
PMID32334266,reaction_2,Compound 64,,,,,,,
PMID32334266,reaction_2,Compound 65,,,,,,,
PMID32334266,reaction_2,Compound 67,,,,,,,
PMID32334266,reaction_2,Compound 68,,,,,,,
PMID32334266,reaction_3,Sunitinib (6),,,,,,,
PMID32334266,reaction_3,Compound 16,,,,,,,"At 5.00 µM, p-ACC level was 97.1% of control."
PMID32334266,reaction_3,Compound 65,,,,,,,"At 5.00 µM, p-ACC level was 23.7% of control. Showed significant reduction of p-ACC levels compared to sunitinib at multiple concentrations."
PMID32334266,reaction_3,Compound 66,,,,,,,"At 5.00 µM, p-ACC level was 34.1% of control."
PMID32334266,reaction_3,Compound 67,,,,,,,"At 5.00 µM, p-ACC level was 29.2% of control. Showed significant reduction of p-ACC levels compared to sunitinib at 3.125 µM and 12.5 µM."
PMID32334266,reaction_4,Sunitinib (6),,,,,,,"Tested as a benchmark inhibitor, but its IC50 value was not reported in the text."
PMID32334266,reaction_4,Compounds 19-23,,,,,,,Retained KDR binding potency similar to that of sunitinib.
PMID32334266,reaction_4,Compound 61,,,,,,,
PMID32334266,reaction_4,Compound 65,,,,,,,
PMID32334266,reaction_4,Compound 66,,,,,,,
PMID32334266,reaction_4,Compound 70,,,,,,,
PMID32334266,reaction_4,Compound 67,,,,,,,
PMID32334266,reaction_5,Sunitinib (6),,,,,,,Strongly inhibited (>90% inhibition at 100 nM).
PMID32334266,reaction_5,Compound 65,,,,,,,Greatly reduced binding compared to sunitinib at 100 nM.
PMID32334266,reaction_5,Compound 67,,,,,,,Greatly reduced binding compared to sunitinib at 100 nM.
PMID32334266,reaction_6,Sunitinib (6),,,,,,,Strongly inhibited (>90% inhibition at 100 nM).
PMID32334266,reaction_6,Compound 65,,,,,,,Greatly reduced binding compared to sunitinib at 100 nM.
PMID32334266,reaction_6,Compound 67,,,,,,,Greatly reduced binding compared to sunitinib at 100 nM.
PMID32334266,reaction_7,Sunitinib (6),,,,,,,Strongly inhibited (>90% inhibition at 100 nM).
PMID32334266,reaction_7,Compound 65,,,,,,,No observable effect at 100 nM.
PMID32334266,reaction_7,Compound 67,,,,,,,No observable effect at 100 nM.
PMID32334266,reaction_8,Sunitinib (6),,,,,,,Strongly inhibited (>90% inhibition at 100 nM).
PMID32334266,reaction_8,Compound 65,,,,,,,Reduced activity with respect to sunitinib at 100 nM.
PMID32334266,reaction_8,Compound 67,,,,,,,Reduced activity with respect to sunitinib at 100 nM.
PMID32335368,reaction_1,Sulfate,Competitive (with molybdate for transport system),,,,,,
PMID32335368,reaction_2,Sulfate,"Competitive (with molybdate for transport system, inferred)",,,,,,
PMID32335504,reaction_1,Quinoline-class inhibitors,Locks MsbA in an inward-facing wide-open conformation.,,,,,,
PMID32335504,reaction_1,Unspecified compound from phenotypic screen,Uncoupler; stimulates ATP hydrolysis while blocking LPS transport.,,,,,,
PMID32335504,reaction_2,Macrocyclic peptidomimetics,Binds to the β-jellyroll domains and blocks LPS transport.,,,,,,
PMID32335504,reaction_2,Thanatin,Binds to the β-jellyroll domains and blocks LPS transport.,,,,,,
PMID32335504,reaction_2,IMB-881,Binds to the β-jellyroll domains and blocks LPS transport.,,,,,,
PMID32335504,reaction_2,Novobiocin,Action mechanism in Gram-negative bacteria is undefined. Binds a functionally irrelevant site in LptB2FGC crystal structure.,,,,,,
PMID32340322,reaction_1,2-[(4-hydroxy-6-methylpyrimidin-2-yl)sulfanyl]-1-(naphthalen-1-yl)ethan-1-one (HMPSNE),Not specified,,,,,,
PMID32346138,reaction_1,GSK-J4,Not specified,,,,,,
PMID32353513,reaction_1,NADPH,Non-nucleoside inhibitor,,,,,,
PMID32353513,reaction_2,NADPH,Not specified,,,,,,
PMID32353513,reaction_3,NADPH,Not specified,,,,,,
PMID32353513,reaction_4,NADPH,Non-nucleoside inhibitor,,,,,"NADPH significantly decreased synthesis of the full-length product but did not act as a chain terminator, as no intermediate products were observed.",
PMID32367441,reaction_12,8-aminoguanine,Inhibition observed,,,,,,Abolished the reaction at 100 μmol/L.
PMID32367441,reaction_12,forodesine,Inhibition observed,,,,,,Abolished the reaction at 5 μmol/L.
PMID32367441,reaction_13,8-aminoguanine,Inhibition observed,,,,,,Abolished the reaction at 100 μmol/L.
PMID32367441,reaction_14,8-aminoguanine,Inhibition observed,,,,,,Abolished the reaction at 100 μmol/L.
PMID32367441,reaction_15,8-aminoguanine,Inhibition observed,,,,,,Abolished the reaction at 100 μmol/L.
PMID32367441,reaction_17,forodesine,Inhibition observed,,,,,,Blocked the increase in adenine levels at 5 μmol/L in perfusate.
PMID32368512,reaction_1,Cobalt nanoparticles (<50 nm),Not specified (Source: Wistar rat serum). Study reports activation.,,,,,,
PMID32368512,reaction_1,Cobalt nanoparticles (<50 nm),Not specified (Source: Wistar rat kidney). Study reports activation.,,,,,,
PMID32368512,reaction_1,Cobalt nanoparticles (<50 nm),Not specified (Source: Wistar rat liver). Study reports activation.,,,,,,
PMID32368512,reaction_2,Cobalt nanoparticles (<50 nm),Not specified (Source: Wistar rat serum). Study reports activation.,,,,,,
PMID32368512,reaction_2,Cobalt nanoparticles (<50 nm),Not specified (Source: Wistar rat kidney). Study reports activation.,,,,,,
PMID32368512,reaction_2,Cobalt nanoparticles (<50 nm),Not specified (Source: Wistar rat liver). Study reports activation.,,,,,,
PMID32373581,reaction_1,Glycosylated Triterpenoid Saponin,Non-competitive inhibition,,,,,,
PMID32373581,reaction_2,2'-F-c-di-GMP,Non-competitive inhibition binding to the DGC I-site,Nc1nc2c(ncn2C2OC3COP(=O)([O-])OC4C(COP(=O)([O-])OC3C2F)OC(n2cnc3c(=O)[nH]c(N)nc32)C4F)c(=O)[nH]1,,,,,
PMID32373581,reaction_2,Ebselen,Covalent modification of cysteine residues near the c-di-GMP binding pocket,O=c1c2ccccc2[se]n1-c1ccccc1,,,,,
PMID32373581,reaction_2,Sulfasalazine,Competitive inhibition of active site,O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O,,,,,
PMID32373581,reaction_2,Eprosartan,Competitive inhibition of active site,CCCCc1ncc(C=C(Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1,,,,,
PMID32373581,reaction_2,N-(4-anilinophenyl)benzamide,Unknown,O=C(Nc1ccc(Nc2ccccc2)cc1)c1ccccc1,,,,,
PMID32373581,reaction_2,LP3134,Competitive inhibition of active site,,,,,,
PMID32373581,reaction_3,c-di-inosinylic acid,Non-competitive inhibition binding to the DGC I-site,O=C1C=NC2=C(N1)N=CN2C3C(C(C(O3)COP(=O)(O)OC4C(C(C(O4)N5C=NC6=C(C5=O)N=CN6)O)O)O)O,,,,,
PMID32373581,reaction_4,DC1058,Non-competitive inhibition binding to the DGC I-site,,,,,,The PleD activity with 100 µM of DC1058 and 100 µM of GTP is ~32% of that without DC1058.
PMID32373581,reaction_4,Amb2250087,Competitive inhibition,O=[N+]([O-])c1cc(S(=O)(=O)N/N=C/c2ccc(O)c(O)c2O)ccc1Cl,,,,,
PMID32373581,reaction_4,Amb379455,Competitive inhibition,Cc1ccc(S(=O)(=O)N/N=C/c2ccc(O)c(O)c2)cc1[N+](=O)[O-],,,,,
PMID32373581,reaction_5,MANT-GTP,Competitive inhibition (probable),CNc1ccccc1C(=O)OC1C(OC)C(COP(=O)(O)OP(=O)(O)OP(=O)(O)O)OC1n1cnc2c(=O)[nH]c(N)nc21,,,,,
PMID32373581,reaction_5,MANT-GTPγS,Competitive inhibition (probable),CNc1ccccc1C(=O)OC1C(OC)C(COP(=O)(O)OP(=O)(O)OP(O)(O)=S)OC1n1cnc2c(=O)[nH]c(N)nc21,,,,,
PMID32373581,reaction_5,TNP-GTP,Competitive inhibition (probable),C1([N+](=O)[O-])=CC(=[N+]([O-])[O-])C=C([N+](=O)[O-])C12OC1C(COP(=O)(O)OP(=O)(O)OP(=O)(O)O)OC(n3cnc4c(=O)[nH]c(N)nc43)C1O2,,,,,
PMID32373581,reaction_5,Sulfasalazine,Competitive inhibition of active site,O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O,,,,,
PMID32373581,reaction_5,Eprosartan,Competitive inhibition of active site,CCCCc1ncc(C=C(Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1,,,,,
PMID32373581,reaction_6,Ebselen,Covalent modification of cysteine residues near the c-di-GMP binding pocket,O=c1c2ccccc2[se]n1-c1ccccc1,,,,,
PMID32373581,reaction_7,N-(4-anilinophenyl)benzamide,Unknown,O=C(Nc1ccc(Nc2ccccc2)cc1)c1ccccc1,,,,,
PMID32373581,reaction_8,"[2- oxo-2-(2-oxopyrrolidin-1-yl)ethyl] 1,3-benzothiazole-6-carboxylate",Non-competitive inhibition binding to the DGC I-site,O=C(OCC(=O)N1CCCC1=O)c1ccc2ncsc2c1,,,,,
PMID32373581,reaction_8,"4-(2,5-dimethylphenoxy)-N-(4-morpholin-4-ylphenyl)butanamide",Non-competitive inhibition binding to the DGC I-site,Cc1ccc(C)c(OCCCC(=O)Nc2ccc(N3CCOCC3)cc2)c1,,,,,
PMID32373581,reaction_9,LP3134,Competitive inhibition of active site,,,,,,"Showed significant inhibitory activity, but a specific IC50 value for tDGC was not provided in the text."
PMID32382667,reaction_1,Ca2+,Inhibitor,,,,,,
PMID32382667,reaction_1,Mn2+,Inhibitor,,,,,,
PMID32382667,reaction_1,EDTA,Inhibitor,,,,,,
PMID32382667,reaction_1,SDS,Inhibitor,,,,,,
PMID32382667,reaction_1,PMSF,Inhibitor,,,,,,
PMID32382667,reaction_1,unlabeled ATP,Competitive,,,,,,
PMID32393899,reaction_1,nordihydroguaiaretic acid,"Redox-type, active site inhibitor",,NDGA,,,,Concentration-dependently inhibited formation of 5-LOX products (0.1–10 µM in cell-free assay; 1 µM in HEK293 cells).
PMID32393899,reaction_1,3-acetyl-11-keto-beta-boswellic acid,"Allosteric, non-competitive inhibitor",,AKBA,,,,Concentration-dependently inhibited formation of 5-LOX products (10–50 µM in cell-free assay; 25 µM in HEK293 cells). IC50 values <10 µM cited from other studies.
PMID32393899,reaction_1,zileuton,Iron-ligand 5-LOX-selective inhibitor,,,,,,Used to confirm 5-LOX as the source of 12-HETE production. Combination with AKBA completely abolished 5-LOX activity.
PMID32399854,reaction_1,9a,,,,,,,
PMID32399854,reaction_1,9b,,,,,,,
PMID32399854,reaction_1,9c,,,,,,,
PMID32399854,reaction_1,9d,,,,,,,
PMID32399854,reaction_1,9e,,,,,,,
PMID32399854,reaction_1,9f,,,,,,,
PMID32399854,reaction_1,9g,,,,,,,
PMID32399854,reaction_1,9h,,,,,,,
PMID32399854,reaction_1,9i,,,,,,,
PMID32399854,reaction_1,9j,,,,,,,
PMID32399854,reaction_1,9k,Noncompetitive,,,,,,
PMID32399854,reaction_1,9l,,,,,,,
PMID32399854,reaction_1,Kojic acid,,,,,,,
PMID32428392,reaction_3,GRL-0617,Not specified,,,,,,
PMID32428392,reaction_3,compound 6,Not specified,,,,,,
PMID32428392,reaction_3,7724772,Not specified,,,,,,
PMID32428392,reaction_3,6577871,Not specified,,,,,,Maximum inhibition of 61% was reached.
PMID32428392,reaction_3,9247873,Not specified,,,,,,
PMID32432915,reaction_1,γ-butyrobetaine,Substrate inhibition,,,,,,"Substrate inhibition was observed at γ-butyrobetaine concentrations ≥ 0.6 mM. The inhibition characteristics (complete vs. partial) varied with animal age and tissue source. For liver, the rate constant for complete inhibition (K'/K) ranged from 0.18-0.57 mM and for partial inhibition (K'si) from 0.0002-0.28 mM. For kidney, K'/K ranged from 0.09-0.67 mM and K'si from 0.003-0.24 mM."
PMID32436380,reaction_1,L-Cysteine,Substrate inhibition,,,,,Enzyme activity was inhibited in the presence of >1.0 mM L-Cys.,
PMID32437808,reaction_1,Naringenin,Uncompetitive,,,,,,"Kinetic parameters were determined in the presence of varying concentrations of naringenin. At 1.0 µM: Km=1.12 µM, Vmax=0.065 µM/min. At 5.0 µM: Km=0.65 µM, Vmax=0.034 µM/min. At 10.0 µM: Km=0.46 µM, Vmax=0.023 µM/min."
PMID32457294,reaction_1_neddylation,MLN4924,"Inhibitor of NAE (NEDD8-activating enzyme E1, UBA3)",,,,,,
PMID32459092,reaction_1,PF-06928215,,,,,,,
PMID32459092,reaction_1,RU.521,,,,,,,
PMID32459092,reaction_1,Compound 18,,,,,,,
PMID32459092,reaction_1,Compound S2,,,,,,,
PMID32459092,reaction_1,Compound S3,,,,,,,
PMID32459092,reaction_1,Compound 3,,,,,,,39.9% inhibition at 100 µM. Binding confirmed by TSA (ΔTm = 2.50 °C) and crystallography (PDB: 6LRE).
PMID32459092,reaction_1,Compound 17,,,,,,,29.9% inhibition at 100 µM. Binding confirmed by TSA (ΔTm = 2.90 °C) and crystallography (PDB: 6LRI).
PMID32459092,reaction_1,Compound 23,,,,,,,21.8% inhibition at 100 µM. Binding confirmed by TSA (ΔTm = 1.77 °C) and crystallography (PDB: 6LRJ).
PMID32459092,reaction_1,Compound 40,,,,,,,16.8% inhibition at 100 µM. Binding confirmed by TSA (ΔTm = 1.14 °C) and crystallography (PDB: 6LRK).
PMID32459374,reaction_1_CaCYP51,5b,Type II binding,,,,,,
PMID32459374,reaction_1_CaCYP51,5c,Type II binding,,,,,,
PMID32459374,reaction_1_CaCYP51,5d,Type II binding,,,,,,
PMID32459374,reaction_1_CaCYP51,5e,Type II binding,,,,,,
PMID32459374,reaction_1_CaCYP51,5f,Type II binding,,,,,,
PMID32459374,reaction_1_CaCYP51,5g,Type II binding,,,,,,
PMID32459374,reaction_1_CaCYP51,5h,Type II binding,,,,,,
PMID32459374,reaction_1_CaCYP51,5i,Type II binding,,,,,,
PMID32459374,reaction_1_CaCYP51,5j,Type II binding,,,,,,
PMID32459374,reaction_1_CaCYP51,5k,Type II binding,,,,,,
PMID32459374,reaction_1_CaCYP51,7,Type II binding,,,,,,
PMID32459374,reaction_1_CaCYP51,12a,Type II binding,,,,,,
PMID32459374,reaction_1_CaCYP51,12b,Type II binding,,,,,,
PMID32459374,reaction_1_CaCYP51,12c,Type II binding,,,,,,
PMID32459374,reaction_1_CaCYP51,12d,Type II binding,,,,,,
PMID32459374,reaction_1_CaCYP51,Fluconazole,Type II binding,,,,,,
PMID32459374,reaction_1_CaCYP51,Posaconazole,Type II binding,,,,,,
PMID32459374,reaction_1_CaCYP51,Voriconazole,Type II binding,,,,,,
PMID32459374,reaction_1_CaCYP51,Itraconazole,Type II binding,,,,,,
PMID32459374,reaction_1_CaCYP51,Ketoconazole,Type II binding,,,,,,
PMID32459374,reaction_2_HsCYP51,5d,Type II binding,,,,,,
PMID32459374,reaction_2_HsCYP51,5f,Type II binding,,,,,,
PMID32459374,reaction_2_HsCYP51,12c,Type II binding,,,,,,
PMID32459374,reaction_2_HsCYP51,Fluconazole,Type II binding,,,,,,
PMID32459374,reaction_2_HsCYP51,Posaconazole,Type II binding,,,,,,
PMID32459374,reaction_2_HsCYP51,Voriconazole,Type II binding,,,,,,
PMID32459374,reaction_2_HsCYP51,Itraconazole,Type II binding,,,,,,
PMID32459374,reaction_2_HsCYP51,Ketoconazole,Type II binding,,,,,,
PMID32469443,reaction_1,HMP-15 (N-(1-benzylpiperidin-4-yl)-6-nitroquinazolin-4-amine),,,,,,,
PMID32469443,reaction_1,HMP-05 (N-carbamimidoyl-4-(6-nitroquinazolin-4-ylamino)benzenesulfonamide),,,,,,,
PMID32469443,reaction_1,HMP-14 (2-(2-(6-nitroquinazolin-4-ylamino)ethoxy)ethanol),,,,,,,
PMID32469443,reaction_1,"HMP-21 (N1-(6-nitroquinazolin-4-yl)benzene-1,2-diamine)",,,,,,,
PMID32469443,reaction_1,HMP-07 (N-(6-nitroquinazolin-4-yl)thiazol-2-amine),,,,,,,
PMID32469443,reaction_1,"HMP-10 (N-(6-nitroquinazolin-4-yl)-5-(trifluoromethyl)-1,3,4-thiadiazol-2-amine)",,,,,,,
PMID32469443,reaction_1,"HMP-23 (6-nitro-N-(3,4,5-trimethoxyphenyl)quinazolin-4-amine)",,,,,,,
PMID32469443,reaction_1,HMP-04 (N-(4-(6-nitroquinazolin-4-ylamino)phenylsulfonyl)acetamide),,,,,,,
PMID32485238,reaction_1,acetyl-CoA,Allosteric. Increases KM for L-malate. Sigmoidal inhibition curve (Hill coefficient = 1.9).,,,,,,
PMID32485238,reaction_1,CoASH,Slight inhibitor. Relieves acetyl-CoA inhibition. Sigmoidal binding curve (Hill coefficient = 2.2).,,,,,,
PMID32485238,reaction_2,acetyl-CoA,Strong inhibitor,,,,,,
PMID32485238,reaction_3,acetyl-CoA,Mixed. Increases apparent KM for L-malate and reduces Vmax. Hyperbolic inhibition curve.,,,,,,
PMID32485238,reaction_3,CoASH,Inhibitor. Effect is additive to acetyl-CoA inhibition.,,,,,,
PMID32496217,reaction_1,"2,4-diaminopyrimido[4,5-b]indol-6-ol (1)",Competitive,,,,,,
PMID32531315,reaction_1,4-hydroxybenzoic acid,Competitive,,,,,,
PMID32531315,reaction_1,formic acid,No inhibition observed up to 1.25 mM,,,,,,
PMID32534087,reaction_1,Cu2+,Complete inhibition,,,,,,
PMID32534087,reaction_1,Zn2+,Complete inhibition,,,,,,
PMID32534087,reaction_1,EDTA,Weak inhibition,,,,,,
PMID32534087,reaction_1,diethyldithiocarbamate,Weak inhibition,,,,,,
PMID32544743,reaction_1,Methylmercury chloride,"The study investigated the effect of chronic in vivo administration of MeHg (0.04 mg/kg/day for 60 days) on enzyme activity measured ex vivo. A significant decrease in neuropil reactivity was observed. The mechanism was not determined but suggested to be related to impaired synthesis or transport of the enzyme, or excitotoxicity.",,,,,,
PMID32546622,reaction_1,wortmannin,Not specified,,,,,Significantly inhibited phosphorylation of PI in a concentration-dependent manner (tested at 0.1 µM and 1 µM).,
PMID32546622,reaction_2,wortmannin,Not specified,,,,,"Significantly inhibited phosphorylation of PI(4,5)P2 in a concentration-dependent manner (tested at 0.1 µM and 1 µM).",
PMID32553892,reaction_1,L-(+)-tartrate,,,,,,,
PMID32553892,reaction_1,anthranilic acid,,,,,,,
PMID32553892,reaction_1,5-aminonicotinic acid,Competitive,,5-AN,,,,
PMID32553892,reaction_1,"pyrido[2,3-b]pyrazine-2,3(1H,4H)-dione",Competitive,,DPPD,,,,
PMID32556414,reaction_1,Cu2+,Complete inhibition,,,,,,
PMID32556414,reaction_1,Ag+,Complete inhibition,,,,,,
PMID32556414,reaction_1,Ni2+,Inhibition,,,,,,
PMID32556414,reaction_1,Zn2+,Inhibition,,,,,,
PMID32556414,reaction_1,Co2+,Inhibition,,,,,,
PMID32556414,reaction_1,KCl,Inhibition,,,,,,
PMID32556414,reaction_1,NaCl,Inhibition,,,,,,
PMID32556414,reaction_2,Cu2+,Complete inhibition,,,,,,
PMID32556414,reaction_2,Ag+,Complete inhibition,,,,,,
PMID32556414,reaction_2,Ni2+,Inhibition,,,,,,
PMID32556414,reaction_2,Zn2+,Inhibition,,,,,,
PMID32556414,reaction_2,Co2+,Inhibition,,,,,,
PMID32556414,reaction_2,KCl,Inhibition,,,,,,
PMID32556414,reaction_2,NaCl,Inhibition,,,,,,
PMID32556414,reaction_3,Cu2+,Complete inhibition,,,,,,
PMID32556414,reaction_3,Ag+,Complete inhibition,,,,,,
PMID32556414,reaction_3,Ni2+,Inhibition,,,,,,
PMID32556414,reaction_3,Zn2+,Inhibition,,,,,,
PMID32556414,reaction_3,Co2+,Inhibition,,,,,,
PMID32556414,reaction_3,KCl,Inhibition,,,,,,
PMID32556414,reaction_3,NaCl,Inhibition,,,,,,
PMID32556414,reaction_4,Cu2+,Complete inhibition,,,,,,
PMID32556414,reaction_4,Ag+,Complete inhibition,,,,,,
PMID32556414,reaction_4,Ni2+,Inhibition,,,,,,
PMID32556414,reaction_4,Zn2+,Inhibition,,,,,,
PMID32556414,reaction_4,Co2+,Inhibition,,,,,,
PMID32556414,reaction_4,KCl,Inhibition,,,,,,
PMID32556414,reaction_4,NaCl,Inhibition,,,,,,
PMID32556414,reaction_5,Cu2+,Complete inhibition,,,,,,
PMID32556414,reaction_5,Ag+,Complete inhibition,,,,,,
PMID32556414,reaction_5,Ni2+,Inhibition,,,,,,
PMID32556414,reaction_5,Zn2+,Inhibition,,,,,,
PMID32556414,reaction_5,Co2+,Inhibition,,,,,,
PMID32556414,reaction_5,KCl,Inhibition,,,,,,
PMID32556414,reaction_5,NaCl,Inhibition,,,,,,
PMID32556414,reaction_6,Cu2+,Complete inhibition,,,,,,
PMID32556414,reaction_6,Ag+,Complete inhibition,,,,,,
PMID32556414,reaction_6,Ni2+,Inhibition,,,,,,
PMID32556414,reaction_6,Zn2+,Inhibition,,,,,,
PMID32556414,reaction_6,Co2+,Inhibition,,,,,,
PMID32556414,reaction_6,KCl,Inhibition,,,,,,
PMID32556414,reaction_6,NaCl,Inhibition,,,,,,
PMID32556414,reaction_7,Cu2+,Complete inhibition,,,,,,
PMID32556414,reaction_7,Ag+,Complete inhibition,,,,,,
PMID32556414,reaction_7,Ni2+,Inhibition,,,,,,
PMID32556414,reaction_7,Zn2+,Inhibition,,,,,,
PMID32556414,reaction_7,Co2+,Inhibition,,,,,,
PMID32556414,reaction_7,KCl,Inhibition,,,,,,
PMID32556414,reaction_7,NaCl,Inhibition,,,,,,
PMID32556414,reaction_8,Cu2+,Complete inhibition,,,,,,
PMID32556414,reaction_8,Ag+,Complete inhibition,,,,,,
PMID32556414,reaction_8,Ni2+,Inhibition,,,,,,
PMID32556414,reaction_8,Zn2+,Inhibition,,,,,,
PMID32556414,reaction_8,Co2+,Inhibition,,,,,,
PMID32556414,reaction_8,KCl,Inhibition,,,,,,
PMID32556414,reaction_8,NaCl,Inhibition,,,,,,
PMID32565080,reaction_1,Ascochlorin,,,,,,,
PMID32565080,reaction_1,Ascofuranone,,,,,,,
PMID32565080,reaction_1,Colletochlorin B,,,,,,,
PMID32565080,reaction_1,Colletochlorin D,,,,,,,
PMID32565080,reaction_1,Octyl-gallate,,,,,,,
PMID32565080,reaction_1,Salicylic hydroxamic acid,,,,,,,
PMID32569353,reaction_1,α-methyl-L-tyrosine,Mixed type,,,,,,
PMID32569353,reaction_1,N-methyl-L-tyrosine,Non-competitive,,,,,,
PMID32579353,reaction_1,O2,,,,,,Activity of Y'227C variant is reduced from 40 s⁻¹ (N2) to 7 s⁻¹ in air (20% O2).,
PMID32579353,reaction_1,H2,Product inhibition,,,,,Relieving H2 in headspace increases the reaction rate.,
PMID32580556,reaction_3,Sulfathiazole,Competitive with pABA,,,,,,
PMID32591507,reaction_2,Difluoromethylornithine,Irreversible inhibitor,,DFMO,,,,
PMID32591507,reaction_2,JQ1,Inhibitor,,,,,"JQ1 treatment significantly inhibited ODC activity, likely through repression of MYC which regulates ODC expression.",
PMID32591507,reaction_3,Spermidine,Direct inhibitor,,,,,,
PMID32601391,reaction_3,Hypotaurine,Slight inhibition,,,,,,
PMID32601391,reaction_3,L-Cysteine sulfinic acid,Strong inhibition,,,,,,
PMID32601857,reaction_1,DTT,Not specified,,,,,,Relative activity was 44.16% at 0.05 mM and 59.44% at 0.1 mM.
PMID32601857,reaction_1,EDTA,Not specified,,,,,,Relative activity was 11.16% at 5 mM and 35.12% at 10 mM.
PMID32601857,reaction_1,Sodium azide,Not specified,,,,,,Relative activity was 36.11% at 0.5 mM and 62.22% at 1 mM.
PMID32601857,reaction_1,Zn+2,Not specified,,,,,,Relative activity was 88% at 1 mM and 34% at 3 mM.
PMID32601857,reaction_1,Hg+2,Not specified,,,,,,Relative activity was 56% at 1 mM and 5% at 3 mM.
PMID32608439,reaction_3,dicoumarol,Inhibitor (type not specified),,,,,,
PMID32621793,reaction_1,Triton X-100,Uncompetitive,,,,,,
PMID32621793,reaction_2,Triton X-100,Uncompetitive,,,,,,
PMID32632475,reaction_2,Lanthanum chloride (LaCl3),"Indirect inhibition. LaCl3 (5 mM) acts as a plasma membrane Ca2+ channel blocker, which reduces intracellular Ca2+ and subsequently decreases enzyme expression/secretion, leading to significantly decreased CMCase activity.",,,,,,
PMID32632475,reaction_3,Lanthanum chloride (LaCl3),"Indirect inhibition. LaCl3 (5 mM) acts as a plasma membrane Ca2+ channel blocker, which reduces intracellular Ca2+ and subsequently decreases enzyme expression/secretion, leading to significantly decreased pNPGase activity.",,,,,,
PMID32634742,reaction_1,Nutlin-3a,No inhibition observed,,,,,,Nutlin-3a did not affect the enzymatic activity of recombinant PGAM in vitro (Figure S8C).
PMID32645646,reaction_1,3a (RTC1),,,,,,,
PMID32645646,reaction_1,3i,,,,,,,
PMID32645646,reaction_1,7a,,,,,,,
PMID32645646,reaction_1,9d,,,,,,,
PMID32645646,reaction_1,9f,,,,,,,
PMID32645646,reaction_1,16c,,,,,,,
PMID32645646,reaction_1,3b,,,,,,,
PMID32645646,reaction_1,3e,,,,,,,
PMID32645646,reaction_1,5e,,,,,,,
PMID32645646,reaction_1,7c,,,,,,,
PMID32645646,reaction_1,17,,,,,,,
PMID32645646,reaction_1,rotenone,Known inhibitor used for assay specificity confirmation,,,,,,
PMID32645646,reaction_2,3a (RTC1),,,,,,,
PMID32645646,reaction_3,3a (RTC1),,,,,,,
PMID32645646,reaction_4,3a (RTC1),,,,,,,
PMID32645646,reaction_5,3a (RTC1),,,,,,,
PMID32645646,reaction_6,3a (RTC1),,,,,,,
PMID32653636,reaction_1,Phenylpyruvic acid,No inhibition observed up to 5.0 mM,,,,,,
PMID32653636,reaction_1,L-phenylalanine,No substrate inhibition observed up to 40 mM,,,,,,
PMID32668380,reaction_1,δ-Garcinoic acid (1),,,,,,,
PMID32668380,reaction_1,α-Garcinoic acid (2),,,,,,,
PMID32668380,reaction_1,β-Garcinoic acid (3),,,,,,,
PMID32668380,reaction_1,Garcinamide 4,,,,,,,
PMID32668380,reaction_1,Garcinamide 5,,,,,,,
PMID32668380,reaction_1,Garcinamide 6,,,,,,,
PMID32668380,reaction_1,Garcinamide 7,,,,,,,
PMID32668380,reaction_1,Garcinamide 8,,,,,,,
PMID32668380,reaction_1,Garcinamide 9,,,,,,,
PMID32668380,reaction_1,Garcinamide 10,,,,,,,
PMID32668380,reaction_1,Garcinamide 11,,,,,,,
PMID32668380,reaction_1,Garcinamide 12,,,,,,,
PMID32668380,reaction_1,Garcinamide 15,,,,,,,
PMID32668380,reaction_1,Garcinamide 16,,,,,,,
PMID32668380,reaction_1,Garcinamide 17,,,,,,,
PMID32668380,reaction_1,Garcinamide 18,,,,,,,
PMID32668380,reaction_1,Garcinamide 19,,,,,,,
PMID32668380,reaction_1,Garcinamide 20,,,,,,,
PMID32668380,reaction_1,Garcinamide 21,,,,,,,
PMID32668380,reaction_1,Garcinamide 22,,,,,,,
PMID32668380,reaction_1,Garcinamide 23,,,,,,,
PMID32668380,reaction_1,Garcinamide 24,,,,,,,
PMID32668380,reaction_1,Garcinamide 25,,,,,,,
PMID32668380,reaction_1,Zileuton,,,,,,,
PMID32668380,reaction_2,δ-Garcinoic acid (1),,,,,,,
PMID32668380,reaction_2,α-Garcinoic acid (2),,,,,,,
PMID32668380,reaction_2,β-Garcinoic acid (3),,,,,,,
PMID32668380,reaction_2,Garcinamide 4,,,,,,,
PMID32668380,reaction_2,Garcinamide 5,,,,,,,
PMID32668380,reaction_2,Garcinamide 6,,,,,,,
PMID32668380,reaction_2,Garcinamide 9,,,,,,,
PMID32668380,reaction_2,Garcinamide 10,,,,,,,
PMID32668380,reaction_2,Garcinamide 12,,,,,,,
PMID32668380,reaction_2,Garcinamide 14,,,,,,,
PMID32668380,reaction_2,Garcinamide 16,,,,,,,
PMID32668380,reaction_2,Garcinamide 17,,,,,,,
PMID32668380,reaction_2,Garcinamide 20,,,,,,,
PMID32668380,reaction_2,Garcinamide 21,,,,,,,
PMID32668380,reaction_2,Garcinamide 22,,,,,,,
PMID32668380,reaction_2,Garcinamide 24,,,,,,,
PMID32668380,reaction_2,Garcinamide 25,,,,,,,
PMID32668380,reaction_2,Garcinamide 26,,,,,,,
PMID32668380,reaction_2,Zileuton,,,,,,,
PMID32671046,reaction_1,Hypoxanthine,Substrate inhibition,,,,,,
PMID32685828,reaction_2,darunavir,Protease inhibitor (used to quench reaction),,,,,,
PMID32686865,reaction_2,DAPT,γ-secretase inhibitor,,,,,,
PMID32688200,reaction_1,Compound 7,,,,,,,
PMID32688200,reaction_1,Compound 14a,,,,,,,
PMID32688200,reaction_1,Compound 14b,,,,,,,
PMID32688200,reaction_1,Compound 14c,,,,,,,
PMID32688200,reaction_1,Compound 14d,,,,,,,
PMID32688200,reaction_1,Compound 14e,,,,,,,
PMID32688200,reaction_1,Compound 14f,,,,,,,
PMID32688200,reaction_1,Compound 14g,,,,,,,
PMID32688200,reaction_1,Compound 14h,,,,,,,
PMID32688200,reaction_1,Compound 14i,,,,,,,
PMID32688200,reaction_1,Compound 14j,,,,,,,
PMID32688200,reaction_1,Compound 14k,,,,,,,
PMID32688200,reaction_1,Compound 14l,,,,,,,
PMID32688200,reaction_1,Compound 14m,,,,,,,
PMID32688200,reaction_1,Compound 14n,,,,,,,
PMID32688200,reaction_1,Compound 20a,,,,,,,
PMID32688200,reaction_1,Compound 20b,,,,,,,
PMID32688200,reaction_1,Compound 20c,,,,,,,
PMID32688200,reaction_1,Compound 20d,,,,,,,
PMID32688200,reaction_1,Compound 20e,,,,,,,
PMID32688200,reaction_1,Compound 20f,,,,,,,
PMID32688200,reaction_1,Compound 20g,,,,,,,
PMID32688200,reaction_1,Compound 20h,,,,,,,
PMID32688200,reaction_1,Compound 20i,,,,,,,
PMID32688200,reaction_1,Compound 20j,,,,,,,
PMID32688200,reaction_1,Compound 20k,,,,,,,
PMID32688200,reaction_2,Compound 7,,,,,,,
PMID32688200,reaction_2,Compound 14a,,,,,,,
PMID32688200,reaction_2,Compound 14b,,,,,,,
PMID32688200,reaction_2,Compound 14c,,,,,,,
PMID32688200,reaction_2,Compound 14d,,,,,,,
PMID32688200,reaction_2,Compound 14e,,,,,,,
PMID32688200,reaction_2,Compound 14f,,,,,,,
PMID32688200,reaction_2,Compound 14g,,,,,,,
PMID32688200,reaction_2,Compound 14h,,,,,,,
PMID32688200,reaction_2,Compound 14i,,,,,,,
PMID32688200,reaction_2,Compound 14j,,,,,,,
PMID32688200,reaction_2,Compound 14k,,,,,,,
PMID32688200,reaction_2,Compound 14l,,,,,,,
PMID32688200,reaction_2,Compound 14m,,,,,,,
PMID32688200,reaction_2,Compound 14n,,,,,,,
PMID32688200,reaction_2,Compound 20a,,,,,,,
PMID32688200,reaction_2,Compound 20b,,,,,,,
PMID32688200,reaction_2,Compound 20c,,,,,,,
PMID32688200,reaction_2,Compound 20d,,,,,,,
PMID32688200,reaction_2,Compound 20e,,,,,,,
PMID32688200,reaction_2,Compound 20f,,,,,,,
PMID32688200,reaction_2,Compound 20g,,,,,,,
PMID32688200,reaction_2,Compound 20h,,,,,,,
PMID32688200,reaction_2,Compound 20i,,,,,,,
PMID32688200,reaction_2,Compound 20j,,,,,,,
PMID32688200,reaction_2,Compound 20k,,,,,,,
PMID32714915,reaction_1_free_enzyme,UTP,Substrate inhibition,,,,,,
PMID32714915,reaction_1_free_enzyme,EDTA,Chelation of Mg2+,,,,,50 mM EDTA decreased activity to 1% residual conversion.,
PMID32714915,reaction_2_immobilized_enzyme,UTP,Substrate inhibition,,,,,,
PMID32716961,reaction_9,MG132,Proteasome inhibitor,,,,,,
PMID32717224,reaction_1,diethylaminobenzaldehyde,"Time-dependent, reversible inhibition (slow, tight-binding or covalent reversible).",,,,,,
PMID32730563,reaction_1,benzoate,Competitive,,,,,,
PMID32730563,reaction_2,benzoate,Competitive,,,,,,
PMID32730563,reaction_3,benzoate,Competitive,,,,,,
PMID32731629,reaction_1a,Apoferritin,Mixed,,,,,,
PMID32731629,reaction_1a,Apoferritin-silver nanoparticles,Mixed,,,,,,
PMID32731629,reaction_1a,Apoferritin-gold nanoparticles,Mixed,,,,,,
PMID32731629,reaction_1a,Apoferritin-platinum nanoparticles,Mixed,,,,,,
PMID32731629,reaction_1b,Apoferritin,Mixed,,,,,,
PMID32731629,reaction_1b,Apoferritin-silver nanoparticles,Mixed,,,,,,
PMID32731629,reaction_1b,Apoferritin-gold nanoparticles,Mixed,,,,,,
PMID32731629,reaction_1b,Apoferritin-platinum nanoparticles,Mixed,,,,,,
PMID32732027,reaction_1,Cu2+,,,,,,,Nearly eliminated the enzymatic activity at 10 mM concentration.
PMID32732027,reaction_1,Ca2+,,,,,,,Considerably decreased activity at 10 mM concentration.
PMID32732027,reaction_1,Ba2+,,,,,,,Considerably decreased activity at 10 mM concentration.
PMID32732027,reaction_1,Ni2+,,,,,,,Considerably decreased activity at 10 mM concentration.
PMID32732027,reaction_1,EDTA,,,,,,,"Inhibited activity, likely by chelating Mg2+."
PMID32732035,reaction_1,(-)-Camphor,Competitive,,,,,,
PMID32732035,reaction_2,(-)-Camphor,Competitive,,,,,,
PMID32732035,reaction_3,(+)-Camphor,Competitive,,,,,,
PMID32732035,reaction_4,(+)-Camphor,Competitive,,,,,,
PMID32732043,reaction_1,Cu2+,Not specified,,,,,,
PMID32732043,reaction_1,Zn2+,Not specified,,,,,,
PMID32732043,reaction_1,Hg2+,Not specified,,,,,,
PMID32735861,reaction_2,HQNO,,,,,,100% inhibition at 10µM,
PMID32735861,reaction_2,Antimycin A,,,,,,55% inhibition at 27µM,
PMID32735861,reaction_5,HQNO,,,,,,Completely inhibited by 10µM HQNO,
PMID32735861,reaction_5,KCN,,,,,,90% inhibition at 2mM; 47% inhibition at 500µM,
PMID32735861,reaction_6,HQNO,,,,,,Completely inhibited by 40µM HQNO,
PMID32738969,reaction_1,Jujubogenin,Not specified,,,,,,"Decreased CK-MM activity by 16.9% at 5 μM, 11.9% at 10 μM, and 5.7% at 40 μM. SMILES: [C@H]1(O)CC[C@@]2(C)[C@@H](CC[C@]3(C)[C@@H]2CC[C@H]2[C@H]4[C@@](C)(O)C[C@H](C=C(C)C)O[C@]45C[C@]23CO5)C1(C)C"
PMID32744783,reaction_1,N00,"Conformation-specific nanobody that blocks the opening of the periplasmic side, stabilizing an inward-open conformation.",,,,,,
PMID32745463,reaction_1,N-hydroxy-N-isopropyloxamate,"Slow, tight-binding, competitive",,,,,,
PMID32745463,reaction_1,"cyclopropane-1,1-dicarboxylate","Reversible, competitive",,,,,,
PMID32745463,reaction_1,2-methylphosphinoyl-2-hydroxyacetic acid,"Reversible, competitive",,,,,,
PMID32745463,reaction_3,N-hydroxy-N-isopropyloxamate,"Irreversible, slow-binding",,,,,,
PMID32745463,reaction_3,"cyclopropane-1,1-dicarboxylate","Reversible, competitive",,,,,,
PMID32745463,reaction_3,2-methylphosphinoyl-2-hydroxyacetic acid,"Reversible, competitive",,,,,,
PMID32745735,reaction_1,Compound 14,,,,,,,
PMID32745735,reaction_1,Compound 19,,,,,,,
PMID32745735,reaction_1,Compound 20,,,,,,,
PMID32745735,reaction_1,Compound 21,,,,,,,
PMID32745735,reaction_1,Compound 22,,,,,,,
PMID32745735,reaction_1,Compound 23,,,,,,,
PMID32745735,reaction_1,Compound 24,,,,,,,
PMID32745735,reaction_1,Compound 25,,,,,,,
PMID32745735,reaction_1,Compound 26,,,,,,,
PMID32745735,reaction_1,Compound 27,,,,,,,
PMID32745735,reaction_1,Compound 28,,,,,,,
PMID32745735,reaction_1,Compound 29,,,,,,,
PMID32745735,reaction_1,Compound 30,,,,,,,
PMID32745735,reaction_1,Compound 31,,,,,,,
PMID32745735,reaction_1,Compound 32,,,,,,,
PMID32745735,reaction_1,Compound 33,,,,,,,
PMID32745735,reaction_1,Compound 34,,,,,,,
PMID32748014,reaction_1,Proline,Feedback inhibition,,,,,,
PMID32752273,reaction_1,3-oxo-C12-HSL,Non-inhibitory,,,,,,Tested at 5 µM. Did not significantly affect GLuc bioluminescence.
PMID32752273,reaction_1,C12-TMA,Non-inhibitory,,,,,,Tested at 5 µM. Did not significantly affect GLuc bioluminescence.
PMID32752273,reaction_1,C12-TOA,Non-inhibitory,,,,,,Tested at 5 µM. Was not shown to significantly decrease GLuc bioluminescence.
PMID32762529,reaction_1,Kojic acid,Standard inhibitor,,,,,,
PMID32762529,reaction_1,BT1,,,,,,,
PMID32762529,reaction_1,BT2,Non-competitive,,,,,,
PMID32762529,reaction_1,BT3,,,,,,,
PMID32762529,reaction_1,BT4,,,,,,,
PMID32762529,reaction_1,BT5,,,,,,,
PMID32762529,reaction_1,BT6,,,,,,,
PMID32762529,reaction_1,BT7,,,,,,,
PMID32762529,reaction_1,BT8,,,,,,,
PMID32762529,reaction_1,BT9,,,,,,,
PMID32764148,reaction_1,Apilimod,Not specified,,,,,,
PMID32764148,reaction_1,Vacuolin-1,Not specified,,,,,,
PMID32764148,reaction_1,YM201636,Not specified,,,,,,
PMID32764148,reaction_1,WX8,Not specified,,,,,,
PMID32768460,reaction_1,DMIP 1,Competitive,,,,,,
PMID32768460,reaction_1,DMIP 7,Competitive,,,,,,
PMID32768460,reaction_1,DMIP 8,Competitive,,,,,,
PMID32768460,reaction_2,DMIP 1,Competitive,,,,,,
PMID32768460,reaction_2,DMIP 7,Competitive,,,,,,
PMID32768460,reaction_2,DMIP 8,Competitive,,,,,,
PMID32775880,reaction_1,2-methyl-aspartic acid,Competitive,,,,,,
PMID32786824,reaction_1,Mn2+,Moderate inhibition at 1.0 mM,,,,,,
PMID32786824,reaction_1,Al3+,Moderate inhibition at 1.0 mM,,,,,,
PMID32786824,reaction_1,Ni2+,Moderate inhibition at 1.0 mM,,,,,,
PMID32786824,reaction_1,Co2+,Moderate inhibition at 1.0 mM,,,,,,
PMID32786824,reaction_1,EDTA,Moderate inhibition at 5.0 mM,,,,,,
PMID32786824,reaction_1,Ag+,Severe inhibition at 1.0 mM,,,,,,
PMID32786824,reaction_1,Hg2+,Severe inhibition at 1.0 mM,,,,,,
PMID32786824,reaction_1,Zn2+,Severe inhibition at 1.0 mM,,,,,,
PMID32786824,reaction_1,Cd2+,Severe inhibition at 1.0 mM,,,,,,
PMID32786824,reaction_2,Mn2+,Moderate inhibition at 1.0 mM,,,,,,
PMID32786824,reaction_2,Al3+,Moderate inhibition at 1.0 mM,,,,,,
PMID32786824,reaction_2,Ni2+,Moderate inhibition at 1.0 mM,,,,,,
PMID32786824,reaction_2,Co2+,Moderate inhibition at 1.0 mM,,,,,,
PMID32786824,reaction_2,EDTA,Moderate inhibition at 5.0 mM,,,,,,
PMID32786824,reaction_2,Ag+,Severe inhibition at 1.0 mM,,,,,,
PMID32786824,reaction_2,Hg2+,Severe inhibition at 1.0 mM,,,,,,
PMID32786824,reaction_2,Zn2+,Severe inhibition at 1.0 mM,,,,,,
PMID32786824,reaction_2,Cd2+,Severe inhibition at 1.0 mM,,,,,,
PMID32786824,reaction_3,Mn2+,Moderate inhibition at 1.0 mM,,,,,,
PMID32786824,reaction_3,Al3+,Moderate inhibition at 1.0 mM,,,,,,
PMID32786824,reaction_3,Ni2+,Moderate inhibition at 1.0 mM,,,,,,
PMID32786824,reaction_3,Co2+,Moderate inhibition at 1.0 mM,,,,,,
PMID32786824,reaction_3,EDTA,Moderate inhibition at 5.0 mM,,,,,,
PMID32786824,reaction_3,Ag+,Severe inhibition at 1.0 mM,,,,,,
PMID32786824,reaction_3,Hg2+,Severe inhibition at 1.0 mM,,,,,,
PMID32786824,reaction_3,Zn2+,Severe inhibition at 1.0 mM,,,,,,
PMID32786824,reaction_3,Cd2+,Severe inhibition at 1.0 mM,,,,,,
PMID32786824,reaction_4,Mn2+,Moderate inhibition at 1.0 mM,,,,,,
PMID32786824,reaction_4,Al3+,Moderate inhibition at 1.0 mM,,,,,,
PMID32786824,reaction_4,Ni2+,Moderate inhibition at 1.0 mM,,,,,,
PMID32786824,reaction_4,Co2+,Moderate inhibition at 1.0 mM,,,,,,
PMID32786824,reaction_4,EDTA,Moderate inhibition at 5.0 mM,,,,,,
PMID32786824,reaction_4,Ag+,Severe inhibition at 1.0 mM,,,,,,
PMID32786824,reaction_4,Hg2+,Severe inhibition at 1.0 mM,,,,,,
PMID32786824,reaction_4,Zn2+,Severe inhibition at 1.0 mM,,,,,,
PMID32786824,reaction_4,Cd2+,Severe inhibition at 1.0 mM,,,,,,
PMID32786835,reaction_1,Zn2+,,,,,,,Inhibitory effect observed at 1 mM
PMID32786835,reaction_1,Ca2+,,,,,,,Inhibitory effect observed at 1 mM
PMID32786835,reaction_1,Mn2+,,,,,,,Inhibitory effect observed at 1 mM
PMID32786835,reaction_1,Cu2+,,,,,,,Inhibitory effect observed at 1 mM
PMID32786835,reaction_1,Ni2+,,,,,,,Inhibitory effect observed at 1 mM
PMID32786835,reaction_1,Fe3+,,,,,,,Inhibitory effect observed at 1 mM
PMID32786835,reaction_1,NH4+,,,,,,,Inhibitory effect observed at 1 mM
PMID32786835,reaction_5,Mg2+,,,,,,,Significantly inhibited KsdD5 activity at 1 mM
PMID32792488,reaction_2,ML226,Covalent,,,,,,ML226 treatment inhibited ABHD11 p-nitrophenyl ester hydrolysis in vitro in a dose-dependent manner.
PMID32797038,reaction_1,C3,,,,,,,
PMID32797038,reaction_1,C5,,,,,,,
PMID32797038,reaction_1,C6,,,,,,,
PMID32797038,reaction_1,C9,,,,,,,"Inhibitory effect observed (56±6 % residual activity at 250 µM), but IC50 not determined."
PMID32797038,reaction_1,C18,,,,,,,
PMID32797038,reaction_1,C26,,,,,,,"Inhibitory effect observed (72±6 % residual activity at 250 µM), but IC50 not determined."
PMID32805427,reaction_1,L-Arginine,Feedback inhibition,,,,,,Activity drastically decreased with 0.2 mM L-Arginine and was almost completely lost at 1.0 mM L-Arginine.
PMID32805427,reaction_1,L-Ornithine,,,,,,,No inhibition observed at 10 mM.
PMID32805427,reaction_1,L-Citrulline,,,,,,,No inhibition observed at 10 mM.
PMID32819558,reaction_1,Tiron,"Tiron, a superoxide scavenger, completely blocked the LY83583-induced increase in pepsin-resistant collagen, indicating the reaction is dependent on superoxide.",,,,,,
PMID32823946,reaction_1,Low pH,Conditional inhibition by environmental factor,,,,,"Kinase activity is inhibited at acidic pH (e.g., pH 6.0). The proposed mechanism involves protonation of glutamate residues in the linker region, leading to helix destabilization and interruption of signaling.",
PMID32827973,reaction_1,Mn2+,,,,,,,
PMID32827973,reaction_1,Mg2+,,,,,,,
PMID32827973,reaction_1,K+,,,,,,,
PMID32827973,reaction_1,NH4+,,,,,,,
PMID32827973,reaction_1,Ca2+,,,,,,,
PMID32827973,reaction_1,Fe3+,,,,,,,
PMID32827973,reaction_1,Na+,,,,,,,
PMID32827973,reaction_1,Hg2+,,,,,,,
PMID32827973,reaction_1,Cd2+,,,,,,,
PMID32827973,reaction_1,Ag2+,,,,,,,
PMID32827973,reaction_1,chloroform,,,,,,,
PMID32827973,reaction_1,acetonitrile,,,,,,,
PMID32827973,reaction_1,butanol,,,,,,,
PMID32827973,reaction_1,ethanol,,,,,,,
PMID32827973,reaction_1,methanol,,,,,,,
PMID32827973,reaction_1,DMSO,,,,,,,
PMID32827973,reaction_1,isopropanol,,,,,,,
PMID32827973,reaction_1,ethyl acetate,,,,,,,
PMID32827973,reaction_1,octanol,,,,,,,
PMID32827973,reaction_1,n-propanol,,,,,,,
PMID32844401,reaction_1,H2O2,Substrate inhibition of Compound I intermediate,,,,,,
PMID32844401,reaction_1,4-ethylbenzoic acid,Substrate inhibition of resting state enzyme,,,,,,
PMID32851826,reaction_1,Iodide,Binds to the CuI-CuIV edge of the CuZ center,,,,,,
PMID32866191,reaction_1,sodium orthovanadate,Specific inhibitor of P-type H+-ATPase,,,,,Used at 100 μM in assays to differentiate P-type ATPase activity from other ATPases.,
PMID32869889,reaction_1,reduced glutathione,Non-competitive with catechol as substrate; anti-competitive with 4-methylcatechol as substrate,,,,,,
PMID32869889,reaction_1,Ascorbic acid,,,,,,,
PMID32869889,reaction_1,L-cysteine,,,,,,,
PMID32869889,reaction_1,Citric acid,,,,,,,
PMID32869889,reaction_8,Ascorbic acid,Mixed-type with chlorogenic acid as substrate; competitive with catechol as substrate,,,,,,
PMID32869889,reaction_8,L-cysteine,,,,,,,
PMID32869889,reaction_8,reduced glutathione,,,,,,,
PMID32869889,reaction_8,Citric acid,,,,,,,
PMID32869889,reaction_15,L-cysteine,Non-competitive with catechol and chlorogenic acid as substrates,,,,,,
PMID32869889,reaction_15,Ascorbic acid,,,,,,,
PMID32869889,reaction_15,reduced glutathione,,,,,,,
PMID32869889,reaction_15,Citric acid,,,,,,,
PMID32885332,reaction_2,Cu2+,Inhibition observed,,,,,,
PMID32886480,reaction_1,ALS-8112-TP,,,,,,,A CTP analog. IC50 values determined in filtration plate and SPA assays correlated well (within 3-fold). Specific IC50 value not provided.
PMID32886480,reaction_1,non-nucleoside inhibitor,,,,,,,IC50 values determined in filtration plate and SPA assays correlated well (within 3-fold). Specific IC50 value not provided.
PMID32900992,reaction_3,T863,Pharmacological inhibition,,,,,,
PMID32900992,reaction_4,avasimibe,Pharmacological inhibition,,,,,,
PMID32900992,reaction_5,Atglistatin,Pharmacological inhibition,,,,,,
PMID32905773,reaction_2,oxamate,Not specified,,,,,,Inhibition by oxamate reduced intracellular ATP levels by 30% in day-0 cells and ~60% in day-7 osteoblasts. The text also notes that oxamate may inhibit aspartate aminotransferase.
PMID32905773,reaction_3,UK-5099,Not specified,,,,,,Inhibition of pyruvate entry to the mitochondria by UK-5099 did not have any effect on the steady-state ATP levels.
PMID32905773,reaction_4,oligomycin,Not specified,,,,,,Inhibition of mitochondrial ATP production by oligomycin did not have any effect on the steady-state ATP levels.
PMID32905773,reaction_5,aminooxyacetate (AOA),Not specified,,,,,,"AOA dose dependently reduced glucose consumption in day-4 and day-7 cells, indicating the importance of the malate-aspartate shuttle."
PMID32905773,reaction_6,2-deoxy-glucose (2-DG),Not specified,,,,,,"Inhibition by 2-DG abruptly reduced steady-state ATP levels by 56% (day-0), 63% (day-4), and 75% (day-7) within 30 minutes."
PMID32905773,reaction_7,BPTES,Not specified,,,,,,Inhibition of glutamine consumption by BPTES had no consistent effect on ATP levels.
PMID32905773,reaction_8,etomoxir,Not specified,,,,,,Inhibition of fatty acid consumption by etomoxir had no consistent effect on ATP levels.
PMID32911631,reaction_1,anti-Fd antibody,Not specified,,,,,,Significantly inhibited cyclase activity in assays with barley plastid fractions (p < 0.001).
PMID32911631,reaction_1,anti-FNR antibody,Not specified,,,,,,Significantly inhibited cyclase activity in assays with barley plastid fractions (p < 0.001).
PMID32913059,reaction_2,Hydroxylamine,Competitive,,,,,,
PMID32915249,reaction_1,MK-571,The inhibitor (50 µM) reduced the efflux ratio (ER) from 9.51 to 2.87. The apparent permeability coefficient for apical-to-basolateral transport (PappA-B) was reduced from 0.0378 cm/s to 0.0102 cm/s.,,,,,,
PMID32919113,reaction_1,21a,Not specified,,,,,,
PMID32919113,reaction_1,21c,Not specified,,,,,,
PMID32919113,reaction_1,21e,Not specified,,,,,,
PMID32919113,reaction_1,21g,Not specified,,,,,,
PMID32919113,reaction_1,25b,Not specified,,,,,,
PMID32919113,reaction_1,25c,Not specified,,,,,,
PMID32919113,reaction_1,25d,Not specified,,,,,,
PMID32919113,reaction_1,25e,Not specified,,,,,,
PMID32919113,reaction_1,25f,Not specified,,,,,,
PMID32919113,reaction_1,25g,Not specified,,,,,,
PMID32919113,reaction_1,25h,Not specified,,,,,,
PMID32919113,reaction_1,29a,Not specified,,,,,,
PMID32919113,reaction_1,29b,Not specified,,,,,,
PMID32919113,reaction_1,29c,Not specified,,,,,,
PMID32919113,reaction_1,Compound 13,Not specified,,,,,,
PMID32930481,reaction_1,2a,,,,,,,
PMID32930481,reaction_1,2b,,,,,,,
PMID32930481,reaction_1,18,,,,,,,
PMID32930481,reaction_1,19,,,,,,,
PMID32930481,reaction_1,4a,,,,Not active (inhibitory effect less than 50% at 100 µM),,,
PMID32930481,reaction_1,4b,,,,Not active (inhibitory effect less than 50% at 100 µM),,,
PMID32930481,reaction_1,4c,,,,Not active (inhibitory effect less than 50% at 100 µM),,,
PMID32930481,reaction_1,4d,,,,Not active (inhibitory effect less than 50% at 100 µM),,,
PMID32930481,reaction_1,8,,,,Not active (inhibitory effect less than 50% at 100 µM),,,
PMID32930481,reaction_1,2c,,,,,,,
PMID32930481,reaction_1,2d,,,,Not active (inhibitory effect less than 50% at 100 µM),,,
PMID32930481,reaction_1,2e,,,,,,,
PMID32930481,reaction_1,2f,,,,,,,
PMID32930481,reaction_1,2g,,,,,,,
PMID32930481,reaction_1,2h,,,,,,,
PMID32930481,reaction_1,2i,,,,,,,
PMID32930481,reaction_1,2j,,,,Not active (inhibitory effect less than 50% at 100 µM),,,
PMID32930481,reaction_1,2k,,,,Not active (inhibitory effect less than 50% at 100 µM),,,
PMID32930481,reaction_1,2l,,,,,,,
PMID32930481,reaction_1,2m,,,,Not active (inhibitory effect less than 50% at 100 µM),,,
PMID32930481,reaction_1,2n,,,,,,,
PMID32930481,reaction_1,2o,,,,,,,
PMID32930481,reaction_1,2p,,,,,,,
PMID32930481,reaction_1,2q,,,,,,,
PMID32930481,reaction_1,2r,,,,,,,
PMID32930481,reaction_1,2s,,,,,,,
PMID32930481,reaction_1,2t,,,,,,,
PMID32930481,reaction_1,11a,,,,Not active (inhibitory effect less than 50% at 100 µM),,,
PMID32930481,reaction_1,11b,,,,Not active (inhibitory effect less than 50% at 100 µM),,,
PMID32930481,reaction_1,11c,,,,Not active (inhibitory effect less than 50% at 100 µM),,,
PMID32930481,reaction_1,11d,,,,Not active (inhibitory effect less than 50% at 100 µM),,,
PMID32930481,reaction_1,14a,,,,,,,
PMID32930481,reaction_1,14b,,,,Not determined due to limited solubility,,,
PMID32930481,reaction_1,14c,,,,Not active (inhibitory effect less than 50% at 100 µM),,,
PMID32930481,reaction_1,14d,,,,,,,
PMID32930481,reaction_1,14e,,,,Not active (inhibitory effect less than 50% at 100 µM),,,
PMID32930481,reaction_1,14f,,,,Not active (inhibitory effect less than 50% at 100 µM),,,
PMID32930481,reaction_1,14g,,,,Not determined due to limited solubility,,,
PMID32930481,reaction_1,14h,,,,,,,
PMID32930481,reaction_1,14i,,,,Not active (inhibitory effect less than 50% at 100 µM),,,
PMID32930481,reaction_1,14j,,,,,,,
PMID32930481,reaction_1,14k,,,,,,,
PMID32930481,reaction_1,14l,,,,,,,
PMID32930481,reaction_1,17,,,,,,,
PMID32930481,reaction_2,2a,,,,,,,
PMID32930481,reaction_2,4d,,,,Not active,,,
PMID32930481,reaction_2,2c,,,,,,,
PMID32930481,reaction_2,2e,,,,Not active,,,
PMID32930481,reaction_2,2f,,,,,,,
PMID32930481,reaction_2,2g,,,,,,,
PMID32930481,reaction_2,2h,,,,Not active,,,
PMID32930481,reaction_2,2i,,,,,,,Cell-based assay on SARS-CoV-2-infected Vero E6 cells showed EC50 = 1.77 ± 1.60 µM and CC50 = 376 ± 1.36 µM.
PMID32930481,reaction_2,2n,,,,,,,Cell-based assay on SARS-CoV-2-infected Vero E6 cells showed EC50 = 4.74 ± 1.35 µM and CC50 > 500 µM.
PMID32930481,reaction_2,2p,,,,,,,Cell-based assay on SARS-CoV-2-infected Vero E6 cells showed EC50 = 15.75 ± 1.59 µM and CC50 > 500 µM.
PMID32930481,reaction_2,2r,,,,,,,
PMID32930481,reaction_2,2s,,,,,,,
PMID32930481,reaction_2,2t,,,,,,,
PMID32930481,reaction_2,11a,,,,Not active,,,
PMID32930481,reaction_2,14a,,,,Not active,,,
PMID32930481,reaction_2,14d,,,,Not active,,,
PMID32930481,reaction_2,14h,,,,,,,Cell-based assay on SARS-CoV-2-infected Vero E6 cells showed EC50 = 7.85 ± 1.50 µM and CC50 = 442 ± 1.37 µM.
PMID32930481,reaction_2,14i,,,,Not active,,,
PMID32930481,reaction_2,14k,,,,,,,Cell-based assay on SARS-CoV-2-infected Vero E6 cells showed no activity (n.a.) and CC50 > 500 µM.
PMID32931912,reaction_1,"Mycophenolic acid (MPA, 7)",Ki reported (cited value from ref 22),,,,,,
PMID32931912,reaction_1,Compound 8,"Apparent Ki (Ki,app) reported",,,,,,
PMID32931912,reaction_1,Compound 9,"Apparent Ki (Ki,app) reported",,,,,,
PMID32931912,reaction_1,Compound 10,"Apparent Ki (Ki,app) reported",,,,,,
PMID32931912,reaction_1,Compound 11,"Apparent Ki (Ki,app) reported",,,,,,
PMID32931912,reaction_1,Compound 12,"Apparent Ki (Ki,app) reported",,,,,,
PMID32931912,reaction_1,Compound 13,"Apparent Ki (Ki,app) reported",,,,,,
PMID32931912,reaction_1,Compound 14,"Apparent Ki (Ki,app) reported",,,,,,
PMID32931912,reaction_1,Compound 15,"Apparent Ki (Ki,app) reported",,,,,,
PMID32931912,reaction_1,Compound 16,"Apparent Ki (Ki,app) reported",,,,,,
PMID32931912,reaction_1,Compound 17,"Apparent Ki (Ki,app) reported",,,,,,
PMID32931912,reaction_1,Compound 18,"Apparent Ki (Ki,app) reported",,,,,,
PMID32931912,reaction_1,Compound 31a,"Apparent Ki (Ki,app) reported",,,,,,
PMID32931912,reaction_1,Compound 31b,"Apparent Ki (Ki,app) reported",,,,,,
PMID32931912,reaction_1,Compound 38,"Apparent Ki (Ki,app) reported, error is range",,,,,,
PMID32931912,reaction_1,Compound 42a,"Apparent Ki (Ki,app) reported",,,,,,
PMID32931912,reaction_1,Compound 42b,"Apparent Ki (Ki,app) reported, error is range",,,,,,
PMID32931912,reaction_1,Compound 44,"Apparent Ki (Ki,app) reported",,,,,,
PMID32931912,reaction_2,"Mycophenolic acid (MPA, 7)",Ki reported (cited value from ref 20),,,,,,
PMID32931912,reaction_2,Compound 8,"Apparent Ki (Ki,app) reported",,,,,,
PMID32931912,reaction_2,Compound 9,"Apparent Ki (Ki,app) reported",,,,,,
PMID32931912,reaction_2,Compound 10,"Apparent Ki (Ki,app) reported",,,,,,
PMID32931912,reaction_2,Compound 12,"Apparent Ki (Ki,app) reported",,,,,,
PMID32931912,reaction_2,Compound 13,"Apparent Ki (Ki,app) reported",,,,,,
PMID32931912,reaction_2,Compound 14,"Apparent Ki (Ki,app) reported",,,,,,
PMID32931912,reaction_2,Compound 15,"Apparent Ki (Ki,app) reported",,,,,,
PMID32931912,reaction_2,Compound 31a,"Apparent Ki (Ki,app) reported",,,,,,
PMID32931912,reaction_2,Compound 31b,"Apparent Ki (Ki,app) reported",,,,,,
PMID32931912,reaction_2,Compound 38,"Apparent Ki (Ki,app) reported",,,,,,
PMID32931912,reaction_2,Compound 42a,"Apparent Ki (Ki,app) reported",,,,,,
PMID32931912,reaction_2,Compound 42b,"Apparent Ki (Ki,app) reported",,,,,,
PMID32931912,reaction_2,Compound 44,"Apparent Ki (Ki,app) reported",,,,,,
PMID32931912,reaction_3,Compound 10,"Apparent Ki (Ki,app) reported",,,,,,
PMID32933017,reaction_1,Thapsigargin,"Specific inhibitor, fully suppressed current",,,,,,
PMID32933017,reaction_2,Bathocuproinedisulfonate (BCS),Substrate chelation (Cu+),,,,,,
PMID32933017,reaction_4,Orthovanadate,"ATPase inhibitor, completely suppressed current",,,,,,
PMID32936835,reaction_1,Antimycin A,"Indirect; inhibitor of mitochondrial respiratory complex III, which prevents the mitochondrial function required for Gdh2-dependent alkalization.",,,,,,
PMID32936835,reaction_1,Chloramphenicol,"Indirect; inhibitor of mitochondrial translation, which prevents the mitochondrial function required for Gdh2-dependent alkalization.",,,,,,
PMID32942681,reaction_1,anti-SMS2 antibody,Not specified,,,,,,"A concentration of 20 µg/mL decreased in vitro enzyme activity by 47.0 ± 5.32%. In whole sperm cells, this treatment led to a 27.67 ± 4.85% decrease in total sphingomyelin content."
PMID32945115,reaction_1,S-(2-aminoethyl)-L-cysteine (AEC),Feedback inhibition,,,,,"Wild-type enzyme is sensitive to 12 mM AEC, leading to poor growth of E. coli host. Mutants are insensitive.",
PMID32945115,reaction_2,S-(2-aminoethyl)-L-cysteine (AEC),Feedback inhibition,,,,,"Wild-type enzyme is sensitive to 12 mM AEC, leading to poor growth of E. coli host. Mutants are insensitive.",
PMID32961871,reaction_1,A939572,Not specified,,,,,,
PMID32961871,reaction_2,A939572,Not specified,,,,,,
PMID32961948,reaction_1,ethyl-2-methylacetoacetate,Substrate inhibition,,,,,Free enzymes were significantly inhibited at substrate concentrations higher than 70 mM. Immobilized enzymes showed high tolerance up to 700 mM.,
PMID32962020,reaction_1,Salicylhydroxamic acid,Not specified,,,,,,About 70% inhibition of LOX activity was observed in the presence of 1 mM SHAM.
PMID32962020,reaction_1,Propyl gallate,Not specified,,,,,,Almost complete inhibition (99%) occurred in the presence of 1 mM PG.
PMID32962020,reaction_2,Salicylhydroxamic acid,Not specified,,,,,,About 70% inhibition of LOX activity was observed in the presence of 1 mM SHAM.
PMID32962020,reaction_2,Propyl gallate,Not specified,,,,,,Almost complete inhibition (99%) occurred in the presence of 1 mM PG.
PMID32962020,reaction_3,Salicylhydroxamic acid,Not specified,,,,,,About 70% inhibition of LOX activity was observed in the presence of 1 mM SHAM.
PMID32962020,reaction_3,Propyl gallate,Not specified,,,,,,Almost complete inhibition (99%) occurred in the presence of 1 mM PG.
PMID32966327,reaction_1,succinic semialdehyde,Competitive substrate inhibition (against NADP+),,,,,,
PMID32966327,reaction_2,succinic semialdehyde,Substrate inhibition,,,,,,
PMID32967812,reaction_1,Cu2+,Not specified,,,,,Relative activity of 6.8% at 0.25 mM concentration.,
PMID32967812,reaction_1,Ag+,Not specified,,,,,Relative activity of 18.5% at 1.0 mM concentration.,
PMID32967812,reaction_1,b-Mercaptoethanol,Not specified,,,,,"Showed inhibitory effect, especially at 10 mM concentration.",
PMID32967812,reaction_2,Cu2+,Not specified,,,,,Relative activity of 12.9% at 0.25 mM concentration.,
PMID32967812,reaction_2,Ag+,Not specified,,,,,Relative activity of 17.8% at 1.0 mM concentration.,
PMID32967812,reaction_2,b-Mercaptoethanol,Not specified,,,,,Relative activity <60% at 10 mM concentration.,
PMID32967812,reaction_3,Cu2+,Not specified,,,,,Relative activity of 2.5% at 0.25 mM concentration.,
PMID32967812,reaction_3,Ag+,Not specified,,,,,Activity not detected at 1.0 mM concentration.,
PMID32967812,reaction_3,Furfural,Substrate inhibition,,,,,Relative activity remained less than 55% after treatment with 10 mM furfural for 2 hours.,
PMID32972135,reaction_1,rhein,,,,,,,
PMID32972135,reaction_1,diacerein,Competitive with respect to m6A-containing substrate,,,,,,
PMID32972135,reaction_1,plumbagin,,,,,,,
PMID32972135,reaction_2,diacerein,,,,Inhibition observed at 100 µM.,,,
PMID32972135,reaction_2,emodin,,,,Inhibition observed at 100 µM.,,,
PMID32972135,reaction_2,alizarin red,,,,Inhibition observed at 100 µM.,,,
PMID32972135,reaction_2,plumbagin,,,,Inhibition observed at 100 µM.,,,
PMID32972135,reaction_2,"5-hydroxy-1,4-naphthoquinone",,,,Inhibition observed at 100 µM.,,,
PMID32972135,reaction_2,rhein,,,,Inhibition observed at 100 µM.,,,
PMID32972135,reaction_2,5-hydroxyisophthalic acid,,,,No inhibition observed at 100 µM.,,,
PMID32972135,reaction_3,rhein,,,,No inhibition observed.,,,
PMID32972135,reaction_3,diacerein,,,,No inhibition observed.,,,
PMID32972135,reaction_3,plumbagin,,,,,,,
PMID32972135,reaction_4,emodin,,,,Inhibition observed at 100 µM.,,,
PMID32972135,reaction_4,alizarin red,,,,Inhibition observed at 100 µM.,,,
PMID32972135,reaction_4,plumbagin,,,,Inhibition observed at 100 µM.,,,
PMID32972135,reaction_4,"5-hydroxy-1,4-naphthoquinone",,,,Inhibition observed at 100 µM.,,,
PMID32972135,reaction_4,diacerein,,,,No significant inhibition observed at 100 µM.,,,
PMID32972135,reaction_4,5-hydroxyisophthalic acid,,,,No inhibition observed at 100 µM.,,,
PMID32972135,reaction_4,rhein,,,,No significant inhibition observed at 100 µM.,,,
PMID32972135,reaction_5,rhein,,,,Inhibited endogenous demethylase activity in a concentration-dependent manner.,,,
PMID32972135,reaction_5,diacerein,,,,Inhibited endogenous demethylase activity in a concentration-dependent manner.,,,
PMID32980741,reaction_1,3,tRNA-amino acid dual-site inhibitor,,,,,,
PMID32980741,reaction_1,8g,"Competitive with L-threonine, tRNAThr, and ATP",,,,,,
PMID32980741,reaction_1,9a,,,,,,,
PMID32980741,reaction_1,9b,,,,,,,
PMID32980741,reaction_1,9c,,,,,,,
PMID32980741,reaction_1,9d,,,,,,,
PMID32980741,reaction_1,9e,,,,,,,
PMID32980741,reaction_1,VIII (11d),ATP-amino acid dual-site inhibitor,,,,,,
PMID32989128,reaction_6,UDP-GalNAc,Competitive,,,,,Labeling with UDP-GalNAzMe was competed out by increasing concentrations of UDP-GalNAc in vitro (Fig. 5B).,
PMID32998973,reaction_1,BRD7929,Not specified,,,,,,
PMID33011272,reaction_4,Staurosporine,"Inhibitor of PKC, which is upstream of NADK activation.",,,,,,
PMID33011272,reaction_4,Staurosporine,"Inhibitor of PKC, which is upstream of NADK activation.",,,,,,
PMID33011272,reaction_4,Gö 6983,"Inhibitor of PKC, which is upstream of NADK activation.",,,,,,
PMID33011272,reaction_4,Gö 6983,"Inhibitor of PKC, which is upstream of NADK activation.",,,,,,
PMID33031917,reaction_1,N-Ethylmaleimide,No inhibition observed,,,,,,
PMID33038544,reaction_1_GRK2_inhibition,1,,,,,,,
PMID33038544,reaction_1_GRK2_inhibition,Paroxetine,,,,,,,Positive control
PMID33038544,reaction_1_GRK2_inhibition,Takeda 103A,,,,,,,Positive control
PMID33038544,reaction_1_GRK2_inhibition,2a,,,,,,,
PMID33038544,reaction_1_GRK2_inhibition,2b,,,,,,,
PMID33038544,reaction_1_GRK2_inhibition,2c,,,,,,,
PMID33038544,reaction_1_GRK2_inhibition,2d,,,,,,,
PMID33038544,reaction_1_GRK2_inhibition,2e,,,,,,,
PMID33038544,reaction_1_GRK2_inhibition,2f,,,,,,,
PMID33038544,reaction_1_GRK2_inhibition,8a,,,,,,,
PMID33038544,reaction_1_GRK2_inhibition,8b,,,,,,,
PMID33038544,reaction_1_GRK2_inhibition,8c,,,,,,,
PMID33038544,reaction_1_GRK2_inhibition,8d,,,,,,,
PMID33038544,reaction_1_GRK2_inhibition,8e,,,,,,,
PMID33038544,reaction_1_GRK2_inhibition,8f,,,,,,,
PMID33038544,reaction_1_GRK2_inhibition,8g,,,,,,,Value from primary assay (Table 2). A value of 10 nM was reported from Eurofins assay (Table 3).
PMID33038544,reaction_1_GRK2_inhibition,8h,,,,,,,
PMID33038544,reaction_1_GRK2_inhibition,8i,,,,,,,
PMID33038544,reaction_1_GRK2_inhibition,8j,,,,,,,
PMID33038544,reaction_1_GRK2_inhibition,8k,,,,,,,
PMID33038544,reaction_1_GRK2_inhibition,8l,,,,,,,
PMID33038544,reaction_1_GRK2_inhibition,8m (racemic),,,,,,,
PMID33038544,reaction_2_GRK1_selectivity,8g,,,,,,,
PMID33038544,reaction_2_GRK1_selectivity,8h,,,,,,,
PMID33038544,reaction_3_GRK5_selectivity,8g,,,,,,,
PMID33038544,reaction_3_GRK5_selectivity,8h,,,,,,,
PMID33038544,reaction_4_GRK6_selectivity,8g,,,,,,,
PMID33038544,reaction_4_GRK6_selectivity,8h,,,,,,,
PMID33038544,reaction_5_GRK7_selectivity,8g,,,,,,,
PMID33038544,reaction_5_GRK7_selectivity,8h,,,,,,,
PMID33038544,reaction_6_PKA_selectivity,8g,,,,,,,
PMID33038544,reaction_6_PKA_selectivity,8h,,,,,,,
PMID33038544,reaction_7_PKBalpha_selectivity,8g,,,,,,,
PMID33038544,reaction_7_PKBalpha_selectivity,8h,,,,,,,
PMID33038544,reaction_8_PKCalpha_selectivity,8g,,,,,,,
PMID33038544,reaction_8_PKCalpha_selectivity,8h,,,,,,,
PMID33038544,reaction_9_PKCbeta1_selectivity,8g,,,,,,,
PMID33038544,reaction_9_PKCbeta1_selectivity,8h,,,,,,,
PMID33038544,reaction_10_CaMKIIbeta_selectivity,8g,,,,,,,
PMID33038544,reaction_10_CaMKIIbeta_selectivity,8h,,,,,,,
PMID33038544,reaction_11_ROCK1_selectivity,8g,,,,,,,
PMID33038544,reaction_11_ROCK1_selectivity,8h,,,,,,,
PMID33038544,reaction_12_AuroraA_selectivity,8g,,,,,,,
PMID33038544,reaction_12_AuroraA_selectivity,8h,,,,,,,
PMID33038544,reaction_13_Rsk1_selectivity,8g,,,,,,,
PMID33038544,reaction_13_Rsk1_selectivity,8h,,,,,,,
PMID33051013,reaction_1,H2O2,,,,,,,Complete inhibition at 0.05 mM. 42.0% inhibition at 0.01 mM after 1h incubation.
PMID33051013,reaction_1,L-cysteine,,,,,,,Complete inhibition at 0.1 mM. 33.9% inhibition at 0.02 mM after 1h incubation.
PMID33051013,reaction_1,Sodium ascorbate,,,,,,,Complete inhibition at 0.5 mM. 39.5% inhibition at 0.05 mM after 1h incubation.
PMID33051013,reaction_1,Sodium metabisulphite,,,,,,,Complete inhibition at 1.0 mM. 93.5% inhibition at 0.5 mM after 1h incubation.
PMID33051013,reaction_1,p-arbutin,,,,,,,"24.2% inhibition at 1 mM, max inhibition of 66.4% at 50 mM after 1h incubation."
PMID33051013,reaction_1,Sodium azide,,,,,,,"26.6% inhibition at 5 mM, max inhibition of 68.4% at 50 mM after 1h incubation. No significant inhibition up to 2 mM."
PMID33051013,reaction_1,EDTA,,,,,,,No inhibition up to 50 mM.
PMID33051013,reaction_1,SDS,,,,,,,No inhibition up to 50 mM.
PMID33051013,reaction_1,NaCl,,,,,,,No inhibition up to 50 mM.
PMID33051013,reaction_1,Cu2+,,,,,,,Enhanced activity.
PMID33051013,reaction_1,Zn2+,,,,,,,No significant effect on activity.
PMID33051013,reaction_1,Ca2+,,,,,,,No significant effect on activity.
PMID33051013,reaction_1,Mg2+,,,,,,,No significant effect on activity.
PMID33051013,reaction_1,Co2+,,,,,,,Inhibitory effect.
PMID33051013,reaction_1,Fe2+,,,,,,,Inhibitory effect.
PMID33051013,reaction_1,Mn2+,,,,,,,Inhibitory effect.
PMID33051013,reaction_1,Propanol,,,,,,,"Inhibitory effect, significant decrease in activity at 10% v/v."
PMID33051013,reaction_1,Methanol,,,,,,,"Inhibitory effect, significant decrease in activity at 10% v/v."
PMID33051013,reaction_1,Ethanol,,,,,,,"Inhibitory effect, significant decrease in activity at 10% v/v."
PMID33051013,reaction_1,DMSO,,,,,,,"Inhibitory effect, significant decrease in activity at 10% v/v."
PMID33051013,reaction_1,Acetonitrile,,,,,,,"Greatest inhibition among solvents tested, significant decrease in activity at 10% v/v."
PMID33058282,reaction_1,L-serine,No inhibition observed,,,,,,
PMID33059448,reaction_1,Brassinosteroids (BRs),"Negative regulation of activity, primarily through downregulation of gene expression in vivo.",,,,,,
PMID33063604,reaction_1,EDTA,Inferred from metal dependence,,,,,,
PMID33063604,reaction_1,Cellobionic acid,Product inhibition,,,,,,
PMID33063604,reaction_2,EDTA,Inferred from metal dependence,,,,,,
PMID33063604,reaction_3,EDTA,Inferred from metal dependence,,,,,,
PMID33063604,reaction_4,EDTA,Inferred from metal dependence,,,,,,
PMID33063604,reaction_5,EDTA,Inferred from metal dependence,,,,,,
PMID33065002,reaction_1,SidK,Partial inhibition,,,,,,
PMID33067793,reaction_2,Formaldehyde,Substrate inhibition,,,,,High levels of formaldehyde posed an inhibitory effect on the enzymatic degradation.,
PMID33067793,reaction_4,Formaldehyde,Substrate inhibition,,,,,High levels of formaldehyde posed an inhibitory effect on the enzymatic degradation.,
PMID33074120,reaction_1,3a,Not specified,,,,,,
PMID33074120,reaction_1,3b,Not specified,,,,,,
PMID33074120,reaction_1,3c,Not specified,,,,,,
PMID33074120,reaction_1,3d,Not specified,,,,,,
PMID33074120,reaction_1,3e,Not specified,,,,,,
PMID33074120,reaction_1,3f,Not specified,,,,,,
PMID33074120,reaction_1,3g,Not specified,,,,,,
PMID33074120,reaction_1,3h,Not specified,,,,,,
PMID33074120,reaction_1,3i,Not specified,,,,,,
PMID33074120,reaction_1,3j,Not specified,,,,,,
PMID33074120,reaction_1,3k,Not specified,,,,,,
PMID33074120,reaction_1,3l,Not specified,,,,,,
PMID33074120,reaction_1,3m,Not specified,,,,,,
PMID33074120,reaction_1,3n,Not specified,,,,,,
PMID33074120,reaction_1,leflunomide,Not specified,,,,,,
PMID33074120,reaction_1,brequinar,Not specified,,,,,,
PMID33081987,reaction_1,Compound 1,,,,,,,
PMID33081987,reaction_1,"A-2,5",,,,,,,
PMID33081987,reaction_1,"A-2,10",,,,,,,
PMID33081987,reaction_1,"A-2,12",,,,,,,
PMID33081987,reaction_1,"A-2,13",,,,,,,
PMID33081987,reaction_1,"A-2,20",,,,,,,
PMID33081987,reaction_1,"B-1,3",,,,,,,
PMID33081987,reaction_1,"C-1,12",,,,,,,
PMID33081987,reaction_1,"C-1,16",,,,,,,
PMID33081987,reaction_1,"D-2,4",,,,,,,
PMID33081987,reaction_1,"D-2,12",,,,,,,
PMID33081987,reaction_1,"D-3,4",,,,,,,
PMID33081987,reaction_1,"D-3,7",,,,,,,
PMID33081987,reaction_1,Compound 25,,,,,,,
PMID33081987,reaction_1,Compound 26,,,,,,,
PMID33081987,reaction_2,Compound 1,,,,,,,
PMID33081987,reaction_2,Compound 2,,,,,,,
PMID33081987,reaction_2,Compound 3,,,,,,,
PMID33081987,reaction_2,Compound 4b,,,,,,,
PMID33081987,reaction_2,Compound 5,,,,,,,
PMID33081987,reaction_2,Compound 6,,,,,,,
PMID33081987,reaction_2,Compound 7,,,,,,,
PMID33082972,reaction_1,zinc protoporphyrin IX,Not specified,,,,,,
PMID33090543,reaction_1,Thiourea,,,,,,,"Relative activity at 0.1 mM: 85.78%, 1 mM: 40.39%, 5 mM: 22.32%, 10 mM: 0% (complete inhibition)."
PMID33090543,reaction_1,L-cysteine,,,,,,,"Relative activity at 0.1 mM: 85.06%, 1 mM: 46.78%, 5 mM: 23.76%, 10 mM: 8.53%."
PMID33090543,reaction_1,Ascorbic acid,,,,,,,"Relative activity at 0.1 mM: 98.28%, 1 mM: 100.51%, 5 mM: 83.81%, 10 mM: 21.00%."
PMID33090543,reaction_1,Sodium sulfite,,,,,,,"Relative activity at 0.1 mM: 101.31%, 1 mM: 85.33%, 5 mM: 81.46%, 10 mM: 19.34%."
PMID33090543,reaction_1,Kojic acid,,,,,,,"Relative activity at 1 mM: 93.91%, 5 mM: 79.54%, 10 mM: 69.79%."
PMID33090543,reaction_1,β-cyclodextrin,,,,,,,"Relative activity at 1 mM: 89.77%, 5 mM: 79.87%, 10 mM: 72.44%."
PMID33090543,reaction_1,Citric acid,,,,,,,"Relative activity at 1 mM: 95.78%, 5 mM: 91.09%, 10 mM: 83.79%."
PMID33090543,reaction_1,EDTA,,,,,,,"Relative activity at 0.1 mM: 98.00%, 1 mM: 96.24%. No significant inhibition observed."
PMID33090543,reaction_6,Thiourea,,,,,,,"Relative activity at 0.1 mM: 77.29%, 1 mM: 46.06%, 5 mM: 28.68%, 10 mM: 0% (complete inhibition)."
PMID33090543,reaction_6,L-cysteine,,,,,,,"Relative activity at 0.1 mM: 94.34%, 1 mM: 48.37%, 5 mM: 29.51%, 10 mM: 7.33%."
PMID33090543,reaction_6,Ascorbic acid,,,,,,,"Relative activity at 0.1 mM: 91.72%, 1 mM: 91.90%, 5 mM: 51.57%, 10 mM: 31.34%."
PMID33090543,reaction_6,Sodium sulfite,,,,,,,"Relative activity at 0.1 mM: 84.52%, 1 mM: 95.76%, 5 mM: 36.94%, 10 mM: 18.57%."
PMID33090543,reaction_6,Kojic acid,,,,,,,"Relative activity at 1 mM: 99.80%, 5 mM: 83.18%, 10 mM: 70.43%."
PMID33090543,reaction_6,β-cyclodextrin,,,,,,,"Relative activity at 1 mM: 92.77%, 5 mM: 90.29%, 10 mM: 88.67%."
PMID33090543,reaction_6,Citric acid,,,,,,,"Activated the enzyme. Relative activity at 1 mM: 117.68%, 5 mM: 117.43%, 10 mM: 125.06%."
PMID33090543,reaction_6,EDTA,,,,,,,"Relative activity at 0.1 mM: 97.92%, 1 mM: 97.96%. No significant inhibition observed."
PMID33090543,reaction_11,Thiourea,,,,,,,"Relative activity at 0.1 mM: 81.00%, 1 mM: 35.72%, 5 mM: 23.24%, 10 mM: 0% (complete inhibition)."
PMID33090543,reaction_11,L-cysteine,,,,,,,"Relative activity at 0.1 mM: 86.14%, 1 mM: 37.05%, 5 mM: 10.26%, 10 mM: 2.35%."
PMID33090543,reaction_11,Ascorbic acid,,,,,,,"Relative activity at 0.1 mM: 96.77%, 1 mM: 65.87%, 5 mM: 44.99%, 10 mM: 34.11%."
PMID33090543,reaction_11,Sodium sulfite,,,,,,,"Relative activity at 0.1 mM: 101.81%, 1 mM: 89.75%, 5 mM: 62.45%, 10 mM: 19.34% (value for 10mM appears to be from L. lancifolium Thunb column in source table, likely a typo)."
PMID33090543,reaction_11,Kojic acid,,,,,,,"Relative activity at 1 mM: 92.86%, 5 mM: 73.91%, 10 mM: 71.52%."
PMID33090543,reaction_11,β-cyclodextrin,,,,,,,"Relative activity at 1 mM: 102.49%, 5 mM: 96.09%, 10 mM: 89.85%."
PMID33090543,reaction_11,Citric acid,,,,,,,"Relative activity at 1 mM: 105.31%, 5 mM: 103.21%, 10 mM: 88.77%."
PMID33090543,reaction_11,EDTA,,,,,,,"Relative activity at 0.1 mM: 96.76%, 1 mM: 97.42%. No significant inhibition observed."
PMID33110062,reaction_1,finasteride,Irreversible (mechanism-based),,,,,,
PMID33114668,reaction_1,3a,,,,,,,
PMID33114668,reaction_1,3b,,,,,,,
PMID33114668,reaction_1,3c,,,,,,,
PMID33114668,reaction_1,3d,,,,,,,
PMID33114668,reaction_1,3e,,,,,,,
PMID33114668,reaction_1,3f,,,,,,,
PMID33114668,reaction_1,3g,,,,,,,
PMID33114668,reaction_1,3h,,,,,,,
PMID33114668,reaction_1,3i,,,,,,,
PMID33114668,reaction_1,3j,,,,,,,
PMID33114668,reaction_1,3k,,,,,,,
PMID33114668,reaction_1,3l,,,,,,,
PMID33114668,reaction_1,3m,,,,,,,
PMID33114668,reaction_1,3n,,,,,,,
PMID33114668,reaction_1,3o,,,,,,,
PMID33114668,reaction_1,3p,,,,,,,
PMID33114668,reaction_1,4,,,,,,,
PMID33114668,reaction_1,7,,,,,,,
PMID33114668,reaction_1,11a,,,,,,,
PMID33114668,reaction_1,11b,,,,,,,
PMID33114668,reaction_1,11c,,,,,,,
PMID33114668,reaction_1,11d,,,,,,,
PMID33114668,reaction_1,11e,,,,,,,
PMID33114668,reaction_2,11c,,,,,,,
PMID33114668,reaction_2,11e,,,,,,,
PMID33114668,reaction_3,11c,,,,,,,
PMID33114668,reaction_3,11e,,,,,,,
PMID33114668,reaction_4,11c,,,,,,,
PMID33114668,reaction_4,11e,,,,,,,
PMID33114668,reaction_5,11c,,,,,,,
PMID33114668,reaction_5,11e,,,,,,,
PMID33122026,reaction_1,NAD+,Product inhibition,,,,,,
PMID33122026,reaction_2,NADP+,Product inhibition,,,,,,
PMID33122065,reaction_1,Co2+,Activity reduced to 77% of control at 1 mM concentration.,,,,,,
PMID33122065,reaction_1,Na+,Activity reduced to 69% of control at 1 mM concentration.,,,,,,
PMID33122065,reaction_1,Ag+,Activity reduced to 64% of control at 1 mM concentration.,,,,,,
PMID33122065,reaction_1,EDTA,Activity reduced to 59% of control at 1 mM concentration.,,,,,,
PMID33128494,reaction_1,mesotrione,Competitive,,,,,,
PMID33128494,reaction_1,A7,Competitive,,,,,,
PMID33128494,reaction_1,B14,Competitive,,,,,,
PMID33128494,reaction_1,B18,Competitive,,,,,,
PMID33129593,reaction_1,35,Non-covalent,,,,,,
PMID33129593,reaction_1,39,Non-covalent,,,,,,
PMID33129593,reaction_1,46,Non-covalent,,,,,,
PMID33129593,reaction_1,candesartan cilexetic (CDC),Non-covalent,,,,,,
PMID33129593,reaction_1,MLN4924,Covalent,,,,,,
PMID33140461,reaction_1,Mn2+,Partial inhibition,,,,,,Activity reduced to 85% at 2mM and 59% at 5mM.
PMID33140461,reaction_1,Co2+,Strong inhibition,,,,,,Activity reduced to 56% at 2mM and 21% at 5mM.
PMID33140461,reaction_1,Cu2+,Strong inhibition,,,,,,Activity reduced to 54% at 2mM and 15% at 5mM.
PMID33140461,reaction_1,Hg2+,Strong inhibition,,,,,,Activity reduced to 15% at 2mM and 7.2% at 5mM.
PMID33140461,reaction_2,Co2+,Partial inhibition,,,,,,Activity reduced to 99% at 2mM and 80% at 5mM.
PMID33140461,reaction_2,Cu2+,Partial inhibition,,,,,,Activity reduced to 80% at 2mM and 74% at 5mM.
PMID33140461,reaction_2,Hg2+,Partial inhibition,,,,,,Activity reduced to 78% at 2mM and 67% at 5mM.
PMID33142415,reaction_1_nfk_assay,INCB024360,,,,,,,
PMID33142415,reaction_1_nfk_assay,1-L-MT,,,,,,,
PMID33142415,reaction_1_nfk_assay,680C91,,,,,,,
PMID33142415,reaction_1_nfk_assay,LM10,,,,,,,
PMID33142415,reaction_1_nfk_assay,5a,,,,,,,
PMID33142415,reaction_1_nfk_assay,5b,,,,,,,
PMID33142415,reaction_1_nfk_assay,5e,,,,,,,
PMID33142415,reaction_1_nfk_assay,5f,,,,,,,
PMID33142415,reaction_2_kyn_adduct_assay,INCB024360,,,,,,,
PMID33142415,reaction_2_kyn_adduct_assay,1-L-MT,,,,,,,
PMID33142415,reaction_2_kyn_adduct_assay,680C91,,,,,,,
PMID33142415,reaction_2_kyn_adduct_assay,LM10,,,,,,,
PMID33142415,reaction_2_kyn_adduct_assay,5a,,,,,,,
PMID33142415,reaction_2_kyn_adduct_assay,5b,,,,,,,
PMID33142415,reaction_2_kyn_adduct_assay,5e,,,,,,,
PMID33142415,reaction_2_kyn_adduct_assay,5f,,,,,,,
PMID33142415,reaction_3_nfk_assay,INCB024360,,,,,,,
PMID33142415,reaction_3_nfk_assay,1-L-MT,,,,,,,
PMID33142415,reaction_3_nfk_assay,680C91,,,,,,,
PMID33142415,reaction_3_nfk_assay,LM10,,,,,,,
PMID33142415,reaction_3_nfk_assay,5a,,,,,,,
PMID33142415,reaction_3_nfk_assay,5b,,,,,,,
PMID33142415,reaction_3_nfk_assay,5e,,,,,,,
PMID33142415,reaction_3_nfk_assay,5f,,,,,,,
PMID33142415,reaction_4_kyn_adduct_assay,INCB024360,,,,,,,
PMID33142415,reaction_4_kyn_adduct_assay,1-L-MT,,,,,,,
PMID33142415,reaction_4_kyn_adduct_assay,680C91,,,,,,,
PMID33142415,reaction_4_kyn_adduct_assay,LM10,,,,,,,
PMID33142415,reaction_4_kyn_adduct_assay,5a,,,,,,,
PMID33142415,reaction_4_kyn_adduct_assay,5b,,,,,,,
PMID33142415,reaction_4_kyn_adduct_assay,5e,,,,,,,
PMID33142415,reaction_4_kyn_adduct_assay,5f,,,,,,,
PMID33142418,reaction_1,Compound 3,,,,,,,
PMID33142418,reaction_1,Compound 14a,,,,,,,
PMID33142418,reaction_1,Compound 14b,,,,,,,
PMID33142418,reaction_1,Compound 14c,,,,,,,
PMID33142418,reaction_1,Compound 14d,,,,,,,
PMID33142418,reaction_1,Compound 14e,,,,,,,
PMID33142418,reaction_1,Compound 14f,,,,,,,
PMID33142418,reaction_1,Compound 14g,,,,,,,
PMID33142418,reaction_1,Compound 14h,,,,,,,
PMID33142418,reaction_1,Compound 14i,,,,,,,
PMID33142418,reaction_1,Compound 14j,,,,,,,
PMID33142418,reaction_1,Compound 15a,,,,,,,
PMID33142418,reaction_1,Compound 15b,,,,,,,
PMID33142418,reaction_1,Compound 15c,,,,,,,
PMID33142418,reaction_1,Compound 15d,,,,,,,
PMID33142418,reaction_1,Compound 15e,,,,,,,
PMID33142418,reaction_1,Compound 15f,,,,,,,
PMID33142418,reaction_1,Compound 15g,,,,,,,
PMID33142418,reaction_1,Compound 15h,,,,,,,
PMID33142418,reaction_1,Compound 16a,,,,,,,
PMID33142418,reaction_1,Compound 16b,,,,,,,
PMID33142418,reaction_1,Compound 16c,,,,,,,
PMID33142418,reaction_1,Compound 16d,,,,,,,
PMID33142418,reaction_1,Compound 16e,,,,,,,
PMID33142418,reaction_1,Compound 16f,,,,,,,
PMID33142418,reaction_1,Compound 16g,,,,,,,
PMID33142418,reaction_1,Compound 16h,,,,,,,
PMID33142418,reaction_1,Compound 14k,,,,,,,
PMID33142418,reaction_1,Compound 14l,,,,,,,
PMID33142418,reaction_1,Compound 14m,,,,,,,
PMID33142418,reaction_1,Compound 14n,,,,,,,
PMID33142418,reaction_1,Compound 14o,,,,,,,
PMID33142418,reaction_1,Fedratinib (1),,,,,,,
PMID33142418,reaction_1,Pacritinib (2),,,,,,,
PMID33142418,reaction_2,Compound 3,,,,,,,
PMID33142418,reaction_2,Compound 14a,,,,,,,
PMID33142418,reaction_2,Compound 14b,,,,,,,
PMID33142418,reaction_2,Compound 14c,,,,,,,
PMID33142418,reaction_2,Compound 14d,,,,,,,
PMID33142418,reaction_2,Compound 14e,,,,,,,
PMID33142418,reaction_2,Compound 14f,,,,,,,
PMID33142418,reaction_2,Compound 14g,,,,,,,
PMID33142418,reaction_2,Compound 14h,,,,,,,
PMID33142418,reaction_2,Compound 14i,,,,,,,
PMID33142418,reaction_2,Compound 14j,,,,,,,
PMID33142418,reaction_2,Compound 15a,,,,,,,
PMID33142418,reaction_2,Compound 15b,,,,,,,
PMID33142418,reaction_2,Compound 15c,,,,,,,
PMID33142418,reaction_2,Compound 15d,,,,,,,
PMID33142418,reaction_2,Compound 15e,,,,,,,
PMID33142418,reaction_2,Compound 15f,,,,,,,
PMID33142418,reaction_2,Compound 15g,,,,,,,
PMID33142418,reaction_2,Compound 15h,,,,,,,
PMID33142418,reaction_2,Compound 16a,,,,,,,
PMID33142418,reaction_2,Compound 16b,,,,,,,
PMID33142418,reaction_2,Compound 16c,,,,,,,
PMID33142418,reaction_2,Compound 16d,,,,,,,
PMID33142418,reaction_2,Compound 16e,,,,,,,
PMID33142418,reaction_2,Compound 16f,,,,,,,
PMID33142418,reaction_2,Compound 16g,,,,,,,
PMID33142418,reaction_2,Compound 16h,,,,,,,
PMID33142418,reaction_2,Compound 14k,,,,,,,
PMID33142418,reaction_2,Compound 14l,,,,,,,
PMID33142418,reaction_2,Compound 14m,,,,,,,
PMID33142418,reaction_2,Compound 14n,,,,,,,
PMID33142418,reaction_2,Compound 14o,,,,,,,
PMID33142418,reaction_2,Fedratinib (1),,,,,,,
PMID33142418,reaction_2,Pacritinib (2),,,,,,,
PMID33142418,reaction_7,Compound 14l,,,,,,,
PMID33142418,reaction_8,Compound 14l,,,,,,,
PMID33142418,reaction_9,Compound 14l,,,,,,,
PMID33142418,reaction_10,Compound 14l,,,,,,,
PMID33142418,reaction_11,Compound 14l,,,,,,,
PMID33142418,reaction_12,Compound 14l,,,,,,,
PMID33142418,reaction_13,Compound 14l,,,,,,,
PMID33142418,reaction_14,Compound 14l,,,,,,,
PMID33142418,reaction_15,Compound 14l,,,,,,,
PMID33142418,reaction_16,Compound 14l,,,,,,,
PMID33142418,reaction_17,Compound 14l,,,,,,,
PMID33142418,reaction_18,Compound 14l,,,,,,,
PMID33142418,reaction_19,Compound 14l,,,,,,,
PMID33142418,reaction_20,Compound 14l,,,,,,,
PMID33142418,reaction_21,Compound 14l,,,,,,,
PMID33142418,reaction_22,Compound 14l,,,,,,,
PMID33142418,reaction_23,Compound 14l,,,,,,,
PMID33142418,reaction_24,Compound 14l,,,,,,,
PMID33146219,reaction_1,PbCl2,Activity inhibition,,,,,,
PMID33146219,reaction_1,ZnSO4,Activity inhibition,,,,,,
PMID33146219,reaction_1,CdSO4,Activity inhibition and large spectral red-shift,,,,,,
PMID33146219,reaction_1,HgCl2,Activity inhibition and large spectral red-shift,,,,,,
PMID33146575,reaction_8,Disulfiram,,,,,,Activity reduced to 16.4 ± 0.1% of control at 1 mM concentration.,
PMID33146575,reaction_9,Hydralazine hydrochloride,,,,,,Activity reduced to 73.3 ± 0.6% of control at 0.1 mM concentration.,
PMID33146575,reaction_9,Isovanillin,,,,,,Activity reduced to 52.4 ± 7.1% of control at 0.1 mM concentration.,
PMID33146575,reaction_9,6-methoxy-2-naphthaldehyde,,,,,,Activity reduced to 13.1 ± 3.4% of control at 0.1 mM concentration.,
PMID33146857,reaction_1,sodium azide,Competitive,,,,,,
PMID33146857,reaction_1,EDTA,Un-competitive,,,,,,
PMID33155804,reaction_1,fluthiacet-methyl,Competitive,,,,,,
PMID33155804,reaction_1,Compound 1a,Competitive,,,,,,
PMID33155804,reaction_1,Compound 1b,Competitive,,,,,,
PMID33155804,reaction_1,Compound 1c,Competitive,,,,,,
PMID33155804,reaction_1,Compound 2b,Competitive,,,,,,
PMID33155804,reaction_1,Compound 2c,Competitive,,,,,,
PMID33155804,reaction_1,Compound 2d,Competitive,,,,,,
PMID33155804,reaction_1,Compound 2e,Competitive,,,,,,
PMID33155804,reaction_1,Compound 2f,Competitive,,,,,,
PMID33155804,reaction_1,Compound 2g,Competitive,,,,,,
PMID33155804,reaction_1,Compound 2h,Competitive,,,,,,
PMID33155804,reaction_1,Compound 2i,Competitive,,,,,,
PMID33155804,reaction_1,Compound 2j,Competitive,,,,,,
PMID33155804,reaction_1,Compound 2k,Competitive,,,,,,
PMID33155804,reaction_1,Compound 2l,Competitive,,,,,,
PMID33155804,reaction_1,Compound 2m,Competitive,,,,,,
PMID33155804,reaction_1,Compound 2n,Competitive,,,,,,
PMID33155804,reaction_1,Compound 2o,Competitive,,,,,,
PMID33155804,reaction_1,Compound 2p,Competitive,,,,,,
PMID33155804,reaction_1,Compound 2q,Competitive,,,,,,
PMID33155804,reaction_1,Compound 2r,Competitive,,,,,,
PMID33155804,reaction_1,Compound 2s,Competitive,,,,,,
PMID33155804,reaction_1,Compound 2t,Competitive,,,,,,
PMID33155804,reaction_1,Compound 2u,Competitive,,,,,,
PMID33155804,reaction_1,Compound 2v,Competitive,,,,,,
PMID33155804,reaction_1,Compound 2w,Competitive,,,,,,
PMID33155804,reaction_1,Compound 3a,Competitive,,,,,,
PMID33155804,reaction_1,Compound 3b,Competitive,,,,,,
PMID33155804,reaction_1,Compound 3c,Competitive,,,,,,
PMID33155804,reaction_1,Compound 3d,Competitive,,,,,,
PMID33155804,reaction_1,Compound 3e,Competitive,,,,,,
PMID33155804,reaction_1,Compound 3f,Competitive,,,,,,
PMID33155804,reaction_1,Compound 4a,Competitive,,,,,,
PMID33155804,reaction_1,Compound 4b,Competitive,,,,,,
PMID33155804,reaction_1,Compound 5,Competitive,,,,,,
PMID33166455,reaction_2,ZnCl2,,,,,,,
PMID33166455,reaction_2,AlCl3,,,,,,,
PMID33166455,reaction_2,CuCl2,,,,,,,
PMID33168750,reaction_1,Mg-ADP,Product,,,,,,Causes long pauses (~21.3 s) in rotation. Stops rotation at an angular position of +2.6° relative to the ATP binding dwell.
PMID33168750,reaction_1,AMP-PNP,Competitive,,,,,,Nonhydrolyzable ATP analog. Causes irreversible stall of rotation. Stalls at an angular position of -5.5° relative to the ATP binding dwell.
PMID33168750,reaction_1,ζ-subunit,Regulatory,,,,,,Causes stall of rotation for >10 min. Stalls at an angular position of -1.5° relative to the ATP binding dwell.
PMID33168750,reaction_1,Pi,Product,,,,,,High concentrations (300 mM) decrease rotation speed by ~95%. Effect is partly due to high ionic strength.
PMID33187806,reaction_1_LmDHFR,Compound 26,,,,,,,
PMID33187806,reaction_1_LmDHFR,Compound 27,,,,,,,
PMID33187806,reaction_1_LmDHFR,Compound 28,,,,,,,
PMID33187806,reaction_1_LmDHFR,Compound 29,,,,,,,
PMID33187806,reaction_1_LmDHFR,Compound 30,,,,,,,
PMID33187806,reaction_1_LmDHFR,Compound 52,,,,,,,
PMID33187806,reaction_1_LmDHFR,Compound 54,,,,,,,
PMID33187806,reaction_1_LmDHFR,Compound 55,,,,,,,
PMID33187806,reaction_1_LmDHFR,Compound 56,,,,,,,
PMID33187806,reaction_1_LmDHFR,Compound 57,,,,,,,
PMID33187806,reaction_1_LmDHFR,Compound 58,,,,,,,
PMID33187806,reaction_1_LmDHFR,Compound 59,,,,,,,
PMID33187806,reaction_1_LmDHFR,Methotrexate,,,,,,,
PMID33187806,reaction_1_LmDHFR,Trimethoprim (TMP),,,,,,,
PMID33187806,reaction_2_hDHFR,Compound 26,,,,,,,
PMID33187806,reaction_2_hDHFR,Compound 29,,,,,,,
PMID33187806,reaction_2_hDHFR,Compound 30,,,,,,,
PMID33187806,reaction_2_hDHFR,Compound 52,,,,,,,
PMID33187806,reaction_2_hDHFR,Compound 54,,,,,,,
PMID33187806,reaction_2_hDHFR,Compound 55,,,,,,,
PMID33187806,reaction_2_hDHFR,Compound 56,,,,,,,
PMID33187806,reaction_2_hDHFR,Compound 57,,,,,,,
PMID33187806,reaction_2_hDHFR,Compound 58,,,,,,,
PMID33187806,reaction_2_hDHFR,Compound 59,,,,,,,
PMID33187806,reaction_2_hDHFR,Trimethoprim (TMP),,,,,,,
PMID33197770,reaction_2,diphenyleneiodonium chloride (DPI),Pan NOX inhibitor,,,,,,DPI treatment eliminated ROS accumulation in ethanol-stimulated cells and reversed the decline of FASTK expression.
PMID33197770,reaction_3,rotenone,Complex I inhibitor,,,,,,"Rotenone blocked the protective effects of FASTK overexpression against ethanol-induced cell death, confirming the requirement of Complex I activity."
PMID33199626,reaction_1,Rifampicin,Blocks RNA extension,,,,,,
PMID33199626,reaction_1,Sorangicin A,Blocks RNA extension,,,,,,
PMID33199626,reaction_2,Rifampicin,Blocks RNA extension,,,,,,
PMID33199626,reaction_2,Sorangicin A,Blocks promoter unwinding from RP2 to RPo,,,,,,
PMID33199626,reaction_3,Rifampicin,Blocks RNA extension,,,,,,
PMID33199626,reaction_3,Sorangicin A,Blocks RNA extension,,,,,,
PMID33199626,reaction_4,Rifampicin,Blocks RNA extension,,,,,,
PMID33199626,reaction_4,Sorangicin A,Blocks RNA extension,,,,,,
PMID33199626,reaction_5,Sorangicin A,Does not inhibit RPo formation,,,,,,
PMID33199626,reaction_6,Sorangicin A,Blocks transition from RP2 to RPo,,,,,,
PMID33215746,reaction_1,"6-hydroxy-2-methylthiazolo[4,5-d]pyrimidine-5,7(4H,6H)-dione","Competitive, time-dependent, slow-binding",Cc1nc2[nH]c(=O)n([O-])c(=O)c2s1,NSC116565,,,,"Inhibits growth of M. tuberculosis H37Ra and H37Rv with MIC50 values of 2.93 µM and 6.06 µM, respectively. This inhibition is rescued by supplementation with branched-chain amino acids, confirming the in-vivo target."
PMID33215746,reaction_1,"cyclopropane-1,1-dicarboxylate",Competitive,O=C([O-])C1(C(=O)[O-])CC1,CPD,,,,"No significant heat change was observed by ITC in the absence of NADPH, indicating no binding under these conditions. Ki value of 3.03 µM is cited from other literature."
PMID33219201,reaction_1,AZD7545,PDK2 inhibitor,,,,,,"Administered in vivo via intracerebroventricular (icv) injection (6.4 nM of CSF concentration) to mice. Inhibition was confirmed by downstream physiological effects (attenuation of proinflammatory cytokines and food intake), not by direct measurement of enzyme activity."
PMID33240775,reaction_1,Curcumol,Not specified,,,,,,
PMID33241108,reaction_1,Meldonium,"Blocks the catalytic pocket of BBOX1. In mouse xenograft models, Meldonium suppressed tumorigenesis.",,,,,,
PMID33241249,reaction_1,CdSO4,,,,,,,
PMID33241249,reaction_1,HgCl2,,,,,,,
PMID33241249,reaction_1,LiSO4,,,,,,,
PMID33241249,reaction_1,CuSO4,,,,,,,
PMID33241249,reaction_1,PbCl2,,,,,,,
PMID33241249,reaction_1,ZnSO4,,,,,,,
PMID33241249,reaction_1,NiSO4,,,,,,,
PMID33241249,reaction_2,CdSO4,,,,,,,
PMID33241249,reaction_2,HgCl2,,,,,,,
PMID33241249,reaction_2,LiSO4,,,,,,,
PMID33241249,reaction_2,CuSO4,,,,,,,
PMID33241249,reaction_2,PbCl2,,,,,,,
PMID33241249,reaction_2,ZnSO4,,,,,,,
PMID33241249,reaction_2,NiSO4,,,,,,,
PMID33248851,reaction_1,Compound 11a,Competitive,,,,,,
PMID33248851,reaction_1,Compound 11b,Competitive,,,,,,
PMID33248851,reaction_1,Compound 11c,Competitive,,,,,,
PMID33248851,reaction_1,Compound 11d,Competitive,,,,,,
PMID33248851,reaction_1,Compound 11e,Competitive,,,,,,
PMID33248851,reaction_1,Compound 11f,Competitive,,,,,,
PMID33248851,reaction_1,Compound 11g,Competitive,,,,,,
PMID33248851,reaction_1,Compound 11h,Competitive,,,,,,
PMID33248851,reaction_1,Compound 11i,Competitive,,,,,,
PMID33248851,reaction_1,Compound 11j,Competitive,,,,,,
PMID33248851,reaction_1,Compound 11k,Competitive,,,,,,
PMID33248851,reaction_1,Compound 15,Competitive,,,,,,
PMID33248851,reaction_1,Leucyl-sulfamate adenosine (LeuSA),Competitive,,,,,,
PMID33249835,reaction_1,Mn2+,Complete inhibition at 1 mM,,,,,,
PMID33249835,reaction_1,Zn2+,Complete inhibition at 1 mM,,,,,,
PMID33249835,reaction_1,Cu2+,Complete inhibition at 1 mM,,,,,,
PMID33249835,reaction_1,Ni2+,Complete inhibition at 1 mM,,,,,,
PMID33249835,reaction_1,Co2+,Complete inhibition at 1 mM,,,,,,
PMID33249835,reaction_1,EDTA,Complete inactivation at 1 mM,,,,,,
PMID33257538,reaction_1_translocation,pSpy2x (unlabeled),Competitive,,,,,Used in excess to create single-turnover conditions with respect to transport initiation.,
PMID33267982,reaction_1,SDS,,,,,,"Activity increased by 9.06% at 0.25 mM SDS. Activity was significantly reduced with increased SDS concentration, but maintained above 60% at concentrations < 1 mM and above 40% at 30 mM.",
PMID33267982,reaction_2,SDS,,,,,,"Activity increased by 9.06% at 0.25 mM SDS. Activity was significantly reduced with increased SDS concentration, but maintained above 60% at concentrations < 1 mM and above 40% at 30 mM.",
PMID33267982,reaction_3,SDS,,,,,,"Activity increased by 9.06% at 0.25 mM SDS. Activity was significantly reduced with increased SDS concentration, but maintained above 60% at concentrations < 1 mM and above 40% at 30 mM.",
PMID33267982,reaction_4,SDS,,,,,,"Activity increased by 9.06% at 0.25 mM SDS. Activity was significantly reduced with increased SDS concentration, but maintained above 60% at concentrations < 1 mM and above 40% at 30 mM.",
PMID33267982,reaction_5,SDS,,,,,,"Activity increased by 9.06% at 0.25 mM SDS. Activity was significantly reduced with increased SDS concentration, but maintained above 60% at concentrations < 1 mM and above 40% at 30 mM.",
PMID33267982,reaction_6,SDS,,,,,,"Activity increased by 9.06% at 0.25 mM SDS. Activity was significantly reduced with increased SDS concentration, but maintained above 60% at concentrations < 1 mM and above 40% at 30 mM.",
PMID33267982,reaction_7,SDS,,,,,,"Activity increased by 9.06% at 0.25 mM SDS. Activity was significantly reduced with increased SDS concentration, but maintained above 60% at concentrations < 1 mM and above 40% at 30 mM.",
PMID33267982,reaction_8,SDS,,,,,,"Activity was significantly reduced with increased SDS concentration, but maintained above 60% at concentrations < 1 mM and above 40% at 30 mM. No activation observed at low concentrations.",
PMID33267982,reaction_9,SDS,,,,,,"Activity was significantly reduced with increased SDS concentration, but maintained above 60% at concentrations < 1 mM and above 40% at 30 mM. No activation observed at low concentrations.",
PMID33267982,reaction_10,SDS,,,,,,"Activity was significantly reduced with increased SDS concentration, but maintained above 60% at concentrations < 1 mM and above 40% at 30 mM. No activation observed at low concentrations.",
PMID33267982,reaction_11,SDS,,,,,,"Activity was significantly reduced with increased SDS concentration, but maintained above 60% at concentrations < 1 mM and above 40% at 30 mM. No activation observed at low concentrations.",
PMID33267982,reaction_12,SDS,,,,,,"Activity was significantly reduced with increased SDS concentration, but maintained above 60% at concentrations < 1 mM and above 40% at 30 mM. No activation observed at low concentrations.",
PMID33267982,reaction_13,SDS,,,,,,"Activity was significantly reduced with increased SDS concentration, but maintained above 60% at concentrations < 1 mM and above 40% at 30 mM. No activation observed at low concentrations.",
PMID33267982,reaction_14,SDS,,,,,,"Activity was significantly reduced with increased SDS concentration, but maintained above 60% at concentrations < 1 mM and above 40% at 30 mM. No activation observed at low concentrations.",
PMID33267982,reaction_15,SDS,,,,,,"Activity was significantly reduced with increased SDS concentration, but maintained above 60% at concentrations < 1 mM and above 40% at 30 mM. No activation observed at low concentrations.",
PMID33267982,reaction_16,SDS,,,,,,"Activity was significantly reduced with increased SDS concentration, but maintained above 60% at concentrations < 1 mM and above 40% at 30 mM. No activation observed at low concentrations.",
PMID33267982,reaction_17,SDS,,,,,,"Activity was significantly reduced with increased SDS concentration, but maintained above 60% at concentrations < 1 mM and above 40% at 30 mM. No activation observed at low concentrations.",
PMID33267982,reaction_18,SDS,,,,,,"Activity was significantly reduced with increased SDS concentration, but maintained above 60% at concentrations < 1 mM and above 40% at 30 mM. No activation observed at low concentrations.",
PMID33267982,reaction_19,SDS,,,,,,"Activity was significantly reduced with increased SDS concentration, but maintained above 60% at concentrations < 1 mM and above 40% at 30 mM. No activation observed at low concentrations.",
PMID33267982,reaction_20,SDS,,,,,,"Activity was significantly reduced with increased SDS concentration, but maintained above 60% at concentrations < 1 mM and above 40% at 30 mM. No activation observed at low concentrations.",
PMID33267982,reaction_21,SDS,,,,,,"Activity was significantly reduced with increased SDS concentration, but maintained above 60% at concentrations < 1 mM and above 40% at 30 mM. No activation observed at low concentrations.",
PMID33269912,reaction_1,8,Inhibitor of BfrB-Bfd protein-protein interaction,Nc1cccc2c1C(=O)NC2=O,,,,,
PMID33269912,reaction_1,11,Inhibitor of BfrB-Bfd protein-protein interaction,O=C1NC(=O)c2c(NCc3ccccc3O)cccc21,,,,,
PMID33269912,reaction_1,KM-5-29,Inhibitor of BfrB-Bfd protein-protein interaction,O=C1NC(=O)c2c(NCc3c(O)cccc3Cl)cccc21,,,,,
PMID33269912,reaction_1,JAG-5-7,Inhibitor of BfrB-Bfd protein-protein interaction,O=C1NC(=O)c2c(NCc3cc(F)ccc3O)cccc21,,,,,
PMID33269912,reaction_1,KM-5-25,Inhibitor of BfrB-Bfd protein-protein interaction,O=C1NC(=O)c2c(NCc3cc(Cl)ccc3O)cccc21,,,,,
PMID33269912,reaction_1,KM-5-30,Inhibitor of BfrB-Bfd protein-protein interaction,O=C1NC(=O)c2c(NCc3cccc(Cl)c3O)cccc21,,,,,
PMID33269912,reaction_1,BN-XIV-53,Inhibitor of BfrB-Bfd protein-protein interaction,O=C1NC(=O)c2c(NCc3cccc(O)c3)cccc21,,,,,
PMID33269912,reaction_1,KM-5-50,Inhibitor of BfrB-Bfd protein-protein interaction,O=C1NC(=O)c2c(NCc3cc(O)cc(Cl)c3)cccc21,,,,,
PMID33269912,reaction_1,KM-5-28,Inhibitor of BfrB-Bfd protein-protein interaction,O=C1NC(=O)c2c(NCCCc3ccccc3O)cccc21,,,,,
PMID33269912,reaction_1,JAG-5-6,Inhibitor of BfrB-Bfd protein-protein interaction,O=C1NC(=O)c2c(NCCCc3cc(F)ccc3O)cccc21,,,,,
PMID33269912,reaction_1,KM-5-54,Inhibitor of BfrB-Bfd protein-protein interaction,O=C1NC(=O)c2c(NCCCc3cc(Cl)ccc3O)cccc21,,,,,
PMID33269912,reaction_1,16,Inhibitor of BfrB-Bfd protein-protein interaction,O=C1NC(=O)c2c(NCCCc3cccc(O)c3)cccc21,,,,,
PMID33269912,reaction_1,KM-5-57,Inhibitor of BfrB-Bfd protein-protein interaction,O=C1NC(=O)c2c(NCCCc3cc(O)cc(O)c3)cccc21,,,,,
PMID33269912,reaction_1,KM-5-66,Inhibitor of BfrB-Bfd protein-protein interaction,O=C1NC(=O)c2c(NCCCc3cc(O)cc(Cl)c3)cccc21,,,,,
PMID33275878,reaction_1,m-nitrobenzoylalanine (m-NBA),Effector,,,,,,
PMID33275878,reaction_1,"3,4-dichlorobenzoylalanine",Effector,,,,,,
PMID33275878,reaction_1,UPF-648,Effector,,,,,,
PMID33275878,reaction_1,Ro 61-8048,Not specified,,,,,,
PMID33275878,reaction_1,JM6,Prodrug,,,,,,
PMID33275878,reaction_1,CHDI-340246,Not specified,,,,,,
PMID33275878,reaction_1,Compound 1,Not specified,,,,,,
PMID33289180,reaction_1,NaNO2,Not specified,,,,,,
PMID33314785,reaction_1,Methotrexate,"Inhibitor (type not specified, used for selection at 1 nM, 10 nM, 100 nM, and 1 µM)",,,,,,
PMID33318976,reaction_1,NAD+,Competitive product inhibition,,,,,,
PMID33318976,reaction_2,NADP+,Competitive product inhibition,,,,,,
PMID33342435,reaction_1,ETH2120,Ionophore (prevents Na+ accumulation),,,,,Completely prevented accumulation of 22Na+ in proteoliposomes.,
PMID33348877,reaction_1,Lapatinib,EGFR family kinase inhibitor,,,,,,
PMID33348877,reaction_2,Vatalanib,VEGFR2-specific inhibitor,,,,,,
PMID33348877,reaction_3,Chloroquine,Lysosomal degradation inhibitor,,,,,,
PMID33359168,reaction_1_mKMO,Compound 2,,,,,,,
PMID33359168,reaction_1_mKMO,Compound 3,,,,,,,
PMID33359168,reaction_1_mKMO,Compound 4,,,,,,,
PMID33359168,reaction_1_mKMO,Compound 5,,,,,,,
PMID33359168,reaction_1_mKMO,Compound 6,,,,,,,31% inhibition at an unstated concentration.
PMID33359168,reaction_1_mKMO,Compound 7,,,,,,,16% inhibition at an unstated concentration.
PMID33359168,reaction_1_mKMO,Compound 8,,,,,,,
PMID33359168,reaction_1_mKMO,Compound 9,,,,,,,
PMID33359168,reaction_1_mKMO,Compound 10,,,,,,,
PMID33359168,reaction_1_mKMO,Compound 11,,,,,,,
PMID33359168,reaction_1_mKMO,Compound 12,,,,,,,"In an in vivo study, oral administration to R6/2 mice (100 mg/kg, twice daily for 7 weeks) significantly suppressed the increase in 3-HK and increased KYNA in the striatum, and improved cognitive function."
PMID33359168,reaction_1_mKMO,Compound 13,,,,,,,
PMID33359168,reaction_1_mKMO,Compound 14,,,,,,,IC50 > 100 nM
PMID33359168,reaction_1_mKMO,Compound 15,,,,,,,
PMID33359168,reaction_1_mKMO,Compound 16,,,,,,,
PMID33359168,reaction_1_mKMO,Compound 17,,,,,,,
PMID33359168,reaction_1_mKMO,Compound 18,,,,,,,
PMID33359168,reaction_1_mKMO,Compound 19,,,,,,,
PMID33359168,reaction_1_mKMO,Compound 20,,,,,,,
PMID33359168,reaction_1_mKMO,Compound 21,,,,,,,
PMID33359168,reaction_1_mKMO,CHDI-340246,,,,,,,
PMID33359168,reaction_1_mKMO,Ro-61-8048,,,,,,,
PMID33359168,reaction_2_hKMO,Compound 11,,,,,,,
PMID33359168,reaction_2_hKMO,Compound 12,,,,,,,The value of 1.7 nM is from the text; Table 1 reports a value of 3.3 nM.
PMID33359168,reaction_2_hKMO,Compound 16,,,,,,,
PMID33359168,reaction_2_hKMO,Compound 17,,,,,,,36% inhibition at 100 nM.
PMID33359168,reaction_2_hKMO,Compound 21,,,,,,,
PMID33359168,reaction_2_hKMO,CHDI-340246,,,,,,,
PMID33359168,reaction_2_hKMO,Ro-61-8048,,,,,,,
PMID33359308,reaction_1_BV_mediator,Nitrite,No inhibition observed,,,,,,
PMID33359308,reaction_2_AQS_mediator,Nitrite,No inhibition observed,,,,,,
PMID33359609,reaction_1,Sodium metabisulfite,Noncompetitive,,,,,,
PMID33359609,reaction_1,Ascorbic acid,Competitive,,,,,,
PMID33359609,reaction_1,Benzoic acid,Uncompetitive,,,,,,
PMID33359609,reaction_1,L-Cysteine,Competitive,,,,,,
PMID33359609,reaction_1,β-mercaptoethanol,Competitive,,,,,,
PMID33359609,reaction_1,Thiourea,Uncompetitive,,,,,,
PMID33359609,reaction_1,Glutathione,Noncompetitive,,,,,,
PMID33359609,reaction_3,Sodium metabisulfite,Noncompetitive,,,,,,
PMID33359609,reaction_3,Ascorbic acid,Competitive,,,,,,
PMID33359609,reaction_3,Benzoic acid,Uncompetitive,,,,,,
PMID33359609,reaction_3,L-Cysteine,Competitive,,,,,,
PMID33359609,reaction_3,β-mercaptoethanol,Competitive,,,,,,
PMID33359609,reaction_3,Thiourea,Uncompetitive,,,,,,
PMID33359609,reaction_3,Glutathione,Noncompetitive,,,,,,
PMID33359609,reaction_4,Sodium metabisulfite,Uncompetitive,,,,,,
PMID33359609,reaction_4,Ascorbic acid,Competitive,,,,,,
PMID33359609,reaction_4,Benzoic acid,Noncompetitive,,,,,,
PMID33359609,reaction_4,L-Cysteine,Competitive,,,,,,
PMID33359609,reaction_4,β-mercaptoethanol,Uncompetitive,,,,,,
PMID33359609,reaction_4,Thiourea,Noncompetitive,,,,,,
PMID33359609,reaction_4,Glutathione,Competitive,,,,,,
PMID33377777,reaction_1,N2O,Substrate inhibition,,,,,Decreasing specific activities were observed at higher substrate concentrations for D576A and D576A/S550A mutants.,
PMID33387577,reaction_1_human,Posaconazole,,,,,,,
PMID33387577,reaction_1_human,Itraconazole,,,,,,,
PMID33387577,reaction_1_human,Hydroxyitraconazole,,,OHI,,,,
PMID33387577,reaction_2_rat,Posaconazole,,,,,,,
PMID33387577,reaction_2_rat,Itraconazole,,,,,,,
PMID33387577,reaction_2_rat,Hydroxyitraconazole,,,OHI,,,,
PMID33387577,reaction_3_mouse,Posaconazole,,,,,,,
PMID33387577,reaction_3_mouse,Itraconazole,,,,,,,
PMID33387577,reaction_3_mouse,Hydroxyitraconazole,,,OHI,,,,
PMID33387577,reaction_4_zebrafish,Posaconazole,,,,,,,
PMID33387577,reaction_4_zebrafish,Itraconazole,,,,,,,
PMID33387577,reaction_4_zebrafish,Hydroxyitraconazole,,,OHI,,,,
PMID33389495,reaction_1,Cyclophosphamide,Irreversible inactivation by oxidation of active site cysteines,,,,,,
PMID33414463,reaction_1,GSK-J4,Not specified,,,,,,
PMID33423475,reaction_1,Sulfate,Not specified,,,,,Uptake of 40 µM Cr(VI) by wild-type Arabidopsis was significantly suppressed by increasing sulfate concentrations (from 0 to 2000 µM).,
PMID33423475,reaction_2,Sulfate,Not specified,,,,,Uptake of Cr(VI) is inhibited by sulfate.,
PMID33436639,reaction_1,BRD1389,Competitive (vs L-Phe) / Non-competitive (vs ATP),,,,,,The primary Ki value (6 ± 2 nM) is for competitive inhibition with respect to L-Phe. A separate Ki of 10 ± 5 nM was determined for non-competitive inhibition with respect to ATP. Comparative inhibition data for orthologs: PvcFRS IC50 = 25 ± 1 nM; HscFRS IC50 = 12000 ± 1200 nM; HscFRS Kd = 16000 nM.
PMID33438819,reaction_1,Brimonidine,Competitive,,,,,,
PMID33438819,reaction_1,Proparacaine,No inhibition,,,,,,
PMID33438819,reaction_2,Brimonidine,Competitive,,,,,,
PMID33438819,reaction_2,Proparacaine,Competitive,,,,,,
PMID33438819,reaction_3,Brimonidine,Noncompetitive,,,,,,
PMID33438819,reaction_3,Proparacaine,Noncompetitive,,,,,,
PMID33454058,reaction_1,"1,2,3,4,6-pentagalloylglucose",Not specified,,,,,,
PMID33454058,reaction_1,(-)-epigallocatechin-3-gallate,Not specified,,,,,,
PMID33454058,reaction_2,"1,2,3,4,6-pentagalloylglucose",Not specified,,,,,,
PMID33454058,reaction_2,(-)-epigallocatechin-3-gallate,Not specified,,,,,,
PMID33469028,reaction_1,Dutasteride,Not specified,,,,,,
PMID33469028,reaction_1,Finasteride,Not specified,,,Weak inhibitor,,,
PMID33498665,reaction_1,S3,Not specified,,,,,,Also known as 1-hydroxy-8-methoxy-anthraquinone. Treatment of MCF7 cells with 20 µM S3 for 24 hours resulted in a ~25% inhibition of 6PGD specific activity. The IC50 for cell proliferation was determined to be ~30 µM after 72h treatment.
PMID33522611,reaction_1,Ascorbic acid,Competitive,,,,,,
PMID33522611,reaction_1,Sodium metabisulfite,Noncompetitive,,,,,,
PMID33522611,reaction_1,Citric acid,Noncompetitive,,,,,,
PMID33522611,reaction_1,Benzoic acid,Competitive,,,,,,
PMID33522611,reaction_1,Na+,Inhibition observed,,,,,Residual activity was 44.19 ± 1.558 % at 1 mM and 49.45 ± 0.951 % at 10 mM.,
PMID33522611,reaction_1,K+,Inhibition observed,,,,,Residual activity was 50.23 ± 0.587 % at 1 mM and 43.95 ± 0.748 % at 10 mM.,
PMID33522611,reaction_1,Mg2+,Inhibition observed,,,,,Residual activity was 53.53 ± 1.993 % at 1 mM and 34.06 ± 0.763 % at 10 mM.,
PMID33522611,reaction_1,Cu2+,Inhibition observed,,,,,Residual activity was 49.84 ± 1.424 % at 1 mM and 0.94 ± 0.493 % at 10 mM.,
PMID33522611,reaction_1,Al3+,Inhibition observed,,,,,Residual activity was 48.74 ± 0.498 % at 1 mM and 11.61 ± 0.667 % at 10 mM.,
PMID33531363,reaction_1,NADP+,Feedback regulation,,,,,,
PMID33531496,reaction_1,Compound 1 (GRL0617): 5-amino-2-methyl-N-[(1R)-1-naphthalen-1-ylethyl]benzamide,Non-covalent,,,,,,EC50 in whole cell virus replication assay is in the range of 1.4 to 5.2 µM.
PMID33531496,reaction_1,Compound 2: 5-carbamylurea-2-methyl-N-[(1R)-1-naphthalen-1-ylethyl]benzamide,Non-covalent,,,,,,Failed in the viral replication assay.
PMID33531496,reaction_1,Compound 3: 5-acrylamide-2-methyl-N-[(1R)-1-naphthalen-1-ylethyl]benzamide,Non-covalent,,,,,,Failed in the viral replication assay.
PMID33531496,reaction_1,Compound 4: 3-amino-N-(naphthalene-1-yl)-5-trifluoromethyl)benzamide,Non-covalent,,,,,,IC50 is within the range of 5.1–32.8 μM. EC50 in whole cell virus replication assay is in the range of 1.4 to 5.2 µM.
PMID33531496,reaction_1,Compound 5: 5-(butylcarbamoylamino)-2-methyl-N-[(1R)-1-naphthalen-1-ylethyl]benzamide,Non-covalent,,,,,,EC50 in whole cell virus replication assay is 2.5 µM.
PMID33531496,reaction_1,Compound 6: 5-(((4-nitrophenoxy)carbonyl)amino)-2-methyl-N-[(1R)-1-naphthalen-1-ylethyl]benzamide,Non-covalent,,,,,,IC50 is within the range of 5.1–32.8 μM. Inhibited virus replication in whole cell assay.
PMID33531496,reaction_1,Compound 7: 5-pentanoylamino-2-methyl-N-[(1R)-1-naphthalen-1-ylethyl]benzamide,Non-covalent,,,,,,IC50 is within the range of 5.1–32.8 μM. EC50 in whole cell virus replication assay is in the range of 1.4 to 5.2 µM.
PMID33548859,reaction_1,asymmetric dimethylarginine,Competitive,,ADMA,,,,
PMID33548859,reaction_1,4-oxo-2-nonenal,Not specified,,ONE,,,,"Inhibits enzymatic activity by modifying Lys residues (e.g., K519, K1085) involved in cofactor binding sites. Addition of ONE to recombinant eNOS strongly decreased NO production [127]."
PMID33556357,reaction_1,NADP+,Competitive,,,,,,
PMID33556357,reaction_1,2'-AMP,Competitive,,,,,,
PMID33556357,reaction_1,"2',5'-ADP",Competitive,,,,,,
PMID33556357,reaction_2,NAD+,Competitive,,,,,,
PMID33564100,reaction_1,(R)-PFI-2,,,,,,,"Inhibited SRF-dependent gene expression in C2C12 cells, suggesting inhibition of SET7 activity on SRF."
PMID33564100,reaction_1,Sinefungin,,,,,,,Pan-methyltransferase inhibitor that reduced SRF-dependent gene expression in C2C12 cells.
PMID33592267,reaction_1,Mn2+,Not specified,,,,,,
PMID33592267,reaction_1,Fe3+,Not specified,,,,,,
PMID33592267,reaction_2,Mn2+,Not specified,,,,,,
PMID33592267,reaction_2,Fe3+,Not specified,,,,,,
PMID33592267,reaction_3,Mn2+,Not specified,,,,,,
PMID33592267,reaction_3,Fe3+,Not specified,,,,,,
PMID33610817,reaction_1,Euphorbia regis-jubae hydroethanolic extract,Not specified,,,,,,
PMID33610817,reaction_1,Euphorbia regis-jubae aqueous extract,Not specified,,,,,,
PMID33610817,reaction_1,Quercetin,Not specified,,,,,,
PMID33623002,reaction_1,Pyocyanin,Inactivation at high concentration (1 mM).,,,,,,
PMID33624785,reaction_1,Pomolic acid,Suppression of the increase in GPDH activity level in differentiated 3T3-L1 adipocytes. Activity was significantly lower (P < .05) at concentrations >10 µM compared to the DMSO control when added after differentiation induction.,,,,,,
PMID33624785,reaction_1,Oleanolic acid,No apparent effect on GPDH activity in differentiated 3T3-L1 adipocytes.,,,,,,
PMID33624785,reaction_1,Ursolic acid,No apparent effect on GPDH activity in differentiated 3T3-L1 adipocytes.,,,,,,
PMID33649331,reaction_1,ADP,Not specified,,,,,ADP binding to the FAD-binding site inhibits UrdA' activity.,
PMID33668802,reaction_1,NADH,Competitive with respect to NAD+,,,,,,
PMID33668802,reaction_1,AMP,Competitive with respect to NAD+,,,,,,
PMID33668802,reaction_1,"adenosine 5′-O-[S-(4-hydroxy-2,3-dioxobutyl)]-thiophosphate",Irreversible (time-dependent),,,,,"Inactivation follows the Kitz and Wilson model. The maximum rate of inactivation (k3) is 0.198 ± 0.06 min⁻¹. The reaction was carried out in 50 mM borate buffer, pH 8.0 at 25 °C. NAD+ and NADH protect the enzyme from inactivation.",
PMID33677743,reaction_2,"Additives in CFVR (e.g., antioxidants)",Unspecified. Removal of inhibitors by solvent extraction significantly increased product formation from 3.8 a.u. (untreated) to over 22 a.u. (pretreated with chloroform or cyclohexane).,,,,,,
PMID33684554,reaction_1_head,ouabain,,,,,,,
PMID33684554,reaction_2_thorax,ouabain,,,,,,,
PMID33684554,reaction_3_abdomen,ouabain,,,,,,,
PMID33689977,reaction_1,"(E)-3-(4-((3r, 5r, 7r)-adamantan-1-yl) phenoxy)-N-(5-(piperidine-1-carbonyl)-1, 4-dihydroindeno [1, 2-c] pyrazol-3-yl) acrylamide",Predicted NADH-competitive,O=C(/C=C/Oc1ccc(C23CC4CC(CC(C4)C2)C3)cc1)Nc1n[nH]c2c1Cc1c(C(=O)N3CCCCC3)cccc1-2,,,,,
PMID33689977,reaction_1,"2-(4-((3r, 5r, 7r)-adamantan-1-yl)-3-hydroxy phenoxy)-N-(5-(piperidine-1-carbonyl)-1, 4-dihydroindeno [1, 2-c] pyrazol-3-yl) acetamide",Predicted NADH-competitive,O=C(COc1ccc(C23CC4CC(CC(C4)C2)C3)c(O)c1)Nc1n[nH]c2c1Cc1c(C(=O)N3CCCCC3)cccc1-2,,,,,
PMID33689977,reaction_1,"2-(4-((3r, 5r, 7r)-adamantan-1-yl phenoxy)-N-(5-(piperidine-1-carbonyl)-1, 4-dihydroindeno [1, 2-c] pyrazol-3-yl) acetamide",Predicted NADH-competitive,O=C(COc1ccc(C23CC4CC(CC(C4)C2)C3)cc1)Nc1n[nH]c2c1Cc1c(C(=O)N3CCCCC3)cccc1-2,,,,,
PMID33689977,reaction_1,"5-((3r, 5r, 7r)-adamantan-1-yl)-N-(5-(piperidine-1-carbonyl)-1, 4-dihydroindeno [1, 2-c] pyrazol-3-yl) furan-2-carboxamide",Predicted NADH-competitive,O=C(Nc1n[nH]c2c1Cc1c(C(=O)N3CCCCC3)cccc1-2)c1ccc(C23CC4CC(CC(C4)C2)C3)o1,,,,,
PMID33689977,reaction_1,"3-(2-(4-((3r, 5r, 7r)-adamantan-1-yl) phenoxy acetamido)-1, 4-dihydroindeno [1, 2-c] pyrazole-5-carboxylic acid",Predicted NADH-competitive,,,,,,
PMID33689977,reaction_1,"3-(5-((3r, 5r, 7r)-adamantan-1-yl) furan-2-carboxamido)-1, 4-dihydroindeno [1, 2-c] pyrazole-5-carboxylic acid",Predicted NADH-competitive,,,,,,
PMID33691103,reaction_1,6-aminonicotinamide,,,6-AN,,,,"Used at 10 mM concentration in cell culture to pharmacologically inhibit 6PGD. Inhibition recapitulated the phenotype of genetic ablation, including enhanced T effector function and glycogen buildup."
PMID33691103,reaction_2,dehydroepiandrosterone,,,DHEA,,,,Used at 20 mM concentration in cell culture. Inhibition of G6PD with DHEA did not enhance T cell activation and resulted in significantly lower cell viability compared to vehicle control.
PMID33725631,reaction_1,ZCL539,Not specified,,,,,,
PMID33725631,reaction_1,Compound 3,Not specified,,,,,,
PMID33725631,reaction_1,Compound 15,Not specified,,,,,,
PMID33725631,reaction_1,Compound 16,Not specified,,,,,,
PMID33725631,reaction_1,Compound 17,Not specified,,,,,,
PMID33725631,reaction_1,Compound 18,Not specified,,,,,,
PMID33725631,reaction_1,Compound 19,Not specified,,,,,,
PMID33725631,reaction_1,Compound 20,Not specified,,,,,,
PMID33725631,reaction_1,Compound 21,Not specified,,,,,,
PMID33725631,reaction_1,Compound 22,Not specified,,,,,,
PMID33725631,reaction_1,Compound 64,Not specified,,,,,,
PMID33725631,reaction_1,Compound 65,Not specified,,,,,,
PMID33725631,reaction_1,Compound 66,Not specified,,,,,,
PMID33725631,reaction_1,Compound 67,Not specified,,,,,,
PMID33725631,reaction_1,Compound 68,Not specified,,,,,,
PMID33725631,reaction_1,Compound 69,Not specified,,,,,,
PMID33725631,reaction_1,Compound 70,Not specified,,,,,,
PMID33725631,reaction_1,Compound 71,Not specified,,,,,,
PMID33725631,reaction_1,Compound 72,Not specified,,,,,,
PMID33725631,reaction_1,Compound 73,Not specified,,,,,,
PMID33725631,reaction_1,Compound 74,Not specified,,,,,,
PMID33725631,reaction_1,Compound 75,Not specified,,,,,,
PMID33725631,reaction_1,Compound 76,Not specified,,,,,,
PMID33725631,reaction_1,Compound 77,Not specified,,,,,,
PMID33725631,reaction_1,Compound 78,Not specified,,,,,,
PMID33725631,reaction_1,Compound 79,Not specified,,,,,,
PMID33725631,reaction_1,Compound 80,Not specified,,,,,,
PMID33725631,reaction_1,Compound 81,Not specified,,,,,,
PMID33725631,reaction_1,Compound 82,Not specified,,,,,,
PMID33725631,reaction_1,Compound 83,Not specified,,,,,,
PMID33725631,reaction_1,Compound 84,Not specified,,,,,,
PMID33725631,reaction_1,Compound 85,Not specified,,,,,,
PMID33725631,reaction_1,Compound 86,Not specified,,,,,,
PMID33725631,reaction_1,Compound 87,Not specified,,,,,,
PMID33725631,reaction_1,Compound 88,Not specified,,,,,,
PMID33725631,reaction_1,Compound 89,Not specified,,,,,,
PMID33725631,reaction_1,Compound 90,Not specified,,,,,,
PMID33725631,reaction_1,Compound 91,Not specified,,,,,,
PMID33748704,reaction_1,"1,10-phenanthroline",Zn2+ chelation,,,,,,"Treatment of wild-type ProRS with the Zn2+ chelator 1,10-phenanthroline resulted in an ~80% loss of aminoacylation activity."
PMID33750543,reaction_1,Phosphate buffer,Not specified,,,,,Enzyme activity was completely lost in phosphate buffer.,
PMID33750543,reaction_2,Phosphate buffer,Not specified,,,,,Enzyme activity was completely lost in phosphate buffer.,
PMID33750543,reaction_3,Phosphate buffer,Not specified,,,,,Enzyme activity was completely lost in phosphate buffer.,
PMID33750543,reaction_4,Phosphate buffer,Not specified,,,,,Enzyme activity was completely lost in phosphate buffer.,
PMID33750543,reaction_5,Phosphate buffer,Not specified,,,,,Enzyme activity was completely lost in phosphate buffer.,
PMID33750543,reaction_6,Phosphate buffer,Not specified,,,,,Enzyme activity was completely lost in phosphate buffer.,
PMID33774358,reaction_1,Pyrophosphate,Chelation of active species,,,,,Pyrophosphate (2 mM) decreased the oxidation rate from 87.04% to 20.39% by complexing with the active species Mn3+.,
PMID33774358,reaction_1,H2O2,Substrate inhibition,,,,,"H2O2 concentrations above 0.2 mM inhibited the degradation, possibly by oxidizing the enzyme to an inactivated form.",
PMID33787231,reaction_1,1a1,,,,,,,
PMID33787231,reaction_1,2a,,,,,,,
PMID33787231,reaction_1,2b,,,,,,,
PMID33787231,reaction_1,2c,,,,,,,
PMID33787231,reaction_1,2d,,,,,,,
PMID33787231,reaction_1,2e,,,,,,,
PMID33787231,reaction_1,2f,,,,,,,
PMID33787231,reaction_1,2g,,,,,,,
PMID33787231,reaction_1,2h,,,,,,,
PMID33787231,reaction_1,2i,,,,,,,
PMID33787231,reaction_1,2j,,,,,,,
PMID33787231,reaction_1,2l,,,,,,,
PMID33787231,reaction_1,2m,,,,,,,
PMID33787231,reaction_1,2n,,,,,,,
PMID33787231,reaction_1,2o,,,,,,,
PMID33787231,reaction_1,2p,,,,,,,
PMID33787231,reaction_1,2q,,,,,,,
PMID33787231,reaction_1,3a,,,,,,,
PMID33787231,reaction_1,3b,,,,,,,
PMID33787231,reaction_1,3c,,,,,,,
PMID33787231,reaction_1,3d,,,,,,,
PMID33787231,reaction_1,3e,,,,,,,
PMID33787231,reaction_1,4a,,,,,,,
PMID33787231,reaction_1,4b,,,,,,,
PMID33787231,reaction_1,4c,,,,,,,
PMID33787231,reaction_1,4d,,,,,,,
PMID33787231,reaction_1,4e,,,,,,,
PMID33787231,reaction_1,5a,,,,,,,
PMID33787231,reaction_1,5b,,,,,,,
PMID33787231,reaction_1,5c,,,,,,,
PMID33787231,reaction_1,5d,,,,,,,
PMID33787231,reaction_1,5e,,,,,,,
PMID33787231,reaction_1,saflufenacil,,,,,,,
PMID33787231,reaction_1,6a,,,,,,,
PMID33787231,reaction_1,6b,,,,,,,
PMID33787231,reaction_1,6c,,,,,,,
PMID33787231,reaction_1,6d,,,,,,,
PMID33787231,reaction_1,6e,,,,,,,
PMID33787231,reaction_1,6f,,,,,,,
PMID33787231,reaction_1,6g,,,,,,,
PMID33787231,reaction_1,6h,,,,,,,
PMID33787231,reaction_1,6i,,,,,,,
PMID33793849,reaction_1,Chromate,Competitive,,,,,,
PMID33799204,reaction_2,terbufos,suicide inhibitor,,,,,,Pre-treatment of protoplasts with 2 mM terbufos for 2h dramatically lowered the 13-HpOTrE-reductase activity by about 30-fold.
PMID33804376,reaction_1,Kojic acid,,,,,,,
PMID33804376,reaction_1,Undecanoic acid,,,,,,,
PMID33804376,reaction_2,Kojic acid,,,,,,,
PMID33804376,reaction_2,Undecanoic acid,,,,,,,
PMID33811992,reaction_1,TX2,Irreversible,,,,,,
PMID33811992,reaction_1,PF-06282999,Irreversible,,,,,,
PMID33811992,reaction_1,AZD-3241,Irreversible,,,,,,
PMID33811992,reaction_1,Compound 1,,,,,,,
PMID33811992,reaction_1,Compound 2,,,,,,,
PMID33811992,reaction_1,Compound 3,,,,,,,
PMID33811992,reaction_1,Compound 4,,,,,,,
PMID33811992,reaction_1,Compound 5,,,,,,,
PMID33811992,reaction_1,Compound 6,,,,,,,
PMID33811992,reaction_1,Compound 7,,,,,,,
PMID33811992,reaction_1,Compound 8,,,,,,,
PMID33811992,reaction_1,Compound 9,,,,,,,
PMID33811992,reaction_1,Compound 10,,,,,,,
PMID33811992,reaction_1,Compound 11,,,,,,,
PMID33811992,reaction_1,Compound 12,,,,,,,Also showed IC50 of 5.0 µM in a human neutrophil assay.
PMID33811992,reaction_1,Compound 13,,,,,,,
PMID33811992,reaction_1,Compound 14,,,,,,,
PMID33811992,reaction_1,Compound 15,,,,,,,
PMID33811992,reaction_1,Compound 16,,,,,,,
PMID33811992,reaction_1,Compound 17,,,,,,,Also showed IC50 of 2.4 µM in a human neutrophil assay.
PMID33811992,reaction_1,Compound 18,,,,,,,
PMID33811992,reaction_1,Compound 19,,,,,,,
PMID33811992,reaction_1,Compound 20,,,,,,,
PMID33811992,reaction_1,Compound 21,,,,,,,
PMID33811992,reaction_1,Compound 22,,,,,,,
PMID33811992,reaction_1,Compound 23,,,,,,,
PMID33811992,reaction_1,Compound 24,,,,,,,
PMID33811992,reaction_1,Compound 25,,,,,,,
PMID33811992,reaction_1,Compound 26,,,,,,,
PMID33811992,reaction_1,Compound 27,,,,,,,
PMID33811992,reaction_1,Compound 28,,,,,,,
PMID33811992,reaction_1,Compound 29,,,,,,,
PMID33811992,reaction_1,Compound 30,,,,,,,
PMID33811992,reaction_1,Compound 31,,,,,,,
PMID33811992,reaction_2,Compound 1,,,,,,,
PMID33811992,reaction_2,Compound 2,,,,,,,
PMID33811992,reaction_2,Compound 3,,,,,,,
PMID33811992,reaction_2,Compound 4,,,,,,,
PMID33811992,reaction_2,Compound 5,,,,,,,
PMID33811992,reaction_2,Compound 6,,,,,,,
PMID33811992,reaction_2,Compound 7,,,,,,,
PMID33811992,reaction_2,Compound 8,,,,,,,
PMID33811992,reaction_2,Compound 9,,,,,,,
PMID33811992,reaction_2,Compound 10,,,,,,,
PMID33811992,reaction_2,Compound 11,,,,,,,
PMID33811992,reaction_2,Compound 12,,,,,,,
PMID33811992,reaction_2,Compound 13,,,,,,,
PMID33811992,reaction_2,Compound 14,,,,,,,
PMID33811992,reaction_2,Compound 15,,,,,,,
PMID33811992,reaction_2,Compound 16,,,,,,,
PMID33811992,reaction_2,Compound 17,,,,,,,
PMID33811992,reaction_2,Compound 21,,,,,,,
PMID33811992,reaction_2,Compound 30,,,,,,,
PMID33811992,reaction_3,Analogs in Table 1,,,,,,,IC50 values in the range of 3-30 nM.
PMID33811992,reaction_3,Compound 21,,,,,,,
PMID33844297,reaction_1,Cyclohexanone,Substrate inhibition,,,,,,
PMID33844297,reaction_1,NADPH,Substrate inhibition,,,,,,
PMID33844297,reaction_1,Cyclohexanone,Substrate inhibition,,,,,,
PMID33844297,reaction_1,Cyclohexanone,Substrate inhibition,,,,,,
PMID33845332,reaction_2,MG132,Proteasome inhibitor,,,,,,
PMID33852856,reaction_9,Apocynin,,,,,,,Significantly reduced ROS levels and improved function and morphology of ifc-KO photoreceptors.
PMID33852856,reaction_10,Apocynin,,,,,,,Ameliorated high cytoplasmic ROS level in DEGS1H132R cells at 50 µM.
PMID33852856,reaction_10,GKT136901,,,,,,,Reduced the superoxide level of DEGS1H132R cells at 10 µM.
PMID33862020,reaction_1,Lumichrome,Competitive with respect to FAD,,,,,,
PMID33862020,reaction_1,Lumichrome,Noncompetitive with respect to NADH,,,,,,
PMID33862020,reaction_1,NAD+,Noncompetitive with respect to NADH (at 10 µM FAD),,,,,,
PMID33862020,reaction_1,NAD+,Noncompetitive with respect to FAD (at 75 µM NADH),,,,,,
PMID33862020,reaction_2,Lumichrome,Competitive with respect to FAD,,,,,,
PMID33862020,reaction_2,Lumichrome,Noncompetitive with respect to NADH,,,,,,
PMID33862020,reaction_2,NAD+,Competitive with respect to FAD (at 50 µM NADH),,,,,,
PMID33862020,reaction_2,NAD+,Competitive with respect to NADH (at 5 µM FAD),,,,,,
PMID33864621,reaction_1,YM155,,,,,,,
PMID33864621,reaction_1,cryptotanshinone,,,,,,,
PMID33864621,reaction_1,tanshinone I,,,,,,,
PMID33864621,reaction_1,GRL0617,,,,,,,
PMID33890631,reaction_1,"Trans, trans-farnesyl bromide",Competitive,,,,,,
PMID33890631,reaction_1,"Trans, trans-farnesyl chloride",Uncompetitive,,,,,,
PMID33890631,reaction_1,"Trans, trans-farnesyl acetate",Competitive,,,,,,
PMID33890631,reaction_1,"Trans, trans-farnesyl acetone",Noncompetitive,,,,,,
PMID33890631,reaction_1,Hexahydrofarnesylacetone,Noncompetitive,,,,,,
PMID33902660,reaction_1,Anastrozole,Not specified,,,,,Used as a tool to probe conformational changes upon ligand binding in the active site.,
PMID33929595,reaction_1,Trimethylpyruvate,Substrate inhibition,,,,,,Substrate inhibition observed at high TMP concentrations (0.5 M).
PMID33929818,reaction_1_Pf_cPRS,Compound 1 (racemate),ATP-competitive,,,,,,
PMID33929818,reaction_1_Pf_cPRS,Compound 1-S,ATP-competitive,,,,,,
PMID33929818,reaction_1_Pf_cPRS,Compound 1-R,ATP-competitive,,,,,,
PMID33929818,reaction_1_Pf_cPRS,Compound 2,ATP-competitive,,,,,,
PMID33929818,reaction_1_Pf_cPRS,Compound 4-S,ATP-competitive,,,,,,
PMID33929818,reaction_1_Pf_cPRS,Halofuginone,Proline-competitive,,,,,,
PMID33929818,reaction_2_Hs_PRS,Compound 1 (racemate),ATP-competitive,,,,,,
PMID33929818,reaction_2_Hs_PRS,Compound 2,ATP-competitive,,,,,,
PMID33929818,reaction_2_Hs_PRS,Compound 4-S,ATP-competitive,,,,,,
PMID33942867,reaction_1,Hydroxylamine,,,,,,,7% residual activity at 1 mM
PMID33942867,reaction_1,CoCl2,,,,,,,6% residual activity at 1 mM
PMID33942867,reaction_1,CuCl2,,,,,,,20% residual activity at 1 mM
PMID33942867,reaction_1,FeCl3,,,,,,,35% residual activity at 1 mM
PMID33942867,reaction_1,NiCl2,,,,,,,16% residual activity at 1 mM
PMID33942867,reaction_1,ZnSO4,,,,,,,7% residual activity at 1 mM
PMID33942867,reaction_1,MnCl2,,,,,,,60% residual activity at 1 mM
PMID33942867,reaction_1,MgCl2,,,,,,,86% residual activity at 1 mM
PMID33942867,reaction_1,L-Arg,,,,,,,4% residual activity at 10 mM
PMID33942867,reaction_1,L-Lys,,,,,,,26% residual activity at 10 mM
PMID33942867,reaction_1,L-His,,,,,,,55% residual activity at 10 mM
PMID33942867,reaction_1,L-Ile,,,,,,,55% residual activity at 10 mM
PMID33942867,reaction_1,L-Trp,,,,,,,50% residual activity at 10 mM
PMID33950676,reaction_1,3-(3-methoxyquinoxalin-2-yl)propanoic acid (CID 1520179),"Unclear; only a decrease in Vmax was detected, which was attributed to protein aggregation induced by the compound.",,,,,,
PMID33950676,reaction_1,2-methylindole-3-acetic acid (CID 589107),"Mixed-type inhibition competitive with NADPH. At 3 mM of the inhibitor, the Km for NADPH increased from 35.8 ± 2.0 µM to 59.4 ± 5.3 µM, with a slight decrease in Vmax (~10%).",,,,,,
PMID33950676,reaction_1,4-aminopiazthiole (CID 69845),Irreversible and NADPH-dependent. Binding to Site 2 was found not to be responsible for the inhibition mechanism.,,,,,,
PMID33950676,reaction_1,indole-3-carbinol (CID 3712),Irreversible and NADPH-dependent. Binding to Site 2 was found not to be responsible for the inhibition mechanism.,,,,,,
PMID33950676,reaction_1,"4-hydroxy-7-methyl-1,8-naphthyridine-3-carboxylic acid (CID 5373672)",Not determined to be an inhibitor in the functional assay. This compound binds to a crystallographic interface (Site 3) and allosterically stabilizes the enzyme's C-terminus.,,,,,,
PMID33957387,reaction_1,5a,,,,,,,
PMID33957387,reaction_1,5b,,,,,,,
PMID33957387,reaction_1,5c,,,,,,,
PMID33957387,reaction_1,5d,,,,,,,
PMID33957387,reaction_1,5e,,,,,,,
PMID33957387,reaction_1,5f,,,,,,,
PMID33957387,reaction_1,5g,,,,,,,
PMID33957387,reaction_1,5h,,,,,,,
PMID33957387,reaction_1,5i,,,,,,,
PMID33957387,reaction_1,5j,,,,,,,
PMID33957387,reaction_1,5k,,,,,,,
PMID33957387,reaction_1,5l,,,,,,,
PMID33957387,reaction_1,5m,,,,,,,
PMID33957387,reaction_1,5n,,,,,,,
PMID33957387,reaction_1,5o,,,,,,,
PMID33957387,reaction_1,5p,,,,,,,
PMID33957387,reaction_1,5q,,,,,,,
PMID33957387,reaction_1,5r,,,,,,,
PMID33957387,reaction_1,5s,,,,,,,
PMID33957387,reaction_1,6a,,,,,,,
PMID33957387,reaction_1,6b,,,,,,,
PMID33957387,reaction_1,8,,,,,,,
PMID33957387,reaction_1,12,,,,,,,
PMID33957387,reaction_1,16a,,,,,,,
PMID33957387,reaction_1,16b,,,,,,,
PMID33957387,reaction_1,16c,,,,,,,
PMID33957387,reaction_1,16d,,,,,,,
PMID33957387,reaction_1,16e,,,,,,,
PMID33957387,reaction_1,GY-046,,,,,,,
PMID33957387,reaction_1,ORY-1001,,,,,,,
PMID33957387,reaction_1,SAHA,,,,,,,
PMID33957387,reaction_2,5a,,,,,,,
PMID33957387,reaction_2,5b,,,,,,,
PMID33957387,reaction_2,5c,,,,,,,
PMID33957387,reaction_2,5d,,,,,,,
PMID33957387,reaction_2,5e,,,,,,,
PMID33957387,reaction_2,5f,,,,,,,
PMID33957387,reaction_2,5g,,,,,,,
PMID33957387,reaction_2,5h,,,,,,,
PMID33957387,reaction_2,5j,,,,,,,
PMID33957387,reaction_2,5k,,,,,,,
PMID33957387,reaction_2,5l,,,,,,,
PMID33957387,reaction_2,5m,,,,,,,
PMID33957387,reaction_2,5n,,,,,,,
PMID33957387,reaction_2,5o,,,,,,,
PMID33957387,reaction_2,5p,,,,,,,
PMID33957387,reaction_2,5q,,,,,,,
PMID33957387,reaction_2,5r,,,,,,,
PMID33957387,reaction_2,5s,,,,,,,
PMID33957387,reaction_2,6a,,,,,,,
PMID33957387,reaction_2,6b,,,,,,,
PMID33957387,reaction_2,8,,,,,,,
PMID33957387,reaction_2,12,,,,,,,
PMID33957387,reaction_2,16a,,,,,,,
PMID33957387,reaction_2,16c,,,,,,,
PMID33957387,reaction_2,16d,,,,,,,
PMID33957387,reaction_2,16e,,,,,,,
PMID33957387,reaction_2,GY-046,,,,,,,
PMID33957387,reaction_2,SAHA,,,,,,,
PMID33957387,reaction_3,5a,,,,,,,
PMID33957387,reaction_3,5b,,,,,,,
PMID33957387,reaction_3,5d,,,,,,,
PMID33957387,reaction_3,5m,,,,,,,
PMID33957387,reaction_3,SAHA,,,,,,,
PMID33957387,reaction_4,5a,,,,,,,
PMID33957387,reaction_4,5b,,,,,,,
PMID33957387,reaction_4,5c,,,,,,,
PMID33957387,reaction_4,5d,,,,,,,
PMID33957387,reaction_4,5m,,,,,,,
PMID33957387,reaction_4,LBH589,,,,,,,
PMID33957387,reaction_5,5a,,,,,,,
PMID33957387,reaction_5,5b,,,,,,,
PMID33957387,reaction_5,5c,,,,,,,
PMID33957387,reaction_5,5d,,,,,,,
PMID33957387,reaction_5,5e,,,,,,,
PMID33957387,reaction_5,5f,,,,,,,
PMID33957387,reaction_5,5g,,,,,,,
PMID33957387,reaction_5,5h,,,,,,,
PMID33957387,reaction_5,5j,,,,,,,
PMID33957387,reaction_5,5l,,,,,,,
PMID33957387,reaction_5,5m,,,,,,,
PMID33957387,reaction_5,5n,,,,,,,
PMID33957387,reaction_5,5o,,,,,,,
PMID33957387,reaction_5,5p,,,,,,,
PMID33957387,reaction_5,6a,,,,,,,
PMID33957387,reaction_5,6b,,,,,,,
PMID33957387,reaction_5,8,,,,,,,
PMID33957387,reaction_5,16c,,,,,,,
PMID33957387,reaction_5,16d,,,,,,,
PMID33957387,reaction_5,16e,,,,,,,
PMID33957387,reaction_5,SAHA,,,,,,,
PMID33957387,reaction_6,5d,,,,,,,
PMID33957387,reaction_6,5m,,,,,,,
PMID33957387,reaction_6,SAHA,,,,,,,
PMID33957387,reaction_7,5d,,,,,,,
PMID33957387,reaction_7,5m,,,,,,,
PMID33957387,reaction_7,SAHA,,,,,,,
PMID33957387,reaction_8,5d,,,,,,,
PMID33957387,reaction_8,5m,,,,,,,
PMID33957387,reaction_8,Clorgyline,,,,,,,
PMID33957387,reaction_9,5d,,,,,,,
PMID33957387,reaction_9,5m,,,,,,,
PMID33957387,reaction_9,R-(−)-deprenyl,,,,,,,
PMID33957387,reaction_10,5d,,,,,,,
PMID33957387,reaction_10,5m,,,,,,,
PMID33957387,reaction_10,α-Naphthoflavone,,,,,,,
PMID33957387,reaction_11,5d,,,,,,,
PMID33957387,reaction_11,5m,,,,,,,
PMID33957387,reaction_11,Sulfaphenazole,,,,,,,
PMID33957387,reaction_12,5d,,,,,,,
PMID33957387,reaction_12,5m,,,,,,,
PMID33957387,reaction_12,Ticlopidine,,,,,,,
PMID33957387,reaction_13,5d,,,,,,,
PMID33957387,reaction_13,5m,,,,,,,
PMID33957387,reaction_13,Quinidine,,,,,,,
PMID33957387,reaction_14,5d,,,,,,,
PMID33957387,reaction_14,5m,,,,,,,
PMID33957387,reaction_14,Ketoconazole,,,,,,,
PMID33969584,reaction_1,Cladosporin,Competitive with ATP,,,,,,Selective for PfKRS over HsKRS (inactive). Thermal shift (ΔTm) with PfKRS: 17.36 °C. Parasite growth inhibition (EC50): 0.08 µM.
PMID33969584,reaction_1,Cla-A,Competitive with ATP,,,,,,Selective for PfKRS over HsKRS (no binding). Thermal shift (ΔTm) with PfKRS: 12.84 °C. Parasite growth inhibition (EC50): 6.8 µM.
PMID33969584,reaction_1,Cla-B,Competitive with ATP,,,,,,"Selective for PfKRS over HsKRS (no binding). Thermal shift (ΔTm) with PfKRS: 12.84 °C. Parasite growth inhibition (EC50): 7.5 µM. SPR binding kinetics: ka = 105 M⁻¹·s⁻¹, kd = 7.9e-4 s⁻¹."
PMID33969584,reaction_1,Cla-C,Competitive with ATP,,,,,,Selective for PfKRS over HsKRS (no binding). Thermal shift (ΔTm) with PfKRS: 9.97 °C. Parasite growth inhibition (EC50): 8.2 µM.
PMID33969584,reaction_1,Cla-D,Competitive with ATP,,,,,,Selective for PfKRS over HsKRS (no binding). Thermal shift (ΔTm) with PfKRS: 8.75 °C. Parasite growth inhibition (EC50): 8.6 µM.
PMID33969584,reaction_1,Cla-E,Competitive with ATP,,,,,,Selective for PfKRS over HsKRS (no binding). Thermal shift (ΔTm) with PfKRS: 14.3 °C. Parasite growth inhibition (EC50): 5.0 µM.
PMID33969584,reaction_1,Cla-F,Competitive with ATP,,,,,,Selective for PfKRS over HsKRS (no binding). Thermal shift (ΔTm) with PfKRS: 14.6 °C. Parasite growth inhibition (EC50): 3.7 µM.
PMID33969584,reaction_1,"Cla-G, Cla-H, Cla-I, Cla-J, Cla-K, Cla-L",Not applicable,,,,,,"These compounds were found to be non-binders and inert, with no significant thermal shift, enzyme inhibition, or parasite growth inhibition observed."
PMID33979123,reaction_1,Congo red,,c1(S(=O)(=O)O)cc(/N=N/c2ccc(-c3ccc(/N=N/c4cc(S(=O)(=O)O)c5ccccc5c4N)cc3)cc2)c(N)c2ccccc12,,,,,
PMID33979123,reaction_1,Direct violet 1,,c1(S(=O)(=O)O)cc(O)c2c(/N=N/c3ccc(-c4ccc(/N=N/c5c(N)ccc6cc(S(=O)(=O)O)cc(O)c56)cc4)cc3)c(N)ccc2c1,,,,,
PMID33979123,reaction_1,Evans blue,,S(=O)(=O)(O)c1cc(S(=O)(=O)O)c2ccc(/N=N/c3ccc(-c4ccc(/N=N/c5ccc6c(S(=O)(=O)O)cc(S(=O)(=O)O)c(N)c6c5O)c(C)c4)cc3C)c(O)c2c1N,,,,,
PMID33979123,reaction_1,Chlorazol black,,c1(S(=O)(=O)O)cc2cc(S(=O)(=O)O)c(/N=N/c3ccc(-c4ccc(/N=N/c5ccc(N)cc5N)cc4)cc3)c(N)c2c(O)c1/N=N/c1ccccc1,,,,,
PMID33979123,reaction_1,Calcomine scarlet 3B,,c1(S(=O)(=O)O)cc(S(=O)(=O)O)c2c(/N=N/c3ccc(-c4ccc(/N=N/c5ccc(OCC)cc5)c(C)c4)cc3C)c(O)ccc2c1,,,,,
PMID33979123,reaction_1,Methylene blue,,CN(C)c1ccc2nc3ccc(N(C)C)cc3[s+]c2c1,,,,,
PMID33979123,reaction_1,DRI-C21041,,c1([N+](=O)[O-])ccc(C(=O)Nc2ccc(-c3ccc(C(=O)Nc4cccc5cc(S(=O)(=O)O)ccc45)cc3)cc2)cc1,,,,,
PMID33979123,reaction_1,DRI-C23041,,c1([N+](=O)[O-])ccc(C(=O)Nc2ccc(-c3ccc(C(=O)Nc4cccc5cccc(S(=O)(=O)O)c45)cc3)cc2)cc1,,,,,
PMID33979123,reaction_1,DRI-C24041,,c1(S(=O)(=O)O)cccc2c(NC(=O)c3ccc(-c4ccc(NC(=O)c5ccc([N+](=O)[O-])cc5)cc4)cc3)cccc12,,,,,
PMID33979123,reaction_1,DRI-C61041,,c1([N+](=O)[O-])ccc(C(=O)Nc2ccc(-c3ccc(C(=O)Nc4cccc5cccc(S(=O)(=O)O)c45)cc3)nc2)cc1,,,,,
PMID33979123,reaction_1,DRI-C71041,,c1([N+](=O)[O-])ccc(C(=O)Nc2ccc(-c3ccc(C(=O)Nc4cccc5cccc(S(=O)(=O)O)c45)cc3)s2)cc1,,,,,
PMID33979123,reaction_1,DRI-C2204745,,c1(S(=O)(=O)O)cc(O)c2cccc(NC(=O)c3ccc(-c4ccc(NC(=O)c5ccc(C(=O)OC)cc5)cc4)cc3)c2c1,,,,,
PMID33979123,reaction_1,DRI-C91005,,c1(S(=O)(=O)O)cc(O)c2cc(NC(=O)c3ccc(-c4ccc(C(=O)Nc5ccc6cc(S(=O)(=O)O)cc(O)c6c5)cc4)cc3)ccc2c1,,,,,
PMID33979123,reaction_1,Erythrosine B,,,,,,,
PMID33979123,reaction_1,Sunset yellow FCF,,,,,,,
PMID33979123,reaction_1,Naphthol blue black,,,,,,,
PMID33979123,reaction_1,Suramin,,,,,,,
PMID33979123,reaction_1,Chloroquine,,,,,,,
PMID33979123,reaction_2,DRI-C23041,,c1([N+](=O)[O-])ccc(C(=O)Nc2ccc(-c3ccc(C(=O)Nc4cccc5cccc(S(=O)(=O)O)c45)cc3)cc2)cc1,,,,,
PMID33979123,reaction_3,Congo red,,c1(S(=O)(=O)O)cc(/N=N/c2ccc(-c3ccc(/N=N/c4cc(S(=O)(=O)O)c5ccccc5c4N)cc3)cc2)c(N)c2ccccc12,,,,,
PMID33979123,reaction_3,Direct violet 1,,c1(S(=O)(=O)O)cc(O)c2c(/N=N/c3ccc(-c4ccc(/N=N/c5c(N)ccc6cc(S(=O)(=O)O)cc(O)c56)cc4)cc3)c(N)ccc2c1,,,,,
PMID33979123,reaction_3,Evans blue,,S(=O)(=O)(O)c1cc(S(=O)(=O)O)c2ccc(/N=N/c3ccc(-c4ccc(/N=N/c5ccc6c(S(=O)(=O)O)cc(S(=O)(=O)O)c(N)c6c5O)c(C)c4)cc3C)c(O)c2c1N,,,,,
PMID33979123,reaction_3,Calcomine scarlet 3B,,c1(S(=O)(=O)O)cc(S(=O)(=O)O)c2c(/N=N/c3ccc(-c4ccc(/N=N/c5ccc(OCC)cc5)c(C)c4)cc3C)c(O)ccc2c1,,,,,
PMID33979123,reaction_3,DRI-C23041,,c1([N+](=O)[O-])ccc(C(=O)Nc2ccc(-c3ccc(C(=O)Nc4cccc5cccc(S(=O)(=O)O)c45)cc3)cc2)cc1,,,,,
PMID33979123,reaction_3,DRI-C61041,,c1([N+](=O)[O-])ccc(C(=O)Nc2ccc(-c3ccc(C(=O)Nc4cccc5cccc(S(=O)(=O)O)c45)cc3)nc2)cc1,,,,,
PMID33979123,reaction_3,DRI-C71041,,c1([N+](=O)[O-])ccc(C(=O)Nc2ccc(-c3ccc(C(=O)Nc4cccc5cccc(S(=O)(=O)O)c45)cc3)s2)cc1,,,,,
PMID33979123,reaction_3,DRI-C2204745,,c1(S(=O)(=O)O)cc(O)c2cccc(NC(=O)c3ccc(-c4ccc(NC(=O)c5ccc(C(=O)OC)cc5)cc4)cc3)c2c1,,,,,
PMID33979123,reaction_3,DRI-C91005,,c1(S(=O)(=O)O)cc(O)c2cc(NC(=O)c3ccc(-c4ccc(C(=O)Nc5ccc6cc(S(=O)(=O)O)cc(O)c6c5)cc4)cc3)ccc2c1,,,,,
PMID33979649,reaction_2,GRL0617,Competitive,,,,,,
PMID33979649,reaction_2,11,Competitive,,,,,,
PMID33979649,reaction_2,12,Competitive,,,,,,
PMID33979649,reaction_2,13,Competitive,,,,,,
PMID33979649,reaction_2,14,Competitive,,,,,,
PMID33979649,reaction_2,15,Competitive,,,,,,
PMID33979649,reaction_2,16,Competitive,,,,,,
PMID33979649,reaction_2,17,Competitive,,,,,,
PMID33979649,reaction_2,18,Competitive,,,,,,
PMID33979649,reaction_2,19,Competitive,,,,,,
PMID33979649,reaction_3,GRL0617,,,,,,,
PMID33979649,reaction_3,11,,,,,,,
PMID33979649,reaction_3,12,,,,,,,
PMID33979649,reaction_3,13,,,,,,,
PMID33979649,reaction_3,14,,,,,,,
PMID33979649,reaction_3,15,,,,,,,
PMID33979649,reaction_3,16,,,,,,,
PMID33979649,reaction_3,17,,,,,,,
PMID33979649,reaction_3,18,,,,,,,
PMID33979649,reaction_3,19,,,,,,,
PMID33979735,reaction_1,Compound 1,,,,,,,
PMID33979735,reaction_1,Compound 6a,,,,,,,
PMID33979735,reaction_1,Compound 5u,,,,,,,
PMID33979735,reaction_1,Compound 7b,,,,,,,
PMID33979735,reaction_1,Compound 5j,,,,,,,
PMID33979735,reaction_1,Compound 8a,,,,,,,
PMID33979735,reaction_1,Compound 8b,,,,,,,
PMID33999624,reaction_1,compound 10,,,,,,,
PMID33999624,reaction_1,compound 11,,,,,,,
PMID33999624,reaction_1,compound 12,,,,,,,
PMID33999624,reaction_1,compound 13,,,,,,,
PMID33999624,reaction_1,compound 14,,,,,,,
PMID33999624,reaction_1,compound 15,,,,,,,
PMID33999624,reaction_1,compound 16,,,,,,,
PMID33999624,reaction_1,compound 17,,,,,,,
PMID33999624,reaction_1,compound 18,,,,,,,
PMID33999624,reaction_1,compound 19,,,,,,,
PMID33999624,reaction_1,compound 20,,,,,,,
PMID33999624,reaction_1,compound 21,,,,,,,
PMID33999624,reaction_1,compound 22,,,,,,,
PMID33999624,reaction_1,compound 23,,,,,,,
PMID33999624,reaction_1,compound 24,,,,,,,
PMID33999624,reaction_1,compound 25,,,,,,,
PMID33999624,reaction_1,compound 26,,,,,,,
PMID33999624,reaction_1,compound 27,,,,,,,
PMID33999624,reaction_1,compound 28,,,,,,,
PMID33999624,reaction_1,compound 29,,,,,,,
PMID33999624,reaction_1,compound 30,,,,,,,
PMID33999624,reaction_1,compound 31,,,,,,,
PMID33999624,reaction_1,compound 32,,,,,,,
PMID33999624,reaction_1,compound 33,,,,,,,
PMID33999624,reaction_1,compound 34,,,,,,,
PMID33999624,reaction_1,compound 35,,,,,,,
PMID33999624,reaction_1,compound 36,,,,,,,
PMID33999624,reaction_1,mesotrione,,,,,,,
PMID34010508,reaction_1,Econazole,Competitive,,,,,,
PMID34010508,reaction_1,I:47,Competitive,,,,,,
PMID34010508,reaction_1,L10,Competitive,,,,,,
PMID34010508,reaction_1,L14,Competitive,,,,,,
PMID34010508,reaction_1,L15,Competitive,,,,,,
PMID34010508,reaction_1,L21,Competitive,,,,,,
PMID34010508,reaction_1,L44,Competitive,,,,,,
PMID34010508,reaction_1,L45,Competitive,,,,,,
PMID34010508,reaction_1,L46,Competitive,,,,,,
PMID34010508,reaction_1,L76,Competitive,,,,,,
PMID34010508,reaction_1,L78,Competitive,,,,,,
PMID34010508,reaction_1,L94,Competitive,,,,,,
PMID34010508,reaction_1,S2,Competitive,,,,,,
PMID34019767,reaction_3,zinc acetate,Not specified,,,,,Cleavage of the CFP-FOXP3-YFP substrate was inhibited by zinc acetate.,
PMID34048880,reaction_1,Cpd-1,,,,,,,
PMID34048880,reaction_1,Cpd-2,,,,,,,
PMID34048880,reaction_1,Cpd-3,,,,,,,
PMID34048880,reaction_1,Cpd-4,,,,,,,
PMID34048880,reaction_1,Cpd-5,,,,,,,
PMID34048880,reaction_1,Cpd-6,,,,,,,
PMID34048880,reaction_1,Cpd-7,,,,,,,
PMID34056479,reaction_1,2-[(1-hydroxy-2-oxo-2-phenylethyl)sulfanyl]acetic acid (compound 3),Not specified,O=C(O)CSC(O)C(=O)c1ccccc1,,,,,
PMID34056479,reaction_1,"4-{[(furan-2-yl)methyl]amino}-1,2-diazinane-3,6-dione (compound 6)",Not specified,O=C1CC(NCc2ccco2)C(=O)NN1,,,,,
PMID34112370,reaction_1,EDTA,Chelation,,,,,Activity was completely lost (0 nmol/min/mg protein) after treatment with 1 mM or 100 mM EDTA (Table 1).,
PMID34112370,reaction_1,ZnSO4,Not specified,,,,,Exogenous ZnSO4 inhibits activity (Fig. 1).,
PMID34112370,reaction_2,EDTA,Chelation,,,,,Activity was completely lost (0 nmol/min/mg protein) after treatment with 100 mM EDTA. Activity was largely retained (5 ± 1 nmol/min/mg protein) after treatment with 1 mM EDTA (Table 1).,
PMID34112370,reaction_2,ZnSO4,Not specified,,,,,Exogenous ZnSO4 inhibits activity (Fig. 1).,
PMID34112370,reaction_2,CuSO4,Non-specific binding,,,,,Excess exogenous CuSO4 inhibits activity (Fig. 4).,
PMID34123216,reaction_1,NAD+,Substrate inhibition,,,,,Inhibition observed at high NAD+ concentrations (>10 mM) for both wild-type and L252A mutant.,
PMID34123216,reaction_3,1-ethoxy-3-hydroxyacetone,Product inhibition,,,,,"Product inhibition observed at high substrate concentrations (> 25 mM), limiting conversion.",
PMID34123216,reaction_3,Dihydroxyacetone,Product inhibition,,,,,BsGlyDH-L252A underwent a 50% activity decrease when incubated at 100 mM dihydroxyacetone.,
PMID34142217,reaction_1,sodium orthovanadate,PM H+-ATPase inhibitor,,,,,,
PMID34163896,reaction_1,3-methyl-2-oxoglutarate,,,,,,,
PMID34163896,reaction_1,3-ethyl-2-oxoglutarate,,,,,,,
PMID34163896,reaction_1,3-propyl-2-oxoglutarate,,,,,,,
PMID34163896,reaction_1,"3-(3,3-dimethylbutyl)-2-oxoglutarate",,,,,,,
PMID34163896,reaction_1,3-(3-phenylpropyl)-2-oxoglutarate,,,,,,,
PMID34163896,reaction_1,3-benzyl-2-oxoglutarate,,,,,,,
PMID34163896,reaction_1,3-(4-fluorobenzyl)-2-oxoglutarate,,,,,,,
PMID34163896,reaction_1,3-(4-(trifluoromethoxy)benzyl)-2-oxoglutarate,,,,,,,
PMID34163896,reaction_1,3-(4-methoxybenzyl)-2-oxoglutarate,,,,,,,
PMID34163896,reaction_1,"3-(3,5-dimethylbenzyl)-2-oxoglutarate",,,,,,,
PMID34163896,reaction_1,4-methyl-2-oxoglutarate,,,,,,,
PMID34163896,reaction_1,4-ethyl-2-oxoglutarate,,,,,,,
PMID34163896,reaction_1,4-propyl-2-oxoglutarate,,,,,,,
PMID34163896,reaction_1,4-butyl-2-oxoglutarate,,,,,,,
PMID34163896,reaction_1,4-isobutyl-2-oxoglutarate,,,,,,,
PMID34163896,reaction_1,"4-(3,3-dimethylbutyl)-2-oxoglutarate",,,,,,,
PMID34163896,reaction_1,4-benzyl-2-oxoglutarate,,,,,,,
PMID34163896,reaction_1,4-(4-fluorobenzyl)-2-oxoglutarate,,,,,,,
PMID34163896,reaction_1,"4,4-dimethyl-2-oxoglutarate",,,,,,,
PMID34163896,reaction_1,"2,2-dimethyl-1-(carboxycarbonyl)cyclopropane-1-carboxylic acid",,,,,,,
PMID34163896,reaction_1,"(1R,5S,6R)-6-(carboxycarbonyl)-5-methyl-3-cyclohexene-1-carboxylic acid",,,,,,,
PMID34163896,reaction_1,4-(carboxycarbonyl)thiophene-2-carboxylic acid,,,,,,,
PMID34163896,reaction_1,5-(carboxycarbonyl)thiophene-2-carboxylic acid,,,,,,,
PMID34163896,reaction_1,2-carboxyphenylglyoxylic acid,,,,,,,
PMID34163896,reaction_1,3-carboxyphenylglyoxylic acid,,,,,,,
PMID34163896,reaction_1,4-carboxyphenylglyoxylic acid,,,,,,,
PMID34163896,reaction_1,2-(3-fluoro-4-carboxyphenyl)-2-oxoacetic acid,,,,,,,
PMID34163896,reaction_1,2-(2-fluoro-4-carboxyphenyl)-2-oxoacetic acid,,,,,,,
PMID34163896,reaction_1,2-(3-bromo-4-carboxyphenyl)-2-oxoacetic acid,,,,,,,
PMID34163896,reaction_1,2-(2-bromo-4-carboxyphenyl)-2-oxoacetic acid,,,,,,,
PMID34163896,reaction_1,2-(4-carboxy-3-methylphenyl)-2-oxoacetic acid,,,,,,,
PMID34163896,reaction_1,2-oxo-2-(4-carboxy-bicyclo[2.2.2]octan-1-yl)acetic acid,,,,,,,
PMID34163896,reaction_1,1-(carboxycarbonyl)cyclopropane-1-carboxylic acid,,,,,,,
PMID34171691,reaction_1,Arsenate(V),"Substrate inhibition was observed when plants were exposed to 5 mg/L As(V), causing a decrease in AR activity compared to exposure at 3 mg/L.",,,,,,
PMID34189909,reaction_1,Ketoconazole,Competitive protection,,,,,"Co-incubation with 1 µM ketoconazole completely abolished inactivation by 25 µM ERD, indicating inactivation occurs at the active site.",
PMID34189909,reaction_2,Ketoconazole,Competitive protection,,,,,"Co-incubation with 1 µM ketoconazole completely abolished inactivation by 25 µM ERD, indicating inactivation occurs at the active site.",
PMID34246414,reaction_1,non-labeled RBD,Competitive,,,,,,
PMID34246414,reaction_1,LCB1v3 miniprotein,Competitive,,,,,,
PMID34246414,reaction_1,SARS-CoV-1/2 spike RBD Llamabody VHH,Competitive,,,,,,
PMID34246414,reaction_1,Corilagin,,,,,Statistically significant 30% inhibition at 100 µM concentration.,,
PMID34246414,reaction_1,Cangrelor,,,,,No inhibition observed at concentrations up to 100 or 1000 µM.,,
PMID34246414,reaction_1,Elaidic acid,,,,,No inhibition observed at concentrations up to 100 or 1000 µM.,,
PMID34246414,reaction_1,Fenbendazole,,,,,No inhibition observed at concentrations up to 100 or 1000 µM.,,
PMID34246414,reaction_1,Enalapril maleate,,,,,No inhibition observed at concentrations up to 100 or 1000 µM.,,
PMID34246414,reaction_3,Heparin,"Partial (approx. 50%), allosteric",,,,,,
PMID34294705,reaction_1,oxalate,Competitive (implied by assay),,,,,Almost completely inhibited SO42- uptake at 50-fold excess concentration.,
PMID34294705,reaction_1,thiocyanate,Competitive (implied by assay),,,,,Significantly reduced SO42- uptake at 50-fold excess concentration.,
PMID34294705,reaction_1,acetate,Competitive (implied by assay),,,,,Modest inhibitory effect on SO42- transport at 50-fold excess concentration.,
PMID34294705,reaction_1,iodide,Competitive (implied by assay),,,,,Modest inhibitory effect on SO42- transport at 50-fold excess concentration.,
PMID34297466,reaction_1,thapsigargin,Irreversible,,,,,,Used as a control to confirm SERCA activity. 100 nM thapsigargin fully suppressed the ATP-induced current signal.
PMID34315109,reaction_3,Hypochlorous acid,,,,,,,
PMID34315109,reaction_4,Hydrogen peroxide,,,,,,,
PMID34327042,reaction_1,metyrapone,Used as a trap to measure koff for camphor. Binds to ligand-free P450cam.,,,,,,
PMID34340545,reaction_1,Bacteriophage T3 S-Adenosylmethionine lyase,"Allosteric inhibition via induced polymerization. SAMase mediates the head-to-tail assembly of MAT tetramers into filaments, which deforms the active site.",,,,,,
PMID34358993,reaction_1,"ED (N′,N’’-[oxybis (4,1-phenylenecarbonyl)]bis (3-methoxybenzohydrazide))",Not specified,,,,,,
PMID34364941,reaction_1,Tanshinone IIA sulfonate sodium,Competitive,,,,,,"Binding confirmed by Biolayer Interferometry (BLI) and Thermal Shift Assay (TSA), which showed a Tm increase of 1°C at pH 7.0. Docking and MD simulations suggest it inhibits by occupying the active pocket."
PMID34364941,reaction_2,Chloroxine,Interrupts the PLpro-ISG15 binding interface,,,,,,"The IC50 value of 7.24 ± 0.68 μM was determined using an in vitro fluorescence polarization competitive binding assay with inactive PLpro-C111S, not from this catalytic assay. Binding was confirmed by Biolayer Interferometry (BLI) with PLpro-C111S and Thermal Shift Assay (TSA), which showed a Tm increase of 2.5°C at pH 7.0. Docking and MD simulations suggest it binds near Arg65 at the PLpro-ISG15 interface."
PMID34364941,reaction_2,Tanshinone IIA sulfonate sodium,Competitive,,,,,,"Activity was confirmed qualitatively in cell-based assays, showing recovery of cellular ISGylation levels in a dose-dependent manner."
PMID34382711,reaction_1_EcFPR,NADP+,Product inhibition,,,,,,"In the presence of NADP+, the catalytic efficiency (kcat/Km) decreases 10-fold (from 8 to 0.8 µM⁻¹s⁻¹), with Km for NADPH increasing from 6.8 to 79 µM. This inhibition is dependent on residues R144 and R184."
PMID34420183,reaction_1,DMSO,Activity decreased at concentrations above 1% (v/v).,,,,,,
PMID34423563,reaction_1,SJB2-043,,,,,,,"Partial inhibitor, does not fully inhibit PLPro at 200 µM. Likely binds to an allosteric site."
PMID34423563,reaction_1,GRL0617,,,,,,,Fully inhibits PLPro at 200 µM.
PMID34423563,reaction_1,PR-619,,,,,,,Fully inhibits PLPro at 200 µM.
PMID34423563,reaction_1,TCID,,,,,,,Fully inhibits PLPro at 200 µM.
PMID34423563,reaction_1,SJB3-019A,,,,,,,"Partial inhibitor, does not fully inhibit PLPro at 200 µM."
PMID34423563,reaction_1,DUB-IN-3,,,,,,,"Partial inhibitor, does not fully inhibit PLPro at 200 µM."
PMID34423563,reaction_1,S130,,,,,,,Fully inhibits PLPro at 200 µM.
PMID34423563,reaction_2,SJB2-043,,,,,,,"Partial inhibitor, does not fully inhibit PLPro. The lower IC50 with this larger substrate suggests allosteric inhibition that is more sensitive to structural perturbations affecting Ub-AMC binding."
PMID34423563,reaction_2,GRL0617,,,,,,,"IC50 is comparable to that determined with Z-LRGG-AMC, suggesting a similar inhibition mechanism, likely active site binding."
PMID34423563,reaction_2,TCID,,,,,,,IC50 is comparable to that determined with Z-LRGG-AMC.
PMID34423563,reaction_2,PR619,,,,,,,IC50 is comparable to that determined with Z-LRGG-AMC.
PMID34423563,reaction_2,SBJ3-019a,,,,,,,"Displayed a complex, two-stage inhibition curve; IC50 was not calculated."
PMID34423563,reaction_2,DUB-IN-3,,,,,,,Displayed a simple inhibition curve that did not reach its plateau. Estimated IC50 value was above 10 µM.
PMID34604672,reaction_1,"2,4-dibromo-6-{[4-(4-nitro-phenyl)-thiazol-2-yl]-hydrazonomethyl}-phenol",,O=[N+]([O-])c1ccc(-c2csc(N/N=C/c3cc(Br)cc(Br)c3O)n2)cc1,,,,,Residual activity of 27.35% at 100 μM.
PMID34604672,reaction_1,1-(4-methoxy-phenyl)-2-(6-nitro-benzothiazol-2-ylsulfanyl)-ethanone,,COc1ccc(C(=O)CSc2nc3ccc([N+](=O)[O-])cc3s2)cc1,,,,,Residual activity of 11.53% (inhibits by 88.47%) at 100 μM.
PMID34604672,reaction_1,2-(2-tert-butyl-phenoxy)-N-(2-methyl-5-nitro-phenyl)-acetamide,,Cc1ccc([N+](=O)[O-])cc1NC(=O)COc1ccccc1C(C)(C)C,,,,,Residual activity of 14.41% at 100 μM.
PMID34604672,reaction_1,"4-(4-chloro-phenyl)-2-[2-(2,6-dimethyl-morpholin-4-yl)-acetylamino]-thiophene-3-carboxylic acid ethyl ester",,CCOC(=O)c1c(-c2ccc(Cl)cc2)csc1NC(=O)CN1CC(C)OC(C)C1,,,,,Residual activity of 21.67% at 100 μM.
PMID34604672,reaction_1,"2-[1-(4-iodo-2-methyl-phenyl)-2,5-dioxo-pyrrolidin-3-ylsulfanyl]-nicotinic acid",,Cc1cc(I)ccc1N1C(=O)CC(Sc2ncccc2C(=O)O)C1=O,,,,,Residual activity of 21.38% at 100 μM.
PMID35285984,reaction_1,"2-C-vinyl-D-erythritol-2,4-cyclodiphosphate","Irreversible, slow-binding, mechanism-based",,,,,,
PMID35515322,reaction_1,7-OH flavone,,,,,,,
PMID35515322,reaction_1,Chrysin,,,,,,,
PMID35515322,reaction_1,Baicalin,,,,,,,
PMID35515322,reaction_1,Baicalein,,,,,,,
PMID35515322,reaction_1,Apigenin,,,,,,,
PMID35515322,reaction_1,Luteolin,,,,,,,
PMID35515322,reaction_1,Hispidulin,,,,,,,
PMID35515322,reaction_1,Tangeretin,,,,,,,
PMID35515322,reaction_1,Nobiletin,,,,,,,
PMID35515322,reaction_1,Galangin,,,,,,,
PMID35515322,reaction_1,Kaempferol,,,,,,,
PMID35515322,reaction_1,Kaempferitrin,,,,,,,
PMID35515322,reaction_1,Quercetin,,,,,,,
PMID35515322,reaction_1,Myricetin,,,,,,,
PMID35515322,reaction_1,Fisetin,,,,,,,
PMID35515322,reaction_1,Rutin,,,,,,,
PMID35515322,reaction_1,Formononetin,,,,,,,
PMID35515322,reaction_1,Genistein,,,,,,,
PMID35515322,reaction_1,Daidzein,,,,,,,
PMID35515322,reaction_1,Biochanin A,,,,,,,
PMID35515322,reaction_1,Tectorigenin,,,,,,,
PMID35515322,reaction_1,Puerarin,,,,,,,
PMID35515322,reaction_1,Dihydromyricetin,,,,,,,
PMID35515322,reaction_1,Naringenin,,,,,,,
PMID35515322,reaction_1,Naringin,,,,,,,
PMID35515322,reaction_1,"ECG (2,3-cis)",,,,,,,
PMID35515322,reaction_1,"EGCG (2,3-cis)",,,,,,,
PMID35515322,reaction_1,"GCG (2,3-trans)",,,,,,,
PMID35521286,reaction_1,Compound 1,,CC(C)(C)C(O)C(=O)NS(=O)(=O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)C(O)[C@@H]1O,,,,,
PMID35521286,reaction_1,Compound 2,,CC(C)(CO)[C@@H](O)C(=O)OP(=O)([O-])OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)C(O)[C@@H]1O,,,,,
PMID35521286,reaction_1,Compound 3,,CC(C)(C)[C@@H](O)C(=O)NS(=O)(=O)OC[C@H]1O[C@@H](n2cnc3c(N)cccc32)[C@H](O)[C@@H]1O,,,,,
PMID35521286,reaction_1,Compound 4,,CC(C)(C)C([NH3+])C(=O)NS(=O)(=O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)C(O)C1O,,,,,
PMID35521286,reaction_1,Compound 5,,CC(C)C([NH3+])C(=O)NS(=O)(=O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)C(O)C1O,,,,,
PMID35521286,reaction_1,Nafronyl oxalate,,CCN(CC)CCOC(=O)C(Cc1cccc2ccccc12)CC1CCCO1,,,,,
PMID35521286,reaction_1,Compound 6,,CC(C)(C)C1CCc2onc(C(=O)Nc3cnn(Cc4ccc5ccccc5c4)c3)c2C1,,,,,
PMID35521286,reaction_1,Actinomycin D,,,,,,,
PMID35521286,reaction_1,Compound 7,,COC(=O)c1cc2c(OCc3ccccc3)cc(N)cc2[nH]1,,,,,
PMID35521286,reaction_1,Compound 8,,C=C/C=C/C=C/c1cccc(NNC(=O)CCC(=O)O)c1,,,,,
PMID35521286,reaction_1,Compound 9,,C(#N)c1c(-c2ccc(-c3ccccc3)cc2)c(C(=O)O)n(C)c1C,,,,,
PMID35521286,reaction_1,Compound 10,,C(#N)c1ccc(-c2ccc(-c3c(C#N)c(C)n(C)c3C(=O)O)cc2)cc1,,,,,
PMID35521286,reaction_1,Compound 12,,O=C(Nc1ccc([N+](=O)[O-])cc1)N1CCc2c(c(-c3ccccc3)nn2C(=O)c2ccccc2)C1,,,,,
PMID35521286,reaction_1,Compound 14,,COc1ccc2c(c1)C=C(C(=O)NS(=O)(=O)c1cc3ccccc3o1)C2CC(=O)O,,,,,
PMID35521286,reaction_1,Compound 16,,COc1ccc2oc(C(=O)NCc3cc4ccc(OC)cc4n3C(=O)O)cc2c1,,,,,
PMID35521286,reaction_1,Compound 17,,Cc1nc2ccccn2c1C(=O)NNC(O)c1cccc2ccccc12,,,,,
PMID35521286,reaction_1,Compound 18,,O=C(CCN1C(=O)S/C(=C\c2ccc3c(c2)OCO3)C1=O)NNC(=O)c1cccnc1,,,,,
PMID35521286,reaction_1,Compound 19,,COc1cc(/C=C2\SC(=S)N(CCC(=O)NNC(=O)c3ccncc3)C2=O)cc(OC)c1OC,,,,,
PMID35521286,reaction_1,Compound 20,,O=C(CNc1cccc(CNC(=O)C(=O)NCc2ccco2)c1)C(=O)NCc1ccoc1,,,,,
PMID35521286,reaction_1,Compound 21,,Cc1ccc(C(=O)Nc2ccccc2C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)O)cc1,,,,,
PMID35521286,reaction_1,Compound 22,,O=C(Nc1ccccc1C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)O)c1ccc(F)cc1,,,,,
PMID35521286,reaction_1,Compound 23,,Cc1nc2sc3ccccc3n2c1C(=O)NNC(=O)c1ccc(Oc2ccccc2)cc1,,,,,
PMID35521286,reaction_1,Compound 24,,O=C(Nc1ccc([N+](=O)[O-])cc1)N1CCc2c(c(-c3ccccc3)nn2C(=O)c2ccccc2)C1,,,,,
PMID35521286,reaction_1,Compound 26,,C(=O)(OC)c1c(NC(=O)c2ccc([N+](=O)[O-])s2)sc2c1CCN(S(=O)(=O)c1ccc([N+](=O)[O-])cc1)C2,,,,,
PMID35521286,reaction_1,Compound 27,,COc1ccc(-n2cc(Cn3nc(-c4ccccc4)c4c3CCN(C(=O)Nc3ccc([N+](=O)[O-])cc3)C4)nn2)cc1,,,,,
PMID35625344,reaction_1,Verapamil,Not specified,,,,,,Presence of verapamil (at concentrations of 1x10⁻¹⁵ M and more) decreased the IC50 of carbenicillin in P. aeruginosa PAO1 from 29 ± 3.5 µg/mL to 21 ± 2 µg/mL.
PMID35625344,reaction_1,Curine,Not specified,,,,,,"Presence of curine (at plateau concentration, >= 1x10⁻¹⁵ M) decreased the IC50 of carbenicillin in P. aeruginosa IP104116 from 58 ± 3.5 µg/mL to 37 ± 1.5 µg/mL."
PMID35625344,reaction_1,Guattegaumerine,Not specified,,,,,,"Presence of guattegaumerine (at plateau concentration, >= 1x10⁻¹⁵ M) decreased the IC50 of carbenicillin in P. aeruginosa IP104116 from 58 ± 3.5 µg/mL to 42 ± 1 µg/mL."
PMID35625344,reaction_1,Triacetylguattegaumerine,Not specified,,,,,,"Presence of triacetylguattegaumerine (at plateau concentration, >= 1x10⁻¹⁵ M) decreased the IC50 of carbenicillin in P. aeruginosa IP104116 from 58 ± 3.5 µg/mL to 34 ± 1 µg/mL."
PMID35625344,reaction_2,Verapamil,Competitive (inferred from docking analysis),,,,,,"Presence of verapamil (at concentrations of 1x10⁻¹⁵ M and more) decreased the IC50 of novobiocin in P. aeruginosa PAO1 from 193 ± 3 µg/mL to 166 ± 2 µg/mL. At 1x10⁻⁷ M, it increased intracellular novobiocin accumulation by approximately 35%."
PMID35625344,reaction_2,Curine,Not specified,,,,,,Presence of curine (at plateau concentration) decreased the IC50 of novobiocin in P. aeruginosa IP104116 from 289 ± 3.5 µg/mL to 172.52 ± 4.94 µg/mL.
PMID35625344,reaction_2,Guattegaumerine,Not specified,,,,,,Presence of guattegaumerine (at plateau concentration) decreased the IC50 of novobiocin in P. aeruginosa IP104116 from 289 ± 3.5 µg/mL to 180.74 ± 7.28 µg/mL.
PMID35625344,reaction_2,Triacetylguattegaumerine,Not specified,,,,,,Presence of triacetylguattegaumerine (at plateau concentration) decreased the IC50 of novobiocin in P. aeruginosa IP104116 from 289 ± 3.5 µg/mL to 208.54 ± 2.43 µg/mL.
PMID35766403,reaction_1,Coenzyme A,Substrate inhibition,,,,,,
